Page last updated: 2024-11-05

ticlopidine and Bleeding

ticlopidine has been researched along with Bleeding in 937 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
"Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy."9.34Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."9.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor."9.24Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017)
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."9.24Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication."9.24The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."9.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel."9.22Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016)
"The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours."9.22Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016)
"Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use."9.22Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."9.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone."9.22Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."9.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."9.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding."9.20Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015)
"MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel."9.20MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015)
" In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis."9.20Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015)
"In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding."9.20Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015)
"Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist."9.20Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015)
" In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients."9.20Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015)
" Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)."9.20Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."9.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
" clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization."9.19Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014)
"In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding."9.19Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014)
"The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)."9.19Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014)
"This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)."9.19Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014)
"We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism."9.19Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014)
"Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage."9.17Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013)
"A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months."9.17Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013)
"On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel."9.17Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013)
"Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity."9.16Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012)
"The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding."9.16Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012)
"Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death."9.16Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012)
"The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age."9.16Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012)
" Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks."9.16Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)
"In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)."9.15Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011)
" We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation."9.15Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011)
"Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography."9.15Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."9.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"Clopidogrel (Plavix®) therapy, although effective for minimizing risk of thrombotic events, is also associated with potential bleeding risk."9.15Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. ( Carr, ME; Gabriel, D; Khutoryansky, NM; Pusateri, AE; Shenouda, M; Skolnick, BE, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."9.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."9.14Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI."9.14Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009)
"Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel."9.14Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."9.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
" Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding."9.14Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."9.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding."9.14Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."9.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."9.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel."9.14Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010)
"ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events."9.14Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010)
"In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding."9.14Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010)
"In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke."9.14Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."9.14Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
" The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound."9.14Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010)
"In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention."9.13Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."9.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding."9.13Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."9.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding."9.13Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."9.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel."9.13Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008)
"The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction."9.12Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007)
" The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes."9.12Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007)
"Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)."9.12Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007)
"Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention."9.12Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007)
"In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications."9.11Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005)
"To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy."9.11A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005)
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)."9.10Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."9.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)."9.08Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995)
"The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel."8.95Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017)
"Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically."8.93Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016)
"Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events."8.91Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015)
"Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients."8.91Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015)
"The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding."8.91Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015)
"Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin."8.91Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015)
" A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0."8.91Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."8.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."8.91[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."8.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications."8.90Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014)
"In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding."8.90Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014)
"Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke."8.89The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013)
"To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies."8.88Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012)
"Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well."8.88The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012)
"Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel."8.88Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012)
"Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems."8.88Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012)
"To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI."8.88Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012)
" In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk."8.84Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008)
"Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)."8.31miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023)
"Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack."8.12Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022)
"Enhanced platelet inhibition delivered by clopidogrel is associated with an increased risk for major bleeding and death in patients on OAC who undergo PCI."7.91Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. ( Bernlochner, I; Fiedler, KA; Goedel, A; Hoppmann, P; Kastrati, A; Laugwitz, KL; Maeng, M; Massberg, S; Mayer, K; Mehilli, J; Sarafoff, N; Schunkert, H; Schüpke, S; Sibbing, D; von Olshausen, G, 2019)
"Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel."7.88Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018)
"The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China."7.88Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018)
"Bleeding is one of the possible adverse events during clopidogrel therapy."7.88Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018)
" Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk."7.88Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018)
"To report incidence of bleeding after image-guided percutaneous core needle biopsy performed in patients taking clopidogrel within 5 days."7.85Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review. ( Atwell, T; Knudsen, J; McBane, R; McMenomy, B; Pieper, M; Schmitz, J; Wennberg, P, 2017)
"The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear."7.85Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."7.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."7.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel."7.83Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016)
" Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events."7.83Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016)
"Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)."7.83Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016)
"Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported."7.83Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016)
"To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel."7.83One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016)
"To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease."7.83[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016)
" However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2."7.83Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016)
"The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events."7.83A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."7.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"We hypothesized that perioperative measurement of platelet function with a point-of-care P2Y12 inhibitor assay could predict bleeding during CABG in patients exposed to clopidogrel."7.81Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. ( Agnihotri, A; Aranki, S; Cannon, CP; Guo, J; Kumar, A; Maree, AO; McLean, DS; Reed, GW; Rosenfield, K; Shekar, P, 2015)
"There is a known bleeding risk with administration of the antiplatelet drug clopidogrel, but in certain patients the likelihood of thrombosis is too high to cease its administration perioperatively."7.81Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series. ( Bono, J; Nandi, S; Shubert, D, 2015)
"This study is the first to analyze differences in bleeding times between clopidogrel and prasugrel treatments during dental extraction."7.81Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy. ( Braunitzer, G; Dézsi, BB; Dézsi, CA; Hangyási, DB; Koritsánszky, L, 2015)
"Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)."7.81[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015)
" We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population."7.80Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014)
"Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction."7.80Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
"Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel."7.80Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014)
"We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months."7.80Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)
"The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats."7.80Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014)
"To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel."7.80Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014)
"The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)."7.80Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014)
" Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later."7.79Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013)
"Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)."7.79[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013)
" This study sought to determine if trauma patients on preinjury clopidogrel with a higher degree of platelet inhibition (PI), as determined by the VerifyNow P2Y12 Test, experienced bleeding complications more frequently than did patients with a lower degree of PI."7.79Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. ( Ali, K; Cheng, J; Kram, B; Short, S; Taylor, S; Vasquez, D, 2013)
" We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)."7.79Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."7.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0."7.79Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013)
"Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD."7.79Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013)
"The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications."7.79Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013)
" the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days."7.78Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012)
"Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding."7.78Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012)
" This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery."7.78Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012)
"To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel."7.78Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."7.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma."7.78Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)
" Clopidogrel (a compound that inhibits adenosine diphosphate-induced platelet aggregation) is often prescribed for primary or secondary prevention of cardiovascular disease and has been associated with bleeding complications in patients undergoing surgical procedures."7.78Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis. ( Bechara, RI; Berkowitz, DM; Parks, C; Zalt, MB, 2012)
"Coronary artery bypass grafting (CABG) performed within 5 days of clopidogrel administration is associated with increased bleeding."7.77Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. ( Cruden, NL; Hilton, JD; Klinke, WP; Morch, K; Ofiesh, J; Wong, DR, 2011)
"The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)."7.77Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011)
"We do not routinely discontinue clopidogrel before colonoscopy because we have judged the cardiovascular risks of that practice to exceed the risks of post-polypectomy bleeding (PPB)."7.77The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. ( Davila, RE; Feagins, LA; Harford, WV; Spechler, SJ; Uddin, FS, 2011)
" Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj."7.77Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."7.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)."7.77Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011)
" We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage."7.77Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011)
"To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel."7.76Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010)
"The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI."7.76Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
"In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding."7.76Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."7.76Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
"Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain."7.76Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010)
"Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding."7.76Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."7.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications."7.76Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)
"Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern."7.76National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)
"Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)."7.75Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009)
"The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding."7.75Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."7.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
"The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)."7.74Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."7.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
"Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs."7.73Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005)
"We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin."7.73Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005)
" Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown."7.73Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006)
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI."7.73[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006)
"We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)."7.73Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006)
"Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel."7.71Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001)
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."6.79Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" The prevalence of adverse events was assessed at each visit through a direct interview."6.78Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)
"Fatal bleeding was low and did not differ between groups."6.76Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011)
" Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate."6.48Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. ( Davies, JE; Francis, DP; Nijjer, SS, 2012)
" Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1."6.47Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011)
"In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS."5.51Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022)
"to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials."5.51Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."5.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs."5.42Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015)
"Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease."5.42Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015)
" However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor."5.41Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice ( Chen, F; Chen, SL; Gao, DS; Gao, XF; Ge, Z; Han, YL; He, YQ; Kan, J; Kong, XQ; Li, F; Lin, S; Liu, ZZ; Qian, XS; Qu, H; Shao, YB; Tao, L; Tian, NL; Wang, Y; Wang, ZZ; Wen, SY; Xia, Y; Xiao, PX; Yang, Q; Yang, S; Ye, F; Zeng, HS; Zhang, JJ; Zuo, GF, 2021)
"In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective."5.40Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014)
"Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial."5.38Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012)
"Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy."5.34Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020)
" Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding."5.34Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007)
" However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation."5.34Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."5.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor."5.24Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."5.24Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS)."5.24Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V, 2017)
"The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death."5.24Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017)
" Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications."5.24Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017)
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents."5.246- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017)
" However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment."5.24Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. ( Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D, 2017)
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."5.24Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication."5.24The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017)
"In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events."5.24Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017)
"Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis."5.24The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017)
"Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke."5.22Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."5.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post hoc analysis of the PRASugrel compared with clopidogrel For Japanese patIenTs with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (PRASFIT-ACS) study."5.22Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H, 2016)
"The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel."5.22Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016)
"The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours."5.22Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016)
"Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel."5.22Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016)
"Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use."5.22Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016)
" In contrast to overall PLATO results, but similar to PLATO-US cohort, PHILO revealed numerical inferiority of ticagrelor with regard to death, myocardial infarction, stroke, and bleeding over clopidogrel."5.22Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? ( Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A, 2016)
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation."5.226-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."5.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"Despite broad differences in clinical profiles and indications for percutaneous coronary intervention by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end points compared with clopidogrel without an excess in severe bleeding in both the US and non-US subgroups."5.22Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD, 2016)
"Eighty-three acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with planned GPI use were randomized to receive high-dose bolus tirofiban, double-bolus eptifibatide, or abciximab followed by a 12-hour infusion."5.22A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. ( French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S, 2016)
"Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate."5.22Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)
"Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone."5.22Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."5.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization."5.22A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016)
"PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding."5.20Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015)
"We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled."5.20High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015)
"MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel."5.20MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015)
"Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders."5.206- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015)
"This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events."5.20Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015)
" In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis."5.20Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015)
"The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin."5.20Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015)
"Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines."5.20Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. ( Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S, 2015)
"In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding."5.20Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015)
"Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist."5.20Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015)
" In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients."5.20Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015)
" Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)."5.20Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015)
"1% of the patients received polypharmacy and clopidogrel, respectively, which can increase the risk of drug-drug interactions and bleeding."5.19Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. ( Guidoni, CM; Obreli-Neto, PR; Pereira, LR, 2014)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
" clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization."5.19Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014)
"In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding."5.19Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014)
"In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14."5.19An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014)
"The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)."5.19Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014)
"This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)."5.19Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014)
"Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding."5.19Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."5.19Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
"We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism."5.19Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014)
"If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding."5.17Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. ( Adriaenssens, T; De Smet, BJ; Dewilde, WJ; Heestermans, AA; Herrman, JP; Kelder, JC; Oirbans, T; ten Berg, JM; Tijsen, JG; van 't Hof, AW; Verheugt, FW; Vis, MM; Vrolix, M, 2013)
" Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only."5.17Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013)
"Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding."5.17Effect of platelet inhibition with cangrelor during PCI on ischemic events. ( Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P, 2013)
"High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes."5.17Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013)
"Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage."5.17Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013)
"A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months."5.17Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013)
" Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents."5.17Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013)
"On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel."5.17Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013)
"Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity."5.16Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012)
"The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding."5.16Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012)
"A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)."5.16Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012)
"In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common."5.16A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012)
"Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death."5.16Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012)
"The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age."5.16Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012)
" Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks."5.16Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)
"Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes."5.15Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011)
"In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)."5.15Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011)
" We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation."5.15Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011)
"Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin."5.15Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)
"Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography."5.15Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011)
" We explored the relationship between GFR and angiographic and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients receiving pharamacologic reperfusion, with or without clopidogrel."5.15Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. ( Ahmed, S; Cannon, CP; Michael Gibson, C; Murphy, SA; Sabatine, MS, 2011)
"Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard-dose clopidogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis."5.15Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. ( Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."5.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
" As the indications for clopidogrel expand, an increasing number of patients undergoing off-pump coronary artery bypass surgery (OPCAB) are also undergoing dual antiplatelet therapy (DAPT), with its higher risk of bleeding complications."5.15Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. ( Ahn, SW; Kwak, YL; Lee, JS; Shim, JK; Song, JW; Yoo, KJ, 2011)
"Clopidogrel (Plavix®) therapy, although effective for minimizing risk of thrombotic events, is also associated with potential bleeding risk."5.15Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. ( Carr, ME; Gabriel, D; Khutoryansky, NM; Pusateri, AE; Shenouda, M; Skolnick, BE, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."5.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance."5.14Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009)
"Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI."5.14Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009)
"This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications."5.14The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009)
"Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel."5.14Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."5.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
" Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding."5.14Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."5.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding."5.14Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009)
"Cangrelor, when administered intravenously 30 minutes before PCI and continued for 2 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours."5.14Platelet inhibition with cangrelor in patients undergoing PCI. ( Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD, 2009)
"Clopidogrel therapy may be more effective in current smokers, but it may also confer a greater bleeding risk than in nonsmokers."5.14Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. ( Berger, JS; Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Lincoff, AM; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009)
"We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)."5.14Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."5.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
" The baseline corrected bleeding times were not significantly different between the ticlopidine-alone and ticlopidine/ Ginkgo biloba groups, and changes in platelet aggregation were not significantly different between the groups."5.14Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. ( Cho, JY; Jang, IJ; Kim, BH; Kim, JR; Kim, KP; Lee, KH; Lee, YO; Lim, KS; Shin, SG; Yoon, SH; Yu, KS, 2010)
"In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel."5.14Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010)
"In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)."5.14Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010)
" In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5."5.14Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010)
"ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events."5.14Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010)
"In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding."5.14Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010)
"In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke."5.14Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)
"We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation."5.14Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. ( Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S, 2010)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."5.14Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
" The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound."5.14Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010)
"In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention."5.13Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."5.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding."5.13Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008)
"Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)."5.13Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)
"This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding."5.13Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."5.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk."5.13Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008)
"We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel."5.13Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008)
"Clopidogrel in mild or moderate CKD patients may not have the same beneficial effect as it does in patients with normal renal function, but was not associated with a greater relative risk of bleeding based on renal function."5.13The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008)
"Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding."5.13Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008)
" Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes."5.12Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006)
"Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding."5.12Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. ( Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW, 2007)
"The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction."5.12Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007)
" The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes."5.12Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007)
"Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)."5.12Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007)
"Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention."5.12Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007)
"In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke."5.11Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004)
"In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications."5.11Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005)
"In this phase 2 study, which was designed to assess safety when administered at the time of percutaneous coronary intervention, prasugrel and clopidogrel both resulted in low rates of bleeding."5.11Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. ( Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD, 2005)
"To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy."5.11A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005)
"We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)."5.10Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003)
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."5.09Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)
"Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8."5.09Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."5.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)."5.08Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995)
"These results suggest that poststenting treatment by ticlopidine/aspirin is an effective alternative to coumadin anticoagulation, achieving low rates of subacute closure and bleeding complications."5.08Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. ( Aubry, P; Benveniste, E; Bunouf, P; Cattan, S; Chevalier, B; Commeau, P; Cribier, A; Eiferman, C; Grollier, G; Guerin, Y; Henry, M; Karrillon, GJ; Lefevre, T; Livarek, B; Louvard, Y; Makowski, S; Marco, J; Monassier, JP; Morice, MC; Pernes, JM; Rioux, P; Spaulding, C; Zemour, G, 1996)
"As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone."5.08A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998)
"For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding."4.98Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018)
"The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel."4.95Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017)
" With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2."4.95The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017)
"Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding."4.95Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017)
" The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events."4.95The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017)
"The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and minor bleeding compared with aspirin alone."4.95Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. ( Bellesini, M; Donadini, MP; Middeldorp, S; Squizzato, A; Takeda, A, 2017)
"Despite the demonstrated benefits of Prasugrel, a new generation thienopyridine, in the prevention of thrombotic complications after percutaneous coronary interventions (PCI) for Acute Coronary Syndromes (ACS), its use is still precluded to those many patients arriving to the cath lab pre-treated with Clopidogrel."4.93Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. ( Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M, 2016)
" We sought to determine the effect of switching from clopidogrel to a novel P2Y12 receptor inhibitor on the occurrence of major adverse cardiovascular events (MACE) and bleeding."4.93The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. ( Chandrasekhar, J; Froeschl, M; Hibbert, B; May, ML; Mehran, R; So, D, 2016)
"High on-clopidogrel platelet reactivity (HcPR) during dual-antiplatelet therapy is a marker of vascular risk, in particular stent thrombosis, in patients with acute coronary syndromes (ACS)."4.93On-treatment platelet reactivity: State of the art and perspectives. ( Giusti, B; Grifoni, E; Marcucci, R, 2016)
"Switching from clopidogrel to prasugrel does not increase bleeding complications during follow-up of patients undergoing percutaneous coronary intervention; however, the strength of the data is not sufficient to make definitive clinical recommendations."4.93Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. ( Cavallari, I; De Luca, L; Patti, G; Ricottini, E, 2016)
"Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack."4.93Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016)
"Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation."4.93[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation]. ( Du, M; Ma, G; Shi, Y; Zhang, D, 2016)
" The secondary outcome was bleeding events and resistance to the effects of clopidogrel."4.93Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. ( Wang, CH; Wang, YQ; Zhang, JH, 2016)
"Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically."4.93Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016)
"Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events."4.91Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015)
"Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients."4.91Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015)
"The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding."4.91Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015)
"Ticagrelor is recommended in local and international guidelines as first-line therapy in combination with aspirin in patients presenting with acute coronary syndromes (ACS)."4.91Practical experience with ticagrelor: an Australian and New Zealand perspective. ( Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ, 2015)
"Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin."4.91Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015)
" A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0."4.91Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015)
" However, prasugrel and ticagrelor have a more consistent, faster-acting and more potent antiplatelet effect than clopidogrel, which translates into improved clinical outcomes, although at the expense of an increased bleeding risk."4.91Antiplatelet therapy in acute coronary syndromes. ( Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M, 2015)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."4.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
"New P2Y12 inhibitors decreased death in patients undergoing PCI compared with clopidogrel with a considerable safety and tolerability profile; however, the risk/benefit ratio of ischemic and bleeding events should be further investigated."4.91Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. ( Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015)
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."4.91[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."4.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"The two new drugs prasugrel and ticagrelor were included in the current guidelines for the treatment of patients with acute coronary syndrome."4.90[Dual platelet inhibitors in intensive care units]. ( Delle Karth, G; Siller-Matula, JM, 2014)
"Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications."4.90Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014)
" In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis."4.90Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014)
"In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding."4.90Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014)
"Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel."4.90Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014)
" In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin."4.90[Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014)
"Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke."4.89The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013)
" As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors."4.89Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013)
" The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0."4.89Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013)
" The thienopyridines are an integral part of antithrombotic therapy and are prescribed for various indications including acute coronary syndrome, peripheral vascular disease and cerebrovascular disease."4.89Metabolic differences of current thienopyridine antiplatelet agents. ( Fareed, J; Jeske, W; Thethi, I, 2013)
"To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies."4.88Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012)
"Contrary to the findings of post hoc analyses of randomized trials, observational studies showed that recent exposure to clopidogrel before coronary artery bypass grafting is associated with increased risk of postoperative death, reoperations for bleeding, blood loss, and need of blood transfusions."4.88Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. ( Airaksinen, KE; Biancari, F; Lip, GY, 2012)
"Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well."4.88The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012)
"Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events."4.88Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012)
" New platelet inhibitors prasugrel and ticagrelor are more effective than the traditional clopidogrel, but their use is also accompanied by more frequent bleeding complications."4.88[New antithrombotic drugs]. ( Mustonen, P; Puurunen, M, 2012)
"P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization."4.88Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012)
" Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1."4.88Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. ( Benavente, OR; Hart, RG; Palacio, S; Pearce, LA, 2012)
"Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel."4.88Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012)
"Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems."4.88Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012)
"To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI."4.88Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012)
"Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding."4.87Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM, 2011)
"Clinicians will be able to understand the safety profile of using different doses of clopidogrel and the incidence of bleeding when used alone or in combination with other antiplatelet agents."4.87The safety of clopidogrel. ( Kleiman, NS; Mangalpally, KK, 2011)
" The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality."4.87Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011)
"Literature was accessed through MEDLINE (1966-October 2010 week 1), EMBASE (1980-2010 week 40), and a bibliographic review of published articles using the search terms acute coronary syndrome, clopidogrel, and prasugrel."4.87Thienopyridines in Acute Coronary Syndrome. ( Desilets, AR; Goodwin, MM; Willett, KC, 2011)
" The benefits in mortality and reinfarction were driven by the treatment with prasugrel or ticagrelor, without a significant difference in terms of major bleeding complications as compared to standard-dose clopidogrel (5% vs."4.87Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. ( Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M, 2011)
"Prasugrel's clinical benefits were counterbalanced by an increase in bleeding risk compared with conventional thienopyridine treatment with clopidogrel."4.87Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. ( Martin, MT; Nutescu, EA; Spinler, SA, 2011)
"Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y(12) inhibitor, for 6?12 months after percutaneous coronary intervention with drug-eluting stent implantation in all patients and for 1 year in all patients after an acute coronary syndrome (ACS), irrespective of revascularization strategy."4.87Antiplatelet options for secondary prevention in acute coronary syndromes. ( Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J, 2011)
"Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included."4.87CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. ( Casas, JP; Hingorani, AD; Holmes, MV; Perel, P; Shah, T, 2011)
" Aspirin and, more recently, clopidogrel are among the most important treatments of cardiovascular diseases."4.86[Long-term use of oral antiplatelet therapy: from studies to practice]. ( Helft, G, 2010)
"Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)."4.86Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. ( Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010)
" Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy."4.86Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010)
" Recent phase III data demonstrate that prasugrel is superior to clopidogrel in preventing cardiovascular morbidity and mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention, although with a greater risk of bleeding."4.86Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. ( Armani, AM, 2010)
"Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine."4.85Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009)
" Administration of antiplatelet therapy--a glycoprotein IIb-IIIa inhibitor with or without clopidogrel--before catheterization in patients with high-risk features confers substantially reduced risk of ischemic events while potentially increasing bleeding risk."4.85Does timing matter? Upstream or downstream administration of antiplatelet therapy. ( Pollack, CV; Slattery, D, 2009)
" The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial demonstrated a similar ischemic event rate to 30 days with a significantly lower bleeding event rate (enhanced net clinical benefit) in favor of bivalirudin monotherapy (with provisional platelet glycoprotein [GP] IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP IIb/IIIa blockade in patients undergoing primary PCI for STEMI."4.85Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. ( Kereiakes, DJ, 2009)
"Earlier studies may have overestimated the risk of bleeding in patient undergoing CABG with prior clopidogrel exposure (5-10-fold increase)."4.85Coronary bypass surgery in patients treated with clopidogrel. Is it safe? ( Carrel, T; Englberger, L, 2009)
"Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention."4.85Prasugrel: Clinical development and therapeutic application. ( Guerra, DR; Tcheng, JE, 2009)
" In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk."4.84Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008)
"To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease."4.84Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007)
"Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials."4.84Clopidogrel: who, when, and how? ( Cannon, CP, 2007)
" We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks."4.84Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008)
"Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis."4.84Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. ( Gawaz, M; Geisler, T; May, AE, 2008)
"To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin."4.84Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008)
"Prasugrel has demonstrated a greater platelet inhibition and a decreased incidence of ischemic events compared with clopidogrel, but with an increased incidence of bleeding events."4.84Prasugrel: a novel antiplatelet agent. ( Haber, SL; Riley, AB; Tafreshi, MJ, 2008)
"The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published."4.83MATCH results: implications for the internist. ( Lutsep, HL, 2006)
" Addition of aspirin and clopidogrel to patients already on warfarin increases the risk of bleeding, while withholding antiplatelet therapy increases the risk of stent thrombosis."4.82Antiplatelet therapy in anticoagulated patients requiring coronary intervention. ( Arab, D; Cho, L; Joyal, D; Lewis, B; Leya, F; Steen, L, 2005)
" The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events."4.80Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999)
"Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)."4.31miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023)
"Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack."4.12Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022)
"To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel."4.12P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment. ( Fujii, S; Fujita, K; Hirai, S; Ishikawa, M; Karakama, J; Miki, K; Nemoto, S; Sumita, K; Yamaoka, H; Yoshimura, M, 2022)
"Enhanced platelet inhibition delivered by clopidogrel is associated with an increased risk for major bleeding and death in patients on OAC who undergo PCI."3.91Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. ( Bernlochner, I; Fiedler, KA; Goedel, A; Hoppmann, P; Kastrati, A; Laugwitz, KL; Maeng, M; Massberg, S; Mayer, K; Mehilli, J; Sarafoff, N; Schunkert, H; Schüpke, S; Sibbing, D; von Olshausen, G, 2019)
"Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel."3.88Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018)
"The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China."3.88Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018)
"Bleeding is one of the possible adverse events during clopidogrel therapy."3.88Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018)
"Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent."3.88Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018)
" Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk."3.88Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018)
" Prasugrel was associated with fewer MACE, whereas clopidogrel had fewer major bleeding events."3.85Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. ( Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K, 2017)
"We studied 671 myocardial infarction (MI) patients treated with percutaneous coronary intervention in the TRANSLATE-ACS Registry who had VerifyNow platelet function testing performed while on clopidogrel treatment during their index hospitalization (April 2010-October 2012)."3.85Association of measured platelet reactivity with changes in P2Y ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME, 2017)
"Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited."3.85Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2017)
"Results of the current study showed that CYP4F2 rs3093135 TT variant carriers had a higher antiplatelet effect of ticagrelor, and more frequently had nonprocedural bleeding during ticagrelor therapy, as compared with AA and AT variant carriers."3.85The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. ( Giedraitiene, A; Kupstyte, N; Lesauskaite, V; Tatarunas, V; Zaliunas, R, 2017)
" Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel."3.85Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. ( Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R, 2017)
"Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively."3.85CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. ( Borse, MS; Dong, OM; Farley, JF; Lee, CR; Polasek, MJ; Stouffer, GA, 2017)
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES."3.85Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017)
" However, the risk of rebleeding remains high, especially in patients with chronic ICH and those pretreated with clopidogrel."3.85Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage. ( Baschin, M; Greinacher, A; Kohlmann, T; Schroeder, HW; Selleng, S; Thiele, T; Westphal, A; Zeden, JP, 2017)
"The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR."3.85Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017)
" Commonly used medications such as warfarin, heparin, aspirin, clopidogrel, and Opalmon (limaprost alfadex) were included as medications associated with bleeding tendency."3.85Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection. ( Lee, JH; Park, TK; Shin, SJ, 2017)
"CYP2C19 genetic polymorphisms had significant influence on the antiplatelet effect of clopidogrel, and could be considered as risk factors of ischemic or bleeding events and even clinical outcomes of patients with intracranial aneurysms treated with stent-assisted coiling."3.85Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling. ( Ge, H; He, H; Jiang, Y; Jin, H; Li, Y; Liu, P; Lv, X; Ren, H, 2017)
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding."3.85Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017)
"Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)."3.85Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017)
"To report incidence of bleeding after image-guided percutaneous core needle biopsy performed in patients taking clopidogrel within 5 days."3.85Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review. ( Atwell, T; Knudsen, J; McBane, R; McMenomy, B; Pieper, M; Schmitz, J; Wennberg, P, 2017)
"The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear."3.85Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."3.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke."3.85Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017)
" DPP-4 inhibitor-related bleeding was assessed with metformin as negative control, and aspirin, clopidogrel, and prasugrel illustrated positive comparators."3.85Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. ( Hansen, RA; Rahman, MM; Scalese, MJ, 2017)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."3.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
" Compared to patients treated with aspirin+clopidogrel, patients treated with aspirin+prasugrel had fewer BARC 3 or 5 bleedings (two [0."3.83Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). ( Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J, 2016)
"The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel."3.83Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016)
" Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events."3.83Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016)
"Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)."3.83Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016)
"Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period."3.83Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016)
"Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported."3.83Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."3.83Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
"To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel."3.83One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016)
"To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease."3.83[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016)
" However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2."3.83Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016)
"The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events."3.83A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016)
"Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism."3.83Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016)
" The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding."3.83Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016)
"This study explores bleeding risk of warfarin patients undergoing radial catheterization."3.81Warfarin: Impact on hemostasis after radial catheterization. ( Gilchrist, IC; Kunselman, AR; Lippe, CM; Reineck, EA, 2015)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."3.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"We hypothesized that perioperative measurement of platelet function with a point-of-care P2Y12 inhibitor assay could predict bleeding during CABG in patients exposed to clopidogrel."3.81Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. ( Agnihotri, A; Aranki, S; Cannon, CP; Guo, J; Kumar, A; Maree, AO; McLean, DS; Reed, GW; Rosenfield, K; Shekar, P, 2015)
"There is a known bleeding risk with administration of the antiplatelet drug clopidogrel, but in certain patients the likelihood of thrombosis is too high to cease its administration perioperatively."3.81Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series. ( Bono, J; Nandi, S; Shubert, D, 2015)
"This study is the first to analyze differences in bleeding times between clopidogrel and prasugrel treatments during dental extraction."3.81Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy. ( Braunitzer, G; Dézsi, BB; Dézsi, CA; Hangyási, DB; Koritsánszky, L, 2015)
"This observational, nonrandomized study of ST-segment elevation myocardial infarction patients suggests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not associated with an excess of major bleeding events."3.81Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. ( Auer, R; Baumbach, A; Carballo, D; Engstrøm, T; Gencer, B; Heg, D; Jüni, P; Kelbæk, H; Klingenberg, R; Lüscher, TF; Mach, F; Matter, CM; Meier, B; Moschovitis, A; Ostojic, M; Räber, L; Rodondi, N; Roffi, M; Stefanini, GG; Tüller, D; von Birgelen, C; Windecker, S; Zanchin, T, 2015)
"Patients on prasugrel had fewer cardiovascular events as compared to patients on clopidogrel twice daily with no difference in bleeding events."3.81Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. ( Khatri, S; Pierce, T, 2015)
"Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)."3.81[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015)
"Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding."3.81Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015)
"This ecological comparison of bleeding reports and dispensed prescriptions showed a signal towards a higher prevalence of bleeding reports in women on clopidogrel treatment while the opposite was found for low-dose aspirin."3.80Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. ( Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014)
" We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population."3.80Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014)
" However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding."3.80Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014)
"Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction."3.80Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
"Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel."3.80Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014)
"In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routine care during the first 2 years following the approval of prasugrel."3.80Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. ( Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G, 2014)
"We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months."3.80Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)
" We applied this method in examining the effect of an antiplatelet agent, clopidogrel, on events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted in coronary artery."3.80Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment. ( Ho, PM; Magid, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2014)
"The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available."3.80Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014)
" Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk."3.80Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. ( Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO, 2014)
"The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats."3.80Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014)
"To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel."3.80Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014)
"The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)."3.80Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014)
" Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later."3.79Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013)
"Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)."3.79[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013)
" The aim of this study was to ascertain whether it is necessary to stop clopidogrel preoperatively to avoid postoperative complications following hip hemiarthroplasty surgery in patients with intracapsular hip fracture."3.79Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. ( Hossain, FS; Koch, L; Rambani, R; Ribee, H, 2013)
" Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown."3.79Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013)
" This study sought to determine if trauma patients on preinjury clopidogrel with a higher degree of platelet inhibition (PI), as determined by the VerifyNow P2Y12 Test, experienced bleeding complications more frequently than did patients with a lower degree of PI."3.79Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. ( Ali, K; Cheng, J; Kram, B; Short, S; Taylor, S; Vasquez, D, 2013)
" We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)."3.79Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."3.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation."3.79The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013)
"The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0."3.79Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013)
"Clopidogrel is safer than ticagrelor in regard to bleeding."3.79Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. ( Biondi-Zoccai, G; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Niazi, AK; Tomek, A, 2013)
"Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD."3.79Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013)
"The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel."3.79Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013)
"Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions."3.79The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. ( Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S, 2013)
"The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications."3.79Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013)
" the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days."3.78Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012)
" Phenotyping of platelet response to clopidogrel was a better predictor of stent thrombosis than genotyping."3.78Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. ( Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM, 2012)
" We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery."3.78Extension of Kaplan-Meier methods in observational studies with time-varying treatment. ( Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2012)
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel."3.78Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012)
"Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding."3.78Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012)
" This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery."3.78Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012)
"Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype."3.78Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. ( Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES, 2012)
" The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine."3.78Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012)
"Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months."3.78Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. ( Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M, 2012)
"To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel."3.78Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012)
"Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge."3.78Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."3.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
"On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes."3.78Ticagrelor FDA approval issues revisited. ( Serebruany, VL, 2012)
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years."3.78[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012)
", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma."3.78Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)
" Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel."3.78Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012)
"The aim of this study was to evaluate the prevalence of triple antithrombotic therapy (TT) (warfarin, aspirin and clopidogrel) in patients following an acute coronary syndrome (ACS), the bleeding risk compared to double antiplatelet therapy (DAPT) (aspirin and clopidogrel) and evaluate the accuracy of the HAS-BLED risk score in predicting serious bleeding events in TT patients."3.78Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. ( Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M, 2012)
" Clopidogrel (a compound that inhibits adenosine diphosphate-induced platelet aggregation) is often prescribed for primary or secondary prevention of cardiovascular disease and has been associated with bleeding complications in patients undergoing surgical procedures."3.78Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis. ( Bechara, RI; Berkowitz, DM; Parks, C; Zalt, MB, 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"Our results show that renal failure history and clopidogrel and GPIIb/IIIa receptor antagonist use are independent risk factors for in-hospital bleeding in patients with acute coronary syndrome."3.78[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization]. ( Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT, 2012)
"Coronary artery bypass grafting (CABG) performed within 5 days of clopidogrel administration is associated with increased bleeding."3.77Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. ( Cruden, NL; Hilton, JD; Klinke, WP; Morch, K; Ofiesh, J; Wong, DR, 2011)
"The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)."3.77Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011)
"We do not routinely discontinue clopidogrel before colonoscopy because we have judged the cardiovascular risks of that practice to exceed the risks of post-polypectomy bleeding (PPB)."3.77The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. ( Davila, RE; Feagins, LA; Harford, WV; Spechler, SJ; Uddin, FS, 2011)
" Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj."3.77Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011)
"Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes, these benefits are less well established among patients undergoing elective PCI--in particular, when they are treated with the direct thrombin inhibitor, bivalirudin."3.77Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). ( Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN, 2011)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."3.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)."3.77Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011)
" We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage."3.77Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011)
"Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis."3.77Clopidogrel (plavix). ( Comin, J; Kallmes, D, 2011)
"To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel."3.76Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010)
"The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI."3.76Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
"In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding."3.76Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."3.76Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
" This study sought to evaluate procedural major bleeding and myocardial infarction in patients undergoing stent implantation with adjunctive clopidogrel compared with ticlopidine."3.76Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. ( Hayashi, F; Iijima, R; Nakamura, M; Sugi, K, 2010)
"Higher clopidogrel use 12 months after drug-eluting stent implantation was associated with a greater risk of subsequent bleeding events."3.76Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. ( Anstrom, KJ; Barron, JJ; Califf, RM; Curtis, LH; Cziraky, MJ; Eisenstein, EL; Hammill, BG; Krucoff, MW; Petersen, JL; Schulman, KA; Wahl, PM, 2010)
"Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain."3.76Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010)
"Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention."3.76Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010)
"Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding."3.76Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."3.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications."3.76Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)
"Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern."3.76National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)
" Our algorithm, which is in the process of being implemented, is consistent with published and generally accepted standards of care and is based on data from the pivotal Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which compared clopidogrel with prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention."3.76An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. ( Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F, 2010)
"Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)."3.75Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009)
"The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding."3.75Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009)
" Clopidogrel (Plavix), a selective P(2)Y(12) antagonist, prevents platelets from clotting but thereby increases the risk of severe or fatal bleeding."3.75Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ( Andrésson, T; Bjarnadottir, M; Bjornsson, JM; Fabre, JE; Gurney, ME; Hategen, G; Kiselyov, A; Magnusson, O; Mishra, R; Onua, E; Polozov, A; Ramírez, JL; Sigthorsson, G; Singh, J; Stefansson, K; Thorsteinsdottir, M; Yu, P; Zeller, W; Zembower, D; Zhang, J; Zhou, N, 2009)
"(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months."3.75Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009)
"Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events."3.75Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. ( Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T, 2009)
"Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction."3.75Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009)
" 2 patients who were treated with concomitant warfarin had bleeding complications (severe epistaxis and gastrointestinal bleeding)."3.74Safety and efficacy of clopidogrel in children with heart disease. ( Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)
"The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period."3.74Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008)
"The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)."3.74Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008)
"In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding."3.74Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."3.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
" Bleeding caused by some combination of nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2-selective NSAIDS, aspirin, and clopidogrel was the most common reason for ADR-related MICU admissions."3.74Admissions to a medical intensive care unit related to adverse drug reactions. ( Rivkin, A, 2007)
" Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated."3.74A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. ( Badimon, L; Casaní, L; Vilahur, G, 2007)
"To determine the risk of major and minor bleeding associated with the CTT compared with two other regimens using the combination of either ASA and clopidogrel or ASA and warfarin in patients with cardiovascular disease."3.74Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. ( Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007)
"We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)."3.74Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008)
"The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors."3.74What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008)
"In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days."3.74Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008)
" The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel."3.73A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005)
"Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs."3.73Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005)
"We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin."3.73Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005)
" Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown."3.73Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006)
" Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy."3.73Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006)
"Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI."3.73[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006)
"We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)."3.73Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006)
"We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period."3.72Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004)
"Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel."3.71Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001)
" A significant increase in postoperative hemorrhage and a higher percentage of reoperations for this reason was observed in the patients treated with ticlopidine."3.67Ticlopidine as a hemorrhagic risk factor in coronary surgery. ( Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C, 1985)
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."2.84SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)
"Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events."2.84Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017)
"Major bleeding is associated with high subsequent mortality in ACS."2.80Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. ( Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2015)
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."2.79Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI."2.79Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)
" The prevalence of adverse events was assessed at each visit through a direct interview."2.78Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)
"Major bleeding was strongly associated with 30-day mortality (OR 50."2.76Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. ( Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E, 2011)
"Serious bleeding was associated with a significantly increased adjusted hazard ratio of 5."2.76Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- ( Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD, 2011)
"Fatal bleeding was low and did not differ between groups."2.76Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011)
" Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel."2.75High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. ( Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)
" Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0."2.75[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010)
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."2.69A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)
"Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events."2.68A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996)
"Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards."2.53A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. ( Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC, 2016)
"Major bleeding was the primary end point, whereas all-cause death, myocardial infarction (MI), stent thrombosis, and stroke were secondary ones."2.52Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. ( Ballocca, F; Bangalore, S; Barbero, U; Capodanno, D; Cerrato, E; Conrotto, F; D'Ascenzo, F; Dewilde, W; DiNicolantonio, J; Fernández, S; Gaita, F; Giordana, F; Grossomarra, W; Lamberts, M; Meier, P; Meynet, I; Moretti, C; Omedè, P; Persson, J; Quadri, G; Reed, M; Rubboli, A; Taha, S; Zoccai, G, 2015)
" Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities."2.52Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."2.50Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
" Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions."2.50Efficacy and safety of prasugrel in acute coronary syndrome patients. ( Delzor, F; Nanau, RM; Neuman, MG, 2014)
" Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie."2.49[Thrombocyte aggregation inhibitors: what are the risks?]. ( Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013)
" A "one size fits all" approach to clopidogrel dosing is probably flawed."2.49Clopidogrel "resistance": where are we now? ( Hobson, AR; Qureshi, Z, 2013)
" The comparator was standard dosage of clopidogrel."2.49Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. ( Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013)
" Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate."2.48Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. ( Davies, JE; Francis, DP; Nijjer, SS, 2012)
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."2.48Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012)
" Therefore the optimal dosage and duration of clopidogrel therapy is of utmost importance."2.48Clinical use of clopidogrel. ( Byrne, RA; Sarafoff, N; Sibbing, D, 2012)
" The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)."2.47Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. ( Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011)
"Cangrelor is an intravenous direct and reversible inhibitor of the P2Y(12) receptor providing the highest level of inhibition and elinogrel is an intravenous and oral P2Y(12) antagonist with a direct and reversible action."2.47[Myocardial infarction: Role of new antiplatelet agents]. ( Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J, 2011)
"Bleeding is potentially the most significant antiplatelet-associated side effect."2.47Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011)
" Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1."2.47Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011)
"Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile."2.46What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. ( Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ, 2010)
"Tirofiban is safe and effective in patients with ACS."2.46Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010)
" We conclude that the benefits of prasugrel are overestimated, and the risks, especially during chronic use are underestimated."2.45Prasugrel development - claims and achievements. ( Kopyleva, O; Serebruany, V; Shalito, I, 2009)
"Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone."2.45Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009)
" For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important."2.45Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009)
"Despite many recent advancements in the treatment of coronary heart disease, it continues to be an important source of patient morbidity and mortality as well as a significant source of healthcare-related expenditures."2.44The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. ( Collins, JS; Gurm, HS, 2007)
"Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience."2.42Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004)
"Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy."2.40Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997)
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."1.51The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)
"To describe and evaluate the bleeding-related adverse events associated with use of P2Y12 inhibitors utilizing data from the FDA Adverse Event Reporting System (FAERS) database."1.51Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. ( Abou-Ali, A; Fahmy, AI; Mekkawy, MA, 2019)
"to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials."1.51Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019)
"Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit."1.46Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2017)
"Bleeding was the primary outcome."1.46Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017)
"The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear."1.46Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). ( Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC, 2017)
"All hematomas were without clinical consequences."1.43Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy. ( Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P, 2016)
"Immunological TRALI was tested in mice exhibiting severe thrombocytopenia or platelet dysfunction."1.43Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. ( de la Salle, H; El Mdawar, MB; Gachet, C; Hechler, B; Heim, V; Magnenat, S; Maître, B, 2016)
"There was no major adverse cardiac event (MACE) and pouch infection were observed among 3 groups in perioperation."1.43[Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy]. ( Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L, 2016)
"The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage."1.43[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016)
"7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs."1.42Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015)
"Major bleeding was a significant correlate of DAPT ANA within 6 months."1.42Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015)
"Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease."1.42Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015)
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA."1.40Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014)
"Furthermore, using a carotid artery thrombosis model, these agents prolonged the time for thrombotic occlusion in mice in vivo."1.40The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. ( Espinosa, EV; Karim, ZA; Khasawneh, FT; Lin, OA; Vemana, HP, 2014)
"Bleeding was assessed using the Bleeding Academic Research Consortium criteria."1.40Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014)
"In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective."1.40Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014)
" The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI."1.40A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. ( Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG, 2014)
"Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control."1.39Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013)
"Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions."1.38Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012)
"We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0."1.38Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012)
"Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial."1.38Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012)
"An increasing proportion of trauma patients are on anticoagulation or antiplatelet therapy."1.37A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients. ( Bansal, V; Coimbra, R; Doucet, J; Fortlage, D; Lee, J; Potenza, B, 2011)
"Coronary artery disease was associated with increased risk (OR=11."1.36Femoral artery complications after cardiac catheterization: a study of patient profile. ( Almaroof, B; Castillo-Sang, M; Cireddu, J; Engoren, M; Kasper, G; Sferra, J; Tsang, AW; Zelenock, GB, 2010)
"Thrombosis is still the first cause of microsurgery failure."1.36[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. ( Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P, 2010)
"Nuisance bleeding is common in patients on prolonged DAPT post-DES implantation and can impact compliance."1.36Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. ( Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2010)
"Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information."1.36Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010)
"We report on a severely injured trauma patient who suffered a high velocity motorcycle accident."1.36High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. ( Hanke, A; Posch, A; Schöchl, H; Solomon, C; Voelckel, W, 2010)
"Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial."1.36Emerging oral antiplatelet therapies for acute coronary syndromes. ( Pollack, CV, 2010)
" The long-term use of antiplatelet agents is a key component of secondary prevention measures following acute coronary syndromes, including ST-segment elevation myocardial infarction."1.36Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. ( Minarelli, M; Valgimigli, M, 2010)
"Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome."1.35Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. ( Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D, 2009)
"Non-ST-elevation acute coronary syndrome is associated with significant morbidity and mortality."1.35Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. ( Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW, 2009)
" Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding."1.34Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007)
" However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation."1.34Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007)
"Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1."1.32[Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003)
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk."1.31Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001)
"Hemorrhage was present in 9 cases of group B (21."1.30[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997)
"In 8 patients with liver cirrhosis who underwent hepatectomy, one patient with a prolonged T2 (260 secs) and a normal skin BT bled postoperatively, however, 3 patients with a prolonged skin BT (greater than 15 min) and a normal T2 had no hemorrhagic complications."1.27Clinical application of a new in vitro bleeding time device on surgical patients. ( Itoh, T; Kambayashi, J; Mori, T; Sakon, M; Tsujinaka, T; Uemura, Y, 1988)

Research

Studies (937)

TimeframeStudies, this research(%)All Research%
pre-19905 (0.53)18.7374
1990's20 (2.13)18.2507
2000's260 (27.75)29.6817
2010's636 (67.88)24.3611
2020's16 (1.71)2.80

Authors

AuthorsStudies
Lyu, SQ1
Zhu, J2
Wang, J2
Wu, S1
Zhang, H3
Shao, XH1
Yang, YM1
Schultz-Lebahn, A1
Nissen, PH1
Pedersen, TF1
Tang, M1
Hvas, AM1
Piccin Padilla, M1
Macedo, LSDN1
França, ACW1
Meirelles, I1
Magliano, CADS1
Santos, MDS1
Lee, YJ1
Cho, JY3
Yun, KH2
Lee, SJ1
Hong, SJ4
Ahn, CM3
Kim, BK4
Ko, YG3
Choi, D3
Hong, MK6
Jang, Y5
Kim, JS4
Wang, X7
Zhu, Q1
Wu, Y4
Li, H5
Deng, X1
Cheng, J2
Zhang, Z2
Ma, Y1
Shi, T1
Fujita, K1
Fujii, S1
Hirai, S1
Yamaoka, H1
Ishikawa, M1
Karakama, J1
Miki, K1
Yoshimura, M1
Nemoto, S1
Sumita, K1
Moustafa, B1
Testai, FD1
Liu, H4
Shao, T1
Yang, T1
Li, D1
Wang, H3
Cheng, Y1
Zhang, T1
Zhang, J3
Serebruany, VL15
Tanguay, JF5
Gurvich, ML1
Marciniak, TA1
Atar, D2
Mo, ZZ1
Yuan, Z1
Peng, YY1
Zhou, WL1
Dai, W1
Wang, G2
Tang, J1
Zhang, W1
Chen, BL1
Girotra, S1
Stebbins, A1
Wruck, L1
Marquis-Gravel, G1
Gupta, K1
Farrehi, P1
Benziger, CP1
Effron, MB7
Whittle, J1
Muñoz, D1
Kripalani, S1
Anderson, RD1
Jain, SK1
Polonsky, TS1
Ahmad, FS1
Roe, MT14
Rothman, RL1
Harrington, RA24
Hernandez, AF1
Jones, WS2
Lim, GB1
Tan, WK1
Watanabe, H1
Kimura, T8
Jimeno-Sánchez, J1
Fuertes-Ferre, G1
Ruiz-Aranjuelo, A1
Caballero-Jambrina, I1
Diarte-de Miguel, JA1
Ortas-Nadal, MR1
Chiarito, M1
Sanz-Sánchez, J1
Cannata, F1
Cao, D1
Sturla, M1
Panico, C1
Godino, C1
Regazzoli, D1
Reimers, B1
De Caterina, R3
Condorelli, G1
Ferrante, G2
Stefanini, GG3
Cho, YH1
Kim, YH5
Suh, Y1
Her, AY2
Cho, S2
Jeon, DW3
Yoo, SY2
Cho, DK2
Hong, BK1
Kwon, H1
Shin, DH2
Nam, CM1
Ferraris, VA2
Kim, GU1
Lee, S3
Choe, J1
Hwang, SW1
Park, SH2
Ye, BD1
Byeon, JS1
Myung, SJ1
Yang, SK1
Yang, DH1
Ge, Z1
Gao, XF1
Kan, J1
Kong, XQ1
Zuo, GF1
Ye, F1
Tian, NL1
Lin, S1
Liu, ZZ1
Shao, YB1
He, YQ1
Wen, SY1
Yang, Q1
Xia, Y1
Wang, ZZ1
Xiao, PX1
Li, F1
Zeng, HS1
Yang, S2
Wang, Y12
Tao, L1
Gao, DS1
Qu, H1
Qian, XS1
Han, YL4
Chen, F1
Zhang, JJ1
Chen, SL1
Ohman, EM12
Steg, PG34
James, SK13
Povsic, TJ2
White, J2
Rockhold, F1
Plotnikov, A1
Mundl, H1
Strony, J2
Sun, X2
Husted, S17
Tendera, M1
Montalescot, G33
Bahit, MC1
Ardissino, D6
Bueno, H2
Claeys, MJ3
Nicolau, JC3
Cornel, JH10
Goto, S3
Kiss, RG6
Güray, Ü1
Park, DW4
Bode, C3
Welsh, RC6
Gibson, CM16
Rubboli, A5
Saia, F5
Sciahbasi, A3
Leone, AM1
Palmieri, C2
Bacchi-Reggiani, ML2
Calabrò, P4
Bordoni, B1
Piccalò, G1
Franco, N1
Nicolino, A1
Magnavacchi, P2
Vignali, L1
Mameli, S1
Dallago, M1
Maggiolini, S1
Steffanon, L2
Piovaccari, G1
Di Pasquale, G2
De Luca, L3
D'Ascenzo, F5
Musumeci, G6
Parodi, G3
Varbella, F1
Marchese, A1
De Servi, S7
Berti, S1
Bolognese, L3
Zhai, Y1
He, H2
Ma, X1
Xie, J1
Meng, T1
Dong, Y1
Lu, J2
Alfredsson, J1
Neely, B4
Neely, ML4
Bhatt, DL39
Goodman, SG8
Tricoci, P4
Mahaffey, KW15
White, HD16
Fox, KA26
Prabhakaran, D7
Winters, KJ7
Armstrong, PW10
Melkonian, M1
Jarzebowski, W1
Pautas, E1
Siguret, V1
Belmin, J1
Lafuente-Lafuente, C1
Lindholm, D2
Hagström, E2
Becker, RC16
Cannon, CP23
Himmelmann, A9
Katus, HA7
Maurer, G3
López-Sendón, JL2
Storey, RF23
Siegbahn, A3
Wallentin, L20
Sukul, D1
Seth, M1
Dixon, SR1
Khandelwal, A1
LaLonde, TA1
Gurm, HS3
Rao, SV5
Qiao, M1
Bi, Q1
Fu, P1
Song, Z1
Guo, F1
Coons, JC1
Iasella, CJ1
Chanas, T1
Wang, N1
Williams, K1
Boyd, A1
Lyons, J1
Eckardt, J1
Rihtarchik, L1
Merkel, A1
Chambers, A1
Lemon, LS1
Smith, R1
Ensor, CR1
Oimatsu, Y1
Kaikita, K1
Ishii, M1
Mitsuse, T1
Ito, M1
Arima, Y1
Sueta, D1
Takahashi, A1
Iwashita, S1
Yamamoto, E1
Kojima, S1
Hokimoto, S1
Tsujita, K1
Bagai, A2
Peterson, ED10
McCoy, LA3
Zettler, ME2
Stone, GW23
Henry, TD9
Cohen, DJ11
Schulte, PJ4
Anstrom, KJ3
Wang, TY9
Ducrocq, G2
Budaj, A10
Held, C8
Lopes, RD8
Sorbets, E2
Jang, HJ1
Park, SD1
Park, HW1
Suh, J1
Oh, PC2
Moon, J1
Lee, K4
Kang, WC2
Kwon, SW1
Kim, TH2
Xanthopoulou, I7
Davlouros, P1
Deftereos, S3
Hamilos, M4
Sitafidis, G4
Kanakakis, I3
Vavouranakis, M3
Goudevenos, J4
Lekakis, J4
Alexopoulos, D8
Secemsky, EA1
Yeh, RW4
Kereiakes, DJ7
Cutlip, DE4
Massaro, JM2
Apruzzese, PK1
Mauri, L5
Pareek, M1
Ten Berg, JM10
Kristensen, SD4
Grove, EL3
Cuisset, T9
Deharo, P1
Quilici, J7
Johnson, TW1
Deffarges, S1
Bassez, C1
Bonnet, G1
Fourcade, L2
Mouret, JP2
Lambert, M4
Verdier, V1
Morange, PE6
Alessi, MC7
Bonnet, JL7
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K17
Halvorsen, S1
Van de Werf, F5
Rodés-Cabau, J4
Masson, JB1
Garcia Del Blanco, B1
Pelletier, M1
Webb, JG2
Al-Qoofi, F1
Généreux, P8
Maluenda, G3
Thoenes, M1
Paradis, JM1
Chamandi, C1
Serra, V1
Dumont, E1
Côté, M1
Choi, HI1
Ahn, JM3
Kang, SH3
Lee, PH1
Kang, SJ3
Lee, SW6
Lee, CW3
Park, SW3
Park, SJ4
Martin, AC2
Houssany-Pissot, S1
Zlotnik, D1
Taylor, G2
Godier, A3
Hansson, EC1
Jeppsson, A1
Tatarunas, V1
Kupstyte, N1
Zaliunas, R1
Giedraitiene, A1
Lesauskaite, V1
Piccolo, R3
Gargiulo, G3
Franzone, A3
Santucci, A3
Ariotti, S4
Baldo, A2
Tumscitz, C1
Moschovitis, A2
Windecker, S6
Valgimigli, M16
Sun, Q1
Chang, S1
Lu, S1
Zhang, Y5
Chang, Y1
Liu, Y4
Hao, Y1
Hao, Z1
Geng, G1
Han, W1
Chen, Q1
Wang, D4
Liu, L5
Jia, K1
Zhou, Y4
Huang, C1
Yan, H2
Zhu, W1
Xu, W1
Zhang, L6
Buhatem Medeiros, F1
Pepe Medeiros de Rezende, N1
Bertoldi Franco, J1
Porrio de Andrade, AC1
Timerman, L1
Gallottini, M1
Itagiba Neves, IL1
Ortega, KL1
Tscharre, M1
Egger, F2
Machata, M1
Rohla, M2
Michael, N1
Neumayr, M1
Zweiker, R1
Hajos, J1
Adlbrecht, C1
Suppan, M1
Helmreich, W1
Eber, B1
Weiss, TW2
Nakamura, M7
Iijima, R5
Ako, J1
Shinke, T1
Okada, H1
Ito, Y1
Ando, K1
Anzai, H1
Tanaka, H1
Ueda, Y1
Takiuchi, S1
Nishida, Y1
Ohira, H1
Kawaguchi, K1
Kadotani, M1
Niinuma, H1
Omiya, K1
Morita, T1
Zen, K1
Yasaka, Y1
Inoue, K1
Ishiwata, S1
Ochiai, M1
Hamasaki, T1
Yokoi, H5
Didier, R1
Morice, MC4
Barragan, P4
Noryani, AAL2
Noor, HA2
Majwal, T2
Hovasse, T2
Castellant, P3
Schneeberger, M2
Maillard, L2
Bressolette, E2
Wojcik, J2
Delarche, N3
Blanchard, D4
Jouve, B2
Ormezzano, O2
Paganelli, F5
Levy, G2
Sainsous, J2
Carrie, D5
Furber, A3
Berlan, J1
Darremont, O2
Le Breton, H3
Lyuycx-Bore, A2
Gommeaux, A2
Cassat, C2
Kermarrec, A2
Cazaux, P3
Druelles, P3
Dauphin, R2
Armengaud, J2
Dupouy, P3
Champagnac, D2
Ohlmann, P2
Ben Amer, H1
Ungi, I3
Gilard, M4
Gaussem, P2
Belleville-Rolland, T1
Helley, D1
Bachelot-Loza, C2
Yuan, C1
Zhong, L1
Huang, RC1
Park, KH2
Jeong, MH5
Kim, HK1
Ahn, TH2
Seung, KB4
Oh, DJ2
Choi, DJ4
Kim, HS11
Gwon, HC4
Seong, IW3
Hwang, KK3
Chae, SC2
Kim, KB2
Kim, YJ2
Cha, KS3
Oh, SK3
Chae, JK3
Jiang, M1
You, JHS1
Pailleret, C1
Ait Hamou, Z1
Rosencher, N1
Samama, CM2
Eyraud, V1
Chilot, F1
Baillard, C1
Borse, MS1
Dong, OM1
Polasek, MJ1
Farley, JF1
Stouffer, GA1
Lee, CR1
Baber, U6
Chandrasekhar, J4
Sartori, S4
Aquino, M3
Kini, AS2
Kapadia, S1
Weintraub, W1
Muhlestein, JB1
Vogel, B2
Faggioni, M2
Farhan, S2
Weiss, S1
Strauss, C1
Toma, C1
DeFranco, A1
Baker, BA4
Keller, S1
Rao, S1
Pocock, S3
Dangas, G4
Mehran, R15
Stuckey, TD6
Kirtane, AJ7
Brodie, BR7
Witzenbichler, B9
Litherland, C2
Weisz, G6
Rinaldi, MJ7
Neumann, FJ15
Metzger, DC5
Cox, DA7
Duffy, PL5
Mazzaferri, EL5
Gurbel, PA10
Ben-Yehuda, O3
Simonton, CA1
Harada, Y1
Michel, J2
Lohaus, R2
Mayer, K5
Emmer, R1
Lahmann, AL2
Colleran, R1
Giacoppo, D1
Wolk, A2
Han, Y4
Adriaenssens, T4
Tölg, R3
Seyfarth, M4
Maeng, M5
Zrenner, B3
Jacobshagen, C5
Wöhrle, J3
Kufner, S3
Morath, T7
Ibrahim, T3
Bernlochner, I6
Fischer, M3
Schunkert, H6
Laugwitz, KL7
Mehilli, J11
Byrne, RA7
Kastrati, A16
Schulz-Schüpke, S3
Baschin, M1
Selleng, S1
Zeden, JP1
Westphal, A1
Kohlmann, T1
Schroeder, HW1
Greinacher, A1
Thiele, T1
Petousis, S2
Kanakakis, J1
Skalidis, E1
Kochiadakis, G1
Vardas, PE1
Rosenberg, K1
Oldgren, J2
Lip, GYH4
Ellis, SG2
Merkely, B4
Zeymer, U8
Gropper, S1
Nordaby, M1
Kleine, E1
Harper, R1
Manassie, J1
Januzzi, JL1
Hohnloser, SH2
Sibbing, D13
Aradi, D5
Gross, L3
Trenk, D4
Geisler, T4
Orban, M4
Hadamitzky, M3
Komócsi, A4
Dézsi, CA3
Holdt, L2
Felix, SB2
Parma, R3
Klopotowski, M3
Schwinger, RHG1
Rieber, J2
Koltowski, L2
Huczek, Z4
Massberg, S6
Harding, SA2
Holley, A1
Wilkins, B1
Fairley, S1
Simmonds, M1
Larsen, PD1
Benedetto, U2
Bianco, M1
Conrotto, F2
Moretti, C3
D'Onofrio, A1
Agrifoglio, M1
Colombo, A9
Ribichini, F1
Tarantini, G2
D'Amico, M1
Salizzoni, S1
Rinaldi, M1
Ponzetto, A1
Figura, N1
Feagins, LA2
He, RX1
Zhou, TN1
Yuan, WJ1
Liu, YJ1
Fu, WX1
Jing, QM2
Liu, HW1
Wang, XZ2
Ahn, S1
Lee, J4
Min, SK1
Ha, J1
Min, SI1
Kim, SY1
Cho, MJ1
Prader, R1
De Broca, B1
Chevallier, D1
Amiel, J1
Durand, M1
Bossard, M1
Granger, CB5
Faxon, DP4
Jolly, SS2
Widimsky, P7
Niemela, K1
Natarajan, MK2
Gao, P3
Fox, KAA1
Yusuf, S16
Mehta, SR16
Spartalis, M1
Tzatzaki, E1
Spartalis, E1
Damaskos, C1
Athanasiou, A1
Moris, D1
Politou, M1
Castini, D1
Persampieri, S1
Cazzaniga, S1
Centola, M1
Lucreziotti, S1
Salerno-Uriarte, D1
Sponzilli, C1
Carugo, S1
Zocca, P1
van der Heijden, LC1
Kok, MM1
Löwik, MM1
Hartmann, M1
Stoel, MG1
Louwerenburg, JW1
de Man, FHAF1
Linssen, GCM1
Knottnerus, IL1
Doggen, CJM1
van Houwelingen, KG1
von Birgelen, C2
Pappas, C1
Sfantou, D1
Squizzato, A2
Bellesini, M2
Takeda, A1
Middeldorp, S1
Donadini, MP2
Zhong, Z1
Hou, J1
Zhang, Q2
Li, B1
Li, C2
Liu, Z1
Yang, M1
Zhong, W1
He, X1
Wu, H1
Zhong, M1
Zhao, P1
Novkovic, M1
Matic, D1
Kusic-Tisma, J1
Antonijevic, N1
Radojkovic, D1
Rakicevic, L1
Kounis, NG1
Koniari, I2
Tsigkas, G1
Chourdakis, E1
Roumeliotis, A1
Patsouras, N1
Soufras, G1
Hahalis, G3
Bath, PM2
Woodhouse, LJ1
Appleton, JP1
Beridze, M1
Christensen, H1
Dineen, RA1
Duley, L1
England, TJ1
Flaherty, K1
Havard, D1
Heptinstall, S2
James, M1
Krishnan, K1
Markus, HS1
Montgomery, AA1
Pocock, SJ2
Randall, M1
Ranta, A1
Robinson, TG1
Scutt, P1
Venables, GS1
Sprigg, N1
Godschalk, TC1
Gimbel, ME1
Nolet, WW1
van Kessel, DJ1
Amoroso, G1
Dewilde, WJ2
Wykrzykowska, JJ1
Janssen, PW2
Bergmeijer, TO1
Kelder, JC3
Heestermans, T1
Baschera, D1
Oberle, J1
Grubhofer, F1
Schmid, SL1
Peterson, BE1
May, J1
Duerschmied, D1
Brachmann, J1
Darius, H2
Frey, N2
Rottbauer, W2
Schäfer, A3
Thiele, H1
Johnston, SC6
Easton, JD4
Farrant, M1
Barsan, W1
Conwit, RA1
Elm, JJ1
Kim, AS1
Lindblad, AS1
Palesch, YY1
Ding, L2
Peng, B1
Lewis, SR1
Pritchard, MW1
Schofield-Robinson, OJ1
Alderson, P1
Smith, AF1
Hoorntje, JCA1
Kitazono, T1
Ikeda, Y3
Nishikawa, M4
Yoshiba, S1
Abe, K1
Ogawa, A1
Wu, Z1
Liu, AF1
Zhou, J1
Wang, K3
Qiu, H1
Jiang, WJ1
Wang, HY1
Li, Y13
Xu, XM1
Li, J3
Wernly, B1
Lichtenauer, M1
Hoppe, UC1
Lauten, A1
Navarese, EP3
Jung, C1
Fahmy, AI1
Mekkawy, MA1
Abou-Ali, A1
Goedel, A1
Fiedler, KA1
von Olshausen, G1
Schüpke, S1
Hoppmann, P2
Sarafoff, N2
Sonneveld, MJ1
Honkoop, P1
Ter Borg, PCJ1
Radaelli, F1
Mogavero, G1
Paggi, S1
Jeong, HG1
Yoon, JS1
Bae, HJ1
Oirbans, T1
Verheugt, FW8
De Smet, BJ1
Herrman, JP1
Vrolix, M3
Heestermans, AA2
Vis, MM1
Tijsen, JG1
van 't Hof, AW4
Kerneis, M1
Silvain, J7
Abtan, J2
Cayla, G6
O'Connor, SA3
Barthélémy, O4
Vignalou, JB1
Beygui, F7
Brugier, D1
Martin, R1
Collet, JP14
Helft, G2
Le Feuvre, C1
Georges, JL1
Leclercq, F2
Eltchaninoff, H2
Prunier, F1
Sebagh, L1
Cattan, S2
Vicaut, E3
Metzger, JP1
Mischnik, M1
Boyanova, D1
Hubertus, K1
Geiger, J1
Philippi, N1
Dittrich, M1
Wangorsch, G1
Timmer, J1
Dandekar, T1
Hamm, CW9
Price, MJ10
Leonardi, S5
Gallup, D1
Bramucci, E2
Radke, PW1
Tousek, F1
Tauth, J1
Spriggs, D2
McLaurin, BT1
Angiolillo, DJ12
Liu, T2
Prats, J6
Todd, M1
Skerjanec, S2
Turkmen, S1
Fettser, DV3
Kagliian, KÉ1
Serchelik, A1
Arystanova, AZh1
Tekin, K1
Balli, M1
Batyraliev, TA3
Samko, AN2
Sidorenko, BA3
Hossain, FS1
Rambani, R1
Ribee, H1
Koch, L1
Wallace, HC1
Probe, RA1
Chaput, CD1
Patel, KV1
Novitskaya, E2
Rene, C2
Dean, A1
Wang, WE1
Zeng, C1
Osinski, D1
Thevenin, A1
Devys, JM1
Fiorelli, EM1
Bonzi, M1
Oprea, AD1
Popescu, WM1
Netsch, C1
Stoehrer, M1
Brüning, M1
Gabuev, A1
Bach, T1
Herrmann, TR1
Gross, AJ1
Berglund, U1
Nilsson, L1
Janzon, M2
Short, S1
Kram, B1
Taylor, S1
Ali, K1
Vasquez, D1
Diercks, DB1
Kontos, MC1
Hollander, JE2
Mumma, BE1
Holmes, DN1
Wiviott, S2
Saucedo, JF1
de Lemos, JA2
Marino, M3
Campo, G2
Guastaroba, P2
Taglieri, N1
Tondi, S3
Manari, A1
Guiducci, V1
Sangiorgio, P1
Varani, E1
De Palma, R2
Marzocchi, A1
Wheatcroft, S1
Rodriguez, L2
Conde, D2
Lalor, N2
Elissamburu, P2
Trivi, M2
Seivani, Y1
Abdel-Wahab, M2
Geist, V1
Richardt, G3
Sulimov, DS1
El-Mawardy, M1
Toelg, R1
Akin, I1
Wessel, DL1
Berger, F1
Li, JS2
Dähnert, I1
Rakhit, A1
Fontecave, S1
Newburger, JW1
Zhao, X3
Wang, C6
Meng, X3
Cui, L1
Jia, J1
Dong, Q1
Xu, A1
Zeng, J1
Wang, Z3
Xia, H1
Callender, RA1
Mukalel, J1
Altamirano, AV1
Pivalizza, EG2
Cattano, D2
Huang, Y1
Li, M3
Li, JY1
Xia, YP1
Mao, L1
Hu, B1
Stevens, SR3
Hochman, JS3
Gottlieb, S3
Martinez, F2
Dalby, AJ3
Boden, WE5
Aylward, PE3
Bassand, JP4
McGuire, DK1
Steinberg, BA1
Kim, S2
Piccini, JP3
Fonarow, GC1
Thomas, L2
Ezekowitz, MD2
Ansell, J1
Kowey, P1
Singer, DE2
Gersh, B1
Hylek, E1
Go, AS2
Chang, P1
Liang, ZY1
Zhang, XL2
Yan, CH1
Kang, J1
García Rodríguez, LA1
Johansson, S2
Cea Soriano, L1
Liew, D1
De Abreu Lourenço, R1
Adena, M1
Chim, L1
Aylward, P2
DiNicolantonio, JJ2
Tomek, A3
Chatterjee, S3
Niazi, AK1
Biondi-Zoccai, G2
Lee, HY1
Park, KW5
Kang, HJ4
Koo, BK4
Kim, MA1
Oh, BH1
Park, MW1
Her, SH1
Choi, YS2
Park, CS1
Koh, YS1
Park, HJ1
Kim, PJ1
Kim, CJ1
Jeon, DS2
Shin, DI1
Seo, SM1
Yoo, KD1
Kim, DB1
Kim, HY1
Lee, JM2
Chung, WS1
Shin, JG1
Chang, K1
Darvish-Kazem, S1
Gandhi, M1
Marcucci, M1
Douketis, JD1
Tehrani, S1
Rozelle, C1
Solomon, A1
Steele, EA1
Wilhelm, TJ1
Post, S1
Grosdidier, C3
Loundou, AD1
Loosveld, M2
Camoin, L2
Pankert, M3
Beguin, S2
Suh, SY1
Choi, H1
Moon, CI1
Han, SH1
Ahn, T2
Choi, IS1
Shin, EK1
Goudevenos, JA3
Parissis, H1
Ntalas, IV3
Angelidis, C1
Vavuranakis, M1
Stefanadis, C2
Bell, AD1
Ackman, ML2
Bauer, RD1
Cartier, R1
Chan, WS1
Douketis, J1
Roussin, A1
Schnell, G1
Verma, S3
Wong, G2
Callender, R1
Altamirano, A1
Tezino, T1
Al Khudairy, A1
Al-Hadeedi, O1
Sayana, MK1
Galvin, R1
Quinlan, JF1
Lin, TH1
Lai, WT1
Hsin, HT1
Li, AH1
Wang, CL2
Kuo, CT1
Hwang, JJ1
Chiang, FT1
Chang, SC1
Park, JJ2
Yang, HM1
Park, BE1
Rhew, JY1
Jeon, HK2
Shin, ES2
Oh, JH2
Yoon, JH3
Lee, SY1
Park, TH3
Moon, KW1
Kwon, HM2
Chae, IH3
Gulba, D1
Bonello, L7
Chen, Y2
Tang, Y2
Huang, X2
Xie, Y1
Curkovic, I1
Egbring, M1
Kullak-Ublick, GA1
Harris, NS1
Kristensen, SR1
Karon, BS1
Rydberg, DM1
Holm, L1
Mejyr, S1
Loikas, D1
Schenck-Gustafsson, K1
von Euler, M1
Wettermark, B1
Malmström, RE1
Han, S1
Lee, SG1
Rha, SW2
Lim, DS3
Hur, SH3
Yang, JY1
Lee, NH3
Lee, BK1
Kim, KS1
Lee, SU1
Cheong, SS1
Suh, IW1
Park, HS3
Nah, DY1
Jang, JS1
Limbruno, U2
Varenhorst, C4
Jensevik, K2
Jernberg, T2
Sundström, A1
Hasvold, P1
Lagerqvist, B5
James, S10
Bosch, X3
Marrugat, J4
Sanchis, J3
Malloy, RJ1
Kanaan, AO1
Silva, MA2
Donovan, JL2
Park, IC1
Baek, YH1
Han, SY1
Chung, WT1
Cho, DS1
Damman, P1
Koul, S6
Eriksson, P1
Erlinge, D6
Feres, F4
Costa, RA1
Abizaid, A3
Leon, MB4
Marin-Neto, JA2
Botelho, RV1
King, SB1
Negoita, M1
Liu, M2
de Paula, JE1
Mangione, JA2
Meireles, GX1
Castello, HJ1
Nicolela, EL1
Perin, MA1
Devito, FS1
Labrunie, A1
Salvadori, D1
Gusmão, M1
Staico, R2
Costa, JR2
de Castro, JP1
Abizaid, AS1
Nakagawa, I2
Wada, T2
Nishimura, F1
Yamada, S2
Nakagawa, H1
Kichikawa, K2
Nakase, H2
Guidoni, CM1
Obreli-Neto, PR1
Pereira, LR1
Enomoto, Y1
Tokue, M1
Ito, N1
Nagashima, Y1
Araki, T1
Yamazaki, K1
Utsunomiya, M1
Hori, M1
Itaya, H1
Shiba, M1
Hara, H1
Sugi, K2
Ariyaratnam, P1
McLean, LA1
Kotidis, K1
Loubani, M1
Takahashi, S1
Mizuno, O1
Sakaguchi, T1
Yamada, T1
Inuyama, L1
Arntz, HR3
Boudriot, E2
Garlichs, C2
Hoffmann, S2
Ince, H4
Klingenheben, T2
Weil, J2
Zugck, C2
Helms, TM2
Silber, S2
Gasparovic, H2
Petricevic, M4
Lin, OA1
Karim, ZA1
Vemana, HP1
Espinosa, EV1
Khasawneh, FT1
Lamberts, M3
Gislason, GH7
Lip, GY5
Lassen, JF2
Olesen, JB3
Mikkelsen, AP1
Sørensen, R5
Køber, L6
Torp-Pedersen, C8
Hansen, ML5
Lippe, CM1
Reineck, EA1
Kunselman, AR1
Gilchrist, IC3
Tornyos, A1
Pintér, T1
Vorobcsuk, A1
Kónyi, A1
Faluközy, J1
Veress, G1
Magyari, B1
Horváth, IG1
Alcocer, F1
Novak, Z1
Combs, BR1
Lowman, B1
Passman, MA1
Mujib, M1
Jordan, WD1
Gagne, JJ1
Rassen, JA1
Choudhry, NK1
Bohn, RL1
Patrick, AR1
Sridhar, G1
Daniel, GW1
Liu, J1
Schneeweiss, S1
Tang, XF2
Fan, JY2
Meng, J1
Jin, C1
Yuan, JQ2
Yang, YJ1
Kohriyama, T1
Mihara, C1
Yokoyama, T1
Torii, T1
Yamada, A1
Takamatsu, K1
Ota, T1
Noda, K1
Kataoka, S1
Ito, H1
Nomura, E1
Ohtsuki, T1
Aoki, S1
Nezu, T1
Takeda, I1
Mukai, T1
Hosomi, N1
Matsumoto, M1
Xu, S2
Shetterly, S2
Raebel, MA2
Ho, PM2
Tsai, TT2
Magid, D2
Ma, YY1
Xu, B2
Gao, RL2
Kleiman, NS4
Sabouret, P1
Taiel-Sartral, M1
Nanau, RM1
Delzor, F1
Neuman, MG1
De Luca, G5
Bellandi, B1
Comito, V1
Valenti, R2
Marcucci, R3
Carrabba, N1
Migliorini, A2
Ramazzotti, RN1
Gensini, GF1
Abbate, R1
Antoniucci, D2
Bach, RG2
Heras, M3
Horrow, J6
Lassila, R3
Morais, J3
Wojdyla, D3
Ndrepepa, G3
Schulz, S8
Pöhler, A1
Pache, J2
Braun, S4
Hausleiter, J3
Kazi, DS2
Garber, AM1
Shah, RU1
Dudley, RA1
Mell, MW1
Rhee, C1
Moshkevich, S1
Boothroyd, DB1
Owens, DK1
Hlatky, MA1
Maya, J2
Sherwood, MW1
Wiviott, SD10
Peng, SA1
Delemos, J1
Vranckx, P4
Tebaldi, M4
Biscaglia, S1
Parrinello, G1
Saito, S3
Isshiki, T4
Ogawa, H3
Nanto, S3
Takayama, M3
Kitagawa, K3
Miyazaki, S3
Rangé, G1
Yayehd, K1
Belle, L1
Thuaire, C1
Richard, P1
Barbou, F1
Köning, R1
Chassaing, S1
Teiger, E1
Berthier, R1
Decomis, MP1
Claudel, JP1
Brunel, P1
De Poli, F2
Albert, F1
Goedicke, J2
Schirmer, A1
Patel, MR2
Wojdyla, DM2
Emanuelsson, H6
Hiatt, WR3
Rossini, R4
Visconti, LO1
Castiglioni, B1
Lettieri, C4
Lettino, M1
Piccaluga, E1
Savonitto, S2
Trabattoni, D1
Capodanno, D4
Buffoli, F1
Parolari, A1
Dionigi, G1
Boni, L1
Biglioli, F1
Valdatta, L1
Droghetti, A1
Bozzani, A1
Setacci, C1
Ravelli, P1
Crescini, C1
Staurenghi, G1
Scarone, P1
Francetti, L1
D'Angelo, F1
Gadda, F1
Comel, A1
Salvi, L1
Lorini, L1
Antonelli, M1
Bovenzi, F1
Cremonesi, A1
Guagliumi, G4
Liang, J1
Shi, D1
Zhao, Y2
Han, H1
Liu, W1
Yang, L1
Legrand, V3
Chenu, P1
Martinez, C1
Dens, J1
Gach, O1
Boland, J2
Magne, J2
Barbato, E1
Wijns, W1
Takeuchi, K1
Takayama, S1
Izuhara, C1
Siller-Matula, JM5
Delle Karth, G1
Wilcox, R1
Iqbal, K1
Costigan, T1
Lopez-Sendon, J4
Ramos, Y2
Bae, JP2
Faries, DE3
Ernst, FR2
Lipkin, C2
Zhao, Z2
Moretz, C2
Lieu, HD2
Moeckel, D1
Jeong, SS1
Broekman, MJ1
Nguyen, A1
Drosopoulos, JH1
Marcus, AJ1
Robson, SC1
Chen, R1
Abendschein, D1
Chen, S1
Shen, Q1
He, L1
Peng, Y1
Blicher, TM1
Hommel, K1
Kristensen, SL2
Madsen, M1
Kamper, AL1
Sood, A1
Trinh, QD1
Sharma, M1
Pearce, LA3
Benavente, OR3
Anderson, DC1
Connolly, SJ5
Palacio, S2
Coffey, CS2
Hart, RG5
Lapostolle, F2
Cantor, WJ1
Cequier, A1
Chettibi, M1
Hammett, CJ1
Stibbe, O1
Ecollan, P2
Heutz, WM1
Swahn, E1
Willems, FF1
Baradat, C1
Licour, M1
Tsatsaris, A1
Clemmensen, P2
Grieco, N1
Danchin, N3
Schmitt, J1
Goldstein, P1
Tiroch, K2
Zhang, JH2
Yao, Y2
Ma, YL1
Gao, Z1
Chen, J2
Song, L1
Meng, XM1
Kristensen, KE1
Zhu, HJ1
Rasmussen, HB1
Markowitz, JS1
Hansen, PR4
Schrör, K3
Gawaz, M4
Thompson, PL1
Aryal, MR1
Karmacharya, P1
Pandit, A1
Hakim, F1
Pathak, R1
Mainali, NR1
Ukaigwe, A1
Mahmood, M1
Badal, M1
Fortuin, FD1
Almendro-Delia, M1
Blanco Ponce, E1
Gomez-Domínguez, R1
Gonzalez-Matos, C1
Lobo-Gonzalez, M1
Caballero-Garcia, A1
Hidalgo-Urbano, R1
Cruz-Fernandez, MJ1
Garcia-Rubira, JC1
Russo, N1
Calabria, P1
Romano, M2
Inashvili, A1
Sirbu, V2
Valsecchi, O2
Senni, M1
Gavazzi, A3
Vyas, A1
El Accaoui, R1
Blevins, A1
Karrowni, W1
Tantry, US6
Gesheff, M1
Liu, F2
Bliden, KP1
Briguori, C2
Rizzi, A1
Imperadore, F1
Sangiorgi, GM1
Carosio, G1
Steffenino, G1
Galvani, M1
La Vecchia, L1
Maggioni, AP1
Driscoll-Shempp, P1
Normand, SL1
Braunwald, E12
Holmes, DR2
Krucoff, MW3
Hermiller, J1
Dauerman, HL3
Simon, DI1
Kandzari, DE3
Garratt, KN2
Lee, DP1
Pow, TK1
Ver Lee, P1
Jeger, RV1
Pfisterer, ME1
von Felten, S1
Alber, H1
Bonetti, PO1
Eberli, F1
Erne, P1
Pedrazzini, G1
Rickli, H1
Galatius, S1
Kaiser, CA1
Lokhnygina, Y1
Huang, Z1
Chen, E1
Moliterno, DJ7
Jennings, LK3
Berland, J1
Endresen, K1
Benamer, H1
Boschat, J1
Geersing, GJ1
Kappelle, LJ1
Braun, OÖ2
Bico, B1
Chaudhry, U1
Wagner, H1
Tydén, P1
Scherstén, F4
Jovinge, S1
Svensson, PJ2
Gustav Smith, J1
van der Pals, J2
Sáez, ME1
González-Pérez, A1
Nagy, P1
Rodríguez, LA1
Lu, W1
Chen, L2
Fu, C1
Zuo, P1
Ma, G2
Andell, P2
Martinsson, A1
Smith, JG3
Harnek, J1
Götberg, M1
Norström, E1
Björnsson, S1
Mack, M1
Yadav, M1
Xu, K4
Parvataneni, R3
Hahn, R1
Kodali, SK1
Bolanos, MD1
Dzeshka, MS1
Brown, RA1
Zheng, M1
Shang, X1
Yan, C1
Mudra, H2
von Hodenberg, E1
von Merzljak, B1
Rifatov, N1
Feuchtenberger, A1
Valina, C1
Desmet, W3
Hengstenberg, C1
Schömig, A8
Garg, P1
Galper, BZ1
Reed, GW2
Kumar, A3
Guo, J3
Aranki, S2
Shekar, P2
Agnihotri, A2
Maree, AO3
McLean, DS3
Rosenfield, K2
Perperis, A2
Karvounis, H1
Patsilinakos, S1
Ziakas, A1
Barampoutis, N2
Panagiotidis, T1
Akinosoglou, K1
Bultas, J1
Stoler, R1
Cortese, B1
Wilensky, M1
Deliargyris, EN5
Costa, F4
Moscarella, E2
Ando, G2
Oreto, G2
Zijlstra, F2
Patialiakas, A1
Thury, A1
McFadden, E1
Colangelo, S1
Roffi, M3
Menozzi, A1
de Cesare, N1
Garbo, R1
Meliga, E1
Testa, L2
Gabriel, HM1
Airoldi, F1
Ferlini, M1
Liistro, F1
Dellavalle, A1
Kalantzi, KI2
Tsoumani, ME2
Vakalis, JN1
Vasilakopoulos, V2
Vardakis, K2
Vemmos, KN1
Voukelatou, M2
Giannakoulas, G2
Giatrakos, I2
Giogiakas, V2
Goumas, G2
Dimoulis, N2
Draganigos, A2
Efthimiadis, I2
Thoma, M2
Kazakos, E2
Kipouridis, N2
Konstantinou, S2
Bourdakis, A2
Nikolopoulos, D2
Peltekis, L2
Prokopakis, N2
Sinteles, I2
Stroumbis, CS1
Terzoudi, K2
Tsilias, K2
Xaraktsis, I2
Charmpas, C2
Hatziathanasiou, G2
Christogiannis, Z2
Panagiotakos, DB2
Tselepis, AD2
Klingenberg, R2
Heg, D4
Räber, L3
Carballo, D2
Nanchen, D1
Gencer, B2
Auer, R2
Jaguszewski, M1
Stähli, BE1
Jakob, P1
Templin, C1
Meier, B2
Vogt, P1
Maier, W1
Landmesser, U1
Rodondi, N2
Mach, F2
Jüni, P2
Lüscher, TF3
Matter, CM2
Taha, S1
Omedè, P1
Grossomarra, W1
Persson, J2
Dewilde, W1
Fernández, S1
Cerrato, E1
Meynet, I1
Ballocca, F1
Barbero, U1
Quadri, G1
Giordana, F2
DiNicolantonio, J1
Bangalore, S1
Reed, M1
Meier, P1
Zoccai, G1
Gaita, F2
Tangelder, MJ1
Nwachuku, CE1
Jaff, M1
Baumgartner, I3
Duggal, A1
Adams, G1
Ansel, G1
Grosso, M1
Mercuri, M1
Shi, M1
Minar, E3
Moll, FL2
Angoulvant, D1
Villejoubert, O1
Bejan-Angoulvant, T1
Ivanes, F1
Saint Etienne, C1
Fauchier, L1
Cai, TQ1
Wickham, LA1
Sitko, G1
Michener, MS1
Raubertas, R1
Handt, L1
Chintala, M1
Seiffert, D2
Forrest, M1
Lin, L1
Chen, YF1
Lin, WW1
Lin, CH1
Lee, SA1
Suh, JW1
Yoon, CH1
Cho, YS1
Youn, TJ1
Kim, SH2
Jia, M1
Li, Z3
Chu, H1
Li, L2
Chen, K1
Kirtane, A1
Freynhofer, MK2
ten Berg, J2
Janssen, P1
Patti, G7
Mangiacapra, F1
Morel, O1
Palmerini, T3
Adamo, M1
Garcia-Garcia, HM1
Binder, A1
Aledort, L1
Hassell, ME1
Hildick-Smith, D1
Durand, E1
Kikkert, WJ2
Wiegerinck, EM1
Stabile, E1
Ussia, GP1
Sharma, S2
Baan, J1
Rubino, P1
Barbanti, M1
Tamburino, C1
Poliacikova, P1
Piek, JJ1
Delewi, R1
Verdoia, M4
Barbieri, L3
Suryapranata, H3
Shubert, D1
Bono, J1
Nandi, S1
Biocina, B3
Milicic, D1
Rotim, C1
Boban, M1
Gao, F2
Shen, H2
Wang, ZJ2
Yang, SW2
Liu, XL2
Zhou, YJ2
Kochman, J2
Grygier, M1
Scislo, P1
Wilimski, R1
Ochala, A1
Lesiak, M1
Olasinska-Wisniewska, A1
Grabowski, M1
Mazurek, T1
Filipiak, KJ1
Opolski, G1
Yudi, MB2
Eccleston, D2
Andrianopoulos, N3
Farouque, O2
Duffy, SJ3
Brennan, A2
Reid, C1
Clark, DJ3
Ajani, AE3
Clare, RM1
Gao, R1
Lim, ST1
Santoso, A2
Yu, CM1
Chen, HB1
Liang, HB1
Liu, XW1
Zhang, XY1
Huang, BY1
Xiu, J1
Van Gaal, WJ2
Schrale, R1
Gunasekara, A1
Amerena, J1
Mussap, CJ1
Ong, WL1
Koh, TL1
Fletcher, J1
Gruen, R1
Royce, P1
Oh, S1
Peters, JI1
Folch, E1
Dézsi, BB1
Koritsánszky, L1
Braunitzer, G1
Hangyási, DB1
Kelbæk, H1
Tüller, D1
Baumbach, A1
Zanchin, T2
Ostojic, M1
Engstrøm, T1
Guimarães, PO1
Melloni, C1
Hafley, G1
Zamoryakhin, D2
Polzin, A2
Afzal, S1
Balzer, J1
Rassaf, T1
Kelm, M2
Zeus, T2
Tan, S1
Xiao, X1
Ma, H1
Yu, S1
Xu, R1
Hong, H1
Khatri, S1
Pierce, T1
Würtz, M1
Thomas, MR1
Nishi, H1
Nakahara, I1
Matsumoto, S1
Hashimoto, T1
Ohta, T1
Sadamasa, N1
Ishibashi, R1
Gomi, M1
Saka, M1
Miyata, H1
Watanabe, S1
Okata, T1
Sonoda, K1
Kouge, J1
Ishii, A1
Nagata, I1
Kira, J1
Filipini, E1
Nau, G1
Cura, F1
Huang, CH1
Arif, SA1
D'Souza, J1
Gil, M1
Gim, S1
Gutierrez, JA1
Blankenship, JC3
Gan, XD1
Wei, BZ1
Fang, D1
Fang, Q1
Li, KY1
Ding, SL1
Peng, S1
Wan, J1
Bhal, V1
Herr, MJ1
Dixon, M1
Akins, S1
Hord, E1
White, MM1
Kotha, J1
Bertilsson, M1
Bundhun, PK1
Qin, T1
Chen, MH1
Cyr, DD3
Keltai, M6
Hibbert, B3
Froeschl, M4
So, D1
May, ML1
Pokov, AN1
Kim, MH4
Bacquelin, R1
Oger, E1
Filippi, E1
Hacot, JP1
Auffret, V1
Le Guellec, M1
Coudert, I1
Moquet, B1
Rialan, A1
Rouault, G1
Boulanger, B1
Treuil, J1
Leurent, G1
Bedossa, M1
Boulmier, D1
Avez, B1
Grifoni, E1
Giusti, B1
Tanaka, Y1
Karnyski, J1
Dhillon, SS1
Harris, K1
Dannenberg, L1
Sophia Popp, V1
Lee, JH3
Ahn, SG1
Lee, JW1
Youn, YJ1
Ahn, MS1
Kim, JY1
Yoo, BS1
Lee, SH2
Yoon, J1
Kim, J1
Choi, E1
Hung, OY1
Samady, H1
Oliphant, CS1
Trevarrow, BJ1
Dobesh, PP1
Eckart, D1
Morse, MA1
Blackwell, KL1
Ready, NE1
Zafar, SY1
Beaven, AW1
Strickler, JH1
Onken, JE1
Houterloot, L1
Tijssen, JG2
Giatti, S1
Hunter, JB1
Carlson, ML1
Sweeney, AD1
Tombers, NM1
Wanna, GB1
Driscoll, CL1
Haynes, DS1
Huang, F1
Yang, J1
Wu, Q1
Zou, Y1
Zhu, E1
Jackson, LR3
Ju, C2
Zettler, M2
Messenger, JC3
Effron, M1
Shen, DL1
Wang, B1
Bai, J1
Han, Q1
Liu, C1
Huang, XH1
Zhang, JY1
Parikh, PB1
Maehara, A3
Fu, A1
Singh, K1
Abunassar, J1
Malhotra, N1
Le May, M1
Labinaz, M3
Glover, C2
Marquis, JF3
Dick, A2
Chong, AY2
So, DY3
Ricottini, E2
Cavallari, I1
Kwon, TJ1
Park, Y2
Choi, YM1
Ahn, JH1
Kim, KH1
Koh, JS1
Park, JR1
Hwang, SJ2
Kwak, CH2
Hwang, JY2
Smith, SC2
Jeong, YH2
Lemesle, G4
Schurtz, G1
Meurice, T1
Tricot, O1
Lemaire, N1
Caudmont, S1
Philias, A1
Ketelers, R1
Lamblin, N1
Bauters, C2
Hromádka, M1
Bernat, I1
Seidlerová, J1
Jirouš, Š1
Dragounová, E1
Pechman, V1
Tůmová, P1
Rokyta, R1
Yang, C2
Qian, J1
Tang, X3
Hu, Y1
Parker, WA1
Lefkovits, J1
Ramchand, J1
Yip, T1
Oqueli, E1
Reid, CM2
Guo, LZ1
Park, JS1
Jin, E1
Shim, CH1
Choi, SY1
Noh, Y1
Shin, S1
Lim, HS1
Bae, SK1
Oh, E1
Kim, GJ1
Kim, JH1
Jones, DW1
Goodney, PP1
Conrad, MF1
Nolan, BW1
Rzucidlo, EM1
Powell, RJ1
Cronenwett, JL1
Stone, DH1
Niu, PP1
Guo, ZN1
Jin, H2
Xing, YQ1
Yang, Y1
Pan, Y2
Yang, X1
Zhang, C1
Jing, J1
Xian, Y1
Li, R1
Jing, Q1
Wang, Q1
Liu, P2
Zhang, P1
Chin, CT1
Leiva-Pons, JL2
Corbalán, R2
Schiele, F1
Otoshi, T1
Kataoka, Y1
Nakagawa, A1
Otsuka, K1
Tomii, K1
Hechler, B1
Maître, B1
Magnenat, S1
Heim, V1
El Mdawar, MB1
Gachet, C2
de la Salle, H1
Giustino, G3
Ariti, C2
Chieffo, A3
Lattuca, B1
Fabbro-Peray, P1
Schmutz, L1
Ledermann, B1
Cornillet, L1
Benezet, JF1
Macia, JC1
de La Coussaye, JE1
Messner-Pellenc, P1
Milionis, H1
Stroumbis, C1
Vakalis, I1
Vemmos, K1
Basaraba, JE1
Barry, AR1
Yu, J2
Kini, A2
Skurk, C1
Shlofmitz, RA1
Zhou, CF1
Ren, YH1
Song, YQ1
Yi, J1
Han, BS1
Xue, Q1
Fu, ZH1
Li, DY1
Ahn, Y1
Pya, Y1
Bekbossynova, M1
Metzger, C1
Dangas, GD1
Francese, DP1
Ozan, O1
Cong, H1
Zhang, F1
Li, X1
Du, M3
Zhang, D2
Shi, Y1
Shah, RR1
Pillai, A1
Omar, A1
Zhao, J1
Arora, V1
Kapoor, D1
Poommipanit, P1
Eikelboom, JW9
Mancini, GB2
Cohen, EA3
Vijayaraghavan, R1
Cheema, AN2
Udell, JA1
Niznick, J1
Faza, NN1
Mentias, A1
Parashar, A1
Chaudhury, P1
Barakat, AF1
Agarwal, S1
Wayangankar, S1
Murat Tuzcu, E1
Kapadia, SR1
Whalen, JD1
Davies, G2
Oguz, M2
Bash, LD1
Ozer-Stillman, I1
Shimada, YJ1
Bansilal, S2
Vaduganathan, M2
Zhang, YQ1
Wei, CL1
Hu, YH1
Tokgözoğlu, L1
Yamaç, AH1
Göktekin, O1
Holmes, LE1
Gupta, R2
Rajendran, S1
Luu, J1
French, JK1
Juergens, CP2
Liu, X2
Zang, H1
Guo, L1
Zhao, W1
Lin, J1
Lin, Y1
Xu, J1
Brener, SJ2
Montefusco, A1
Scarano, S1
Abu-Assi, E1
Raposeiras-Roubín, S1
Henriques, JP1
Saucedo, J1
González-Juanatey, JR1
Wilton, SB1
Nuñez-Gil, I1
Ariza-Sole, A1
Song, X1
Liebetrau, C1
Kawaji, T1
Nie, SP1
Fujii, T1
Correia, L1
Kawashiri, MA1
García-Acuña, JM1
Southern, D1
Alfonso, E1
Terol, B1
Garay, A1
Osman, N1
Möllmann, H1
Shiomi, H2
Kowara, M1
Filipiak, K1
Yan, Y1
Ikari, Y2
Nakahayshi, T1
Sakata, K1
Yamagishi, M1
Kalpak, O1
Kedev, S1
Hoshi, T1
Sato, A1
Nogami, A1
Gosho, M1
Aonuma, K1
Jin, L1
Yu, H1
Dong, T1
Zhang, B1
Liao, H1
Zou, X1
Westerman, ME1
Sharma, V1
Scales, J1
Gearman, DJ1
Ingimarsson, JP1
Krambeck, AE1
Magnus Ohman, E1
Meena, N1
Abouzgheib, W1
Patolia, S1
Rosenheck, J1
Boujaoude, Z1
Bartter, T1
Chang, CY1
Lin, SY1
Tsai, JR1
Tsai, CH1
Chen, YC1
Camaro, C1
Damen, SA1
Brouwer, MA1
Kedhi, E1
Rognoni, A1
van T Hof, AW1
Ligtenberg, E1
de Boer, MJ2
Magnani, G3
Esposito, G1
Pang, M1
Zhuang, K1
Bhat, A1
Park, TK2
Shin, SJ1
Ge, H1
Lv, X1
Ren, H1
Jiang, Y1
Wang, YQ1
Wang, CH1
Saporito, R1
Michael Gibson, C2
Cohen, D1
Moliterno, D1
Stuckey, T2
Henry, T1
Gabriel Steg, P1
Gori, T1
Thalmeier, A1
Löw, A1
Teupser, D1
Malek, L1
Horstkotte, J1
Baylacher, M1
Schwinger, R1
Abnousi, F1
Ozmete, O1
Bali, C1
Ergenoglu, P1
Suner, HI1
Aribogan, A1
Gunarathne, A1
Hussain, S1
Gershlick, AH1
Schaffer, A2
Pourdjabbar, A1
Le May, MR3
Simard, T1
Ramirez, FD1
Lugomirski, P1
Maze, R1
Bernick, J1
Wells, G1
Jakubowski, JA2
Ferri, LA1
Morici, N1
Grosseto, D1
Tortorella, G1
Bossi, I1
Sganzerla, P1
Cacucci, M1
Sibilio, G1
Toso, A1
Ferrario, M1
Gandolfo, N1
Ravera, A1
Mariani, M2
Corrada, E1
Di Ascenzo, L1
Petronio, AS1
Cavallini, C1
Moffa, N1
Déry, JP2
Fisher, HN1
Zhang, X2
Zhu, YE1
Lavi, S1
Cieza, T1
Henderson, MA1
Lutchmedial, S1
Siega, AJ1
Wong, BY1
Kokis, A1
Dehghani, P1
Wimmer, NJ1
Dufour, AB1
Cho, K1
Gagnon, DR1
Quach, L1
Ly, S1
Do, JM1
Ostrowski, S1
Michael Gaziano, J1
Kinlay, S2
Carrero, JJ1
Szummer, K2
Evans, M1
Spaak, J1
Kinnear, N1
Hennessey, DB1
Douglass-Molloy, H1
Jack, G1
Pieper, M1
Schmitz, J1
McBane, R1
Knudsen, J1
McMenomy, B1
Wennberg, P1
Atwell, T1
Hahn, JY2
Song, YB2
Lee, JB1
Doh, JH1
Yang, JH1
Choi, JH2
Choi, SH2
Kukula, K2
Kunicki, PK1
Jamiolkowski, J2
Debski, A2
Bekta, P2
Polanska-Skrzypczyk, M1
Chmielak, Z2
Witkowski, A2
Fowkes, FG1
Heizer, G1
Berger, JS5
Held, P1
Katona, BG1
Norgren, L2
Blomster, J1
Millegård, M1
Reist, C1
Kunicki, P1
Sawlani, NN1
Xu, H1
Ping, Y1
Lin, H1
He, P1
Li, W1
Dai, H1
Jalal, Z1
Dinet, ML1
Combes, N1
Pillois, X1
Renou, P1
Sibon, I1
Iriart, X1
Thambo, JB1
Zuo, FT1
Wu, HJ1
Su, N1
Liu, JQ1
Dong, AQ1
Della Riva, D1
Bacchi Reggiani, L1
Sangiorgi, D1
Angelini, GD1
Pufulete, M1
Giannopoulos, G1
Oualim, S1
Elharda, CA1
Benzeroual, D1
Hattaoui, ME1
Rahman, MM1
Scalese, MJ1
Hansen, RA1
Chen, YT1
Chen, HT1
Hsu, CY1
Chao, PW1
Kuo, SC1
Ou, SM1
Shih, CJ1
Ooi, SY1
Iliev, L1
Bruno, V1
Hübl, W1
Willheim, M1
Wojta, J1
Cabrera-Fuentes, HA1
Cho, YR1
Park, K1
Kim, YD1
Yoon, SC1
Zuliani Mauro, MF1
Costa, R1
Piva E Mattos, LA1
Siqueira, D1
Sousa, A1
Lee, H1
Lim, SW1
Bae, JW1
Kim, BS1
Chase, M1
Ozan, MO1
Yokoyama, S1
Motoyama, Y1
van Klaveren, D1
Pilgrim, T1
Steyerberg, EW1
Sullivan, J1
Amarshi, N1
Alberts, MJ2
Hanley, DF1
Payne, CD1
Li, YG1
Brandt, JT1
Small, DS1
Farid, NA1
Salazar, DE1
Mertens, L1
Eyskens, B1
Boshoff, D1
Gewillig, M1
Bauersachs, J1
Eigenthaler, M1
Manzano-Fernández, S1
Pastor, FJ1
Marín, F3
Cambronero, F1
Caro, C1
Pascual-Figal, DA1
Garrido, IP1
Pinar, E1
Valdés, M1
Murphy, SA7
Antman, EM9
Weerakkody, G3
Morocutti, G1
McCabe, CH8
Ghosh, S1
Bandyopadhyay, D1
Büttner, HJ1
Khattab, AA1
Minners, J1
Graf, I1
Skelding, KA1
Dirschinger, J2
Berger, PB14
Kent, DM1
Thaler, DE1
Sacco, RL1
Diener, HC3
Cotton, D1
Ounpuu, S1
Lawton, WA1
Palesch, Y1
Martin, RH1
Albers, GW2
Bath, P1
Bornstein, N1
Chan, BP1
Chen, ST1
Cunha, L1
Dahlöf, B1
De Keyser, J1
Donnan, GA1
Estol, C1
Gorelick, P1
Gu, V1
Hermansson, K1
Hilbrich, L1
Kaste, M1
Lu, C1
Machnig, T1
Pais, P1
Roberts, R1
Skvortsova, V1
Teal, P1
Toni, D1
Vandermaelen, C1
Voigt, T1
Weber, M1
Yoon, BW1
Alexander, D1
Ou, FS2
Pollack, CV6
Gibler, WB2
Fintel, DJ1
Brown, DL1
Pogue, J6
Haladyn, K1
Peters, RJ2
Avezum, A1
Gersh, BJ3
Rupprecht, HJ4
Jackevicius, CA1
Tu, JV1
Demers, V1
Melo, M1
Cox, J1
Rinfret, S3
Kalavrouziotis, D1
Johansen, H1
Behlouli, H1
Newman, A1
Pilote, L2
Halperin, JL3
Roldán, V1
Graw, J1
Schwenk, W1
Volk, T1
Satler, LF3
Lansky, AJ1
Tsuchiya, Y1
Brener, M1
Cristea, E1
Pietras, C1
Grines, CL1
Garcia, E1
Tcheng, JE5
Turco, M1
Carroll, JD1
Rutherford, BD1
Moses, J1
Chrolavicius, S6
Diaz, R3
Jolly, S2
Roy, P1
Torguson, R2
de Labriolle, A1
Slottow, TL1
Steinberg, DH1
Kaneshige, K2
Xue, Z2
Kent, KM2
Suddath, WO2
Pichard, AD2
Lindsay, J1
Waksman, R2
Molfese, M1
Mihalcsik, L1
Mantovani, P1
Bass, TA1
Della Rovere, F1
Heer, T2
Juenger, C1
Gitt, AK1
Bauer, T2
Towae, F1
Zahn, R3
Senges, J2
Levin, A1
Ben-Artzi, M1
Beckerman, P1
Haber, G1
Varon, D1
Ben-Yehuda, A1
Muszkat, M1
Mariani, G1
Lortie, E1
Girard, F1
Boudreault, D1
Ruel, M2
Mansour, S1
Blais, N1
Hardy, JF1
Serebruany, V3
Shalito, I1
Kopyleva, O1
Calatzis, A1
Hobson, A1
Curzen, N1
Wong, PC2
Crain, EJ2
Watson, CA2
Hua, J1
Schumacher, WA1
Rehfuss, R1
Tay, KH1
Lane, DA3
Schalekamp, T1
Klungel, OH1
Souverein, PC1
de Boer, A1
Guasch, E1
Sionis, A1
Reverter, JC1
Andrea, R1
Loma-Osorio, P1
Freixa, X1
Lauritzen, B1
Tranholm, M1
Ezban, M1
Aronow, HD1
Steinhubl, SR17
Brennan, DM7
Topol, EJ20
Singh, J1
Zeller, W1
Zhou, N1
Hategen, G1
Mishra, R1
Polozov, A1
Yu, P1
Onua, E1
Zembower, D1
Kiselyov, A1
Ramírez, JL1
Sigthorsson, G1
Bjornsson, JM1
Thorsteinsdottir, M1
Andrésson, T1
Bjarnadottir, M1
Magnusson, O1
Fabre, JE1
Stefansson, K1
Gurney, ME1
Mohler, ER1
Mak, KH6
Shao, M5
Haffner, SM2
Hankey, GJ5
Mahla, E1
Antonino, MJ1
Motovska, Z1
Kala, P1
Merlini, P1
Furlan, AJ1
Zibaeenezhad, MJ1
Mazloum, Y1
Slattery, D1
Mitchell, P1
Pfeffer, M1
Usman, MH1
Notaro, LA1
Nagarakanti, R1
Brahin, E1
Dessain, S1
Gracely, E1
Chua, D1
Ignaszewski, A1
Argüello Viudez, L1
Biller, J1
Lordkipanidzé, M1
Diodati, JG1
Pharand, C1
Jähne, J2
Schirren, J2
Marzot, F1
Pengo, V1
Bölükbas, S1
Sambola, A1
Ferreira-González, I2
Angel, J1
Alfonso, F2
Maristany, J1
Rodríguez, O1
López-Minguez, JR1
Zueco, J1
Fernández-Avilés, F1
San Román, A1
Prendergast, B1
Mainar, V1
García-Dorado, D2
Tornos, P1
Martens, A1
Haverich, A1
Ball, J1
Aleil, B1
Jacquemin, L1
Zaehringer, M1
Cazenave, JP1
Dickele, MC1
Monassier, JP2
Lincoff, AM10
Manoukian, SV2
Chew, D1
Feit, F1
Ware, JH1
Bertrand, ME3
Saw, J4
Densem, C1
Walsh, S1
Jokhi, P1
Starovoytov, A1
Fox, R1
Buller, C1
Ricci, D1
Fung, A1
Frere, C2
Bali, L2
Moro, PJ2
Choe, KS1
Jani, AB1
Liauw, SL1
Alexander, JH1
Cools, F2
Crea, F1
Dellborg, M2
Lewis, BS4
Mohan, P1
Ruda, M1
Ruzyllo, W2
Verheugt, F1
Makarov, LM1
Spinler, SA3
Moussa, ID1
Kittisupamongkol, W1
Van Werkum, JW1
Hamm, C2
Dill, T2
Gosselink, AT2
Van Houwelingen, G2
Hoorntje, JC1
Koopmans, PC1
Carrel, T1
Englberger, L1
Katus, H4
Scirica, BM2
Skene, A1
Freij, A1
Thorsén, M1
Poyet, R1
Gaborit, B3
Castillo-Sang, M1
Tsang, AW1
Almaroof, B1
Cireddu, J1
Sferra, J1
Zelenock, GB1
Engoren, M1
Kasper, G1
Bagur, R2
Bertrand, OF3
Larose, E2
Nguyen, CM2
Noel, B1
Larochellière, RD1
Poirier, P2
Costerousse, O2
Roy, L2
Borderías Clau, L1
Garrapiz López, J1
Caballero, G1
Aranki, SF1
Body, SC1
Goldstein, LB1
Richard, T1
Butaffuoco, F1
Vanhaeverbeek, M1
Watson, PD1
Joy, PS1
Nkonde, C1
Hessen, SE1
Karalis, DG1
Proulx, G1
Gleeton, O1
De Larochellière, R1
Badreldin, A1
Kroener, A1
Kamiya, H1
Lichtenberg, A1
Hekmat, K1
Kannan, AO1
Makarov, L1
Healey, JS1
Apostolakis, S1
Shantsila, E1
Norgard, NB1
Abu-Fadel, M1
McNulty, S1
Amine, M1
Chew, DP2
French, WJ2
Leisch, F1
Parikh, KH1
Hacke, W7
Stegherr, J2
von Beckerath, N2
Kowalczyk, M1
Banach, M2
Mikhailidis, DP1
Hannam, S1
Rysz, J1
Lazar, LD1
Fitchett, D1
Eikelboom, J2
Fremes, S1
Mazer, D1
Singh, S1
Bittira, B1
Brister, S1
Graham, J2
Gupta, M1
Karkouti, K2
Lee, A1
Love, M1
McArthur, R1
Peterson, M1
Yau, T1
Abildstrom, SZ1
Hvelplund, A2
Andersson, C2
Jørgensen, C1
Madsen, JK3
Gunay, R1
Sensoz, Y1
Kayacioglu, I1
Demirtas, MM1
Guerra, DR1
Mahoney, EM1
Arnold, SV1
Proskorovsky, I1
Antman, E1
Chhatriwalla, AK1
Gerber, RT1
Wells, GA3
Glover, CA1
O'Brien, ER1
Turek, M1
Thomas, A1
Kass, M1
Jadhav, S1
Carlhed, R1
Bojestig, M1
Peterson, A1
Aberg, C1
Garmo, H1
Lindahl, B1
Preobrazhenskiĭ, DV2
Vural, A1
Islek, M1
Avsar, O1
Cattaneo, M3
Wartak, SA1
Lotfi, A1
Rothberg, M1
Zafar, MU1
Ibáñez, B1
Choi, BG1
Vorchheimer, DA1
Piñero, A1
Jin, X1
Sharma, RK1
Badimon, JJ1
Koch, W1
Gebhard, D1
Schuster, T1
Izuhara, Y1
Yamaoka, N1
Kodama, H1
Dan, T1
Takizawa, S1
Hirayama, N1
Meguro, K1
van Ypersele de Strihou, C1
Miyata, T1
Tavassoli, N1
Voisin, S1
Lapeyre-Mestre, M1
Galinier, M1
Montastruc, JL1
Pathak, A1
Wait, SD1
Abla, AA1
Killory, BD1
Starke, RM1
Spetzler, RF1
Nakaji, P1
Hayashi, F1
Mokhtar, OA1
Armero, S1
Mancini, J1
Bonello, C1
Tahirou, I1
Dignat-George, F1
Camoin-Jau, L2
Szlam, F1
Tanaka, KA1
Rumph, B1
Bolliger, D1
Levy, JH3
Schwalm, JD1
Ahmad, M1
Salehian, O1
Tsukahara, K1
Kimura, K1
Morita, S1
Ebina, T1
Kosuge, M1
Hibi, K1
Okuda, J1
Iwahashi, N1
Maejima, N1
Nakachi, T1
Ohtsuka, F1
Hashiba, K1
Tahara, Y1
Sugano, T1
Umemura, S1
Kim, BH1
Kim, KP1
Lim, KS1
Kim, JR1
Yoon, SH1
Lee, YO1
Lee, KH1
Jang, IJ1
Shin, SG1
Yu, KS1
Nie, B1
Yan, ZX1
Jia, de A1
Yu, M1
Petersen, JL1
Barron, JJ1
Hammill, BG1
Cziraky, MJ1
Wahl, PM1
Eisenstein, EL1
Califf, RM4
Schulman, KA1
Curtis, LH1
Bhindi, R1
Latini, RA1
Pizzocri, S1
Lanotte, S1
Biondi Zoccai, GG1
Laudisa, ML1
Brambilla, N1
Banning, AP1
Bedogni, F1
Doraiswamy, VA1
Islam, AM1
Patel, PM1
Maegdefessel, L1
Azuma, J1
Tsao, PS1
Dumont, LA1
Rongières, M1
Tchénio, P1
Gangloff, D1
Garrido-Stowhas, I1
Mousa, SA1
Jeske, WP1
Fareed, J2
Geraghty, OC1
Kennedy, J1
Chandratheva, A1
Marquardt, L1
Buchan, AM1
Rothwell, PM1
Pickett, AM1
Taylor, DA1
Stiefelhagen, P1
Ben-Dor, I1
Scheinowitz, M1
Delhaye, C2
Wakabayashi, K1
Syed, AI1
Collins, SD1
Gonzalez, MA1
Gaglia, MA1
Sudre, A1
Lablanche, JM1
Fukushima, K1
Kobayashi, Y1
Kitahara, H1
Iwata, Y1
Kuroda, N1
Ooyama, M1
Nomura, F1
Komuro, I1
Fuster, V3
Ambrosio, G1
Steinhubl, S2
Gresele, P2
Tritto, I1
Zuchi, C1
Moses, JW2
Yusuf, SW1
Iliescu, C1
Bathina, JD1
Daher, IN1
Durand, JB1
Burdess, A1
Nimmo, AF1
Garden, OJ1
Murie, JA1
Dawson, AR1
Newby, DE1
Flather, MD4
Givol, N1
Halkin, A1
Schöchl, H1
Posch, A1
Hanke, A1
Voelckel, W1
Solomon, C1
Aboyans, V1
Le Guyader, A1
Lacroix, P1
Pevzner, DV1
Staroverov, II1
Frolova, NS1
Mazurov, AV1
Ruda, MY1
Pakhomov, IaM1
Hindy-François, C1
Le Bonniec, B1
Grelac, F1
Dizier, B1
Emmerich, J1
Belch, JJ1
Dormandy, J1
Biasi, GM1
Biasi, BM1
Cairols, M1
Diehm, C1
Eikelboom, B1
Golledge, J1
Jawien, A1
Lepäntalo, M1
Becquemin, JP1
Bergqvist, D1
Clement, D1
Stonebridge, P1
Vermassen, F1
Matyas, L1
Leizorovicz, A1
Renda, G1
Merino, A1
Roldán, I1
Worner, F1
Aïssaoui, N2
Marsal, JR1
Ribera, A1
Permanyer-Miralda, G1
García-Del Blanco, B1
Martí, G1
Cascant, P1
Martín-Yuste, V1
Brugaletta, S1
Sabaté, M1
Capote, ML1
De La Torre, JM1
Ruíz-Lera, M1
Sanmiguel, D1
Cárdenas, M1
Pujol, B1
Baz, JA1
Iñiguez, A1
Trillo, R1
González-Béjar, O1
Casanova, J1
Sánchez-Gila, J1
Christ, G2
Kubica, J3
Herkner, H1
Jilma, B2
Kontny, F1
Spinar, J1
Buck, KK1
Parikh, K1
Löwenberg, EC1
Crosby, JR1
MacLeod, AR1
Zhao, C1
Gao, D1
Black, C1
Revenko, AS1
Meijers, JC1
Stroes, ES1
Levi, M1
Monia, BP1
Joyner, CD2
Afzal, R1
Niiazova-Karben, ZA1
Besnili, F1
Clausen, MT1
Fog-Petersen, ML1
Raunsø, J1
Gadsbøll, N1
Folke, F1
Andersen, SS1
Schramm, TK1
Abildstrøm, SZ2
Poulsen, HE1
Kim, IS1
Yun, SE1
Kang, MK1
Bakaeen, F1
Chu, D2
Feldman, DN1
Minutello, RM1
Bergman, G2
Moussa, I2
Wong, SC2
Schlitt, A2
Paré, G2
Anand, SS1
Hirsh, J2
Simonsen, K1
Finkelstein, A1
Kilhamn, J1
Olofsson, S1
Weaver, WD1
Mangalpally, KK1
Sibbald, M1
Yan, AT1
Huang, W1
Gore, JM2
Eagle, KA2
Brieger, D2
Shehab, N1
Sperling, LS1
Kegler, SR1
Budnitz, DS1
Gendlin, GE1
Tronina, OA1
Storozhakov, GI1
Marchini, J1
Morrow, D1
Resnic, F1
Manica, A1
Kirshenbaum, J1
Cannon, C1
Croce, K1
Armani, AM1
Kulik, A1
Voisine, P1
Tardif, JC1
Delarochelliere, R1
Naidoo, S1
Mesana, TG1
Fernandez, A1
Aboodi, MS1
Milewski, K1
Delgado, JA1
Rodríguez, A1
Granada, JF1
Minarelli, M1
Rechner, AR1
Ivandic, B1
Park, JH1
Singh, PP1
Singh, M1
Bedi, U1
Molnar, J1
Arora, R1
Khosla, S1
Bansal, V1
Fortlage, D1
Doucet, J2
Potenza, B1
Coimbra, R1
Václavík, J1
Táborský, M1
Cadiou, G1
Adam, M1
Caussin, M1
Landrin, I1
Mariette, N1
Capet, C1
Mouton-Schleifer, D1
Remy, E1
Kadri, N1
Pasceri, V3
Vizzi, V1
Di Sciascio, G3
Htun, P1
Fateh-Moghadam, S1
Bischofs, C1
Banya, W1
Müller, K1
Bigalke, B1
Stellos, K1
May, AE2
Flather, M2
Cay, S1
Cagirci, G1
Aydogdu, S1
Balbay, Y1
Sen, N1
Maden, O1
Demir, AD1
Erbay, AR1
White, JA1
Giugliano, RP2
Newby, LK1
Goodwin, MM1
Desilets, AR1
Willett, KC1
Cruden, NL1
Morch, K1
Wong, DR1
Klinke, WP1
Ofiesh, J1
Hilton, JD1
Ahmed, S1
Sabatine, MS6
Suissa, S2
Charlot, M2
Fosbøl, EL1
Teirstein, PS1
Puri, S1
Robbins, M2
Stillabower, ME1
Stillablower, ME1
Aragon, JR1
Stinis, CT1
Lee, MS2
Schork, NJ1
Connor, S'1
Payot, L2
Bellemain-Appaix, A3
Aout, M1
Steiger, H1
Uddin, FS1
Davila, RE1
Harford, WV1
Spechler, SJ1
Fujishiro, M1
Scharf, RE1
Bellemain, A1
Lindbäck, J1
Hofman-Bang, C1
Stenestrand, U1
Samnegard, A1
Ziegelstein, RC2
Green, A1
Sauder, M1
Guthrie, R1
Khder, Y1
Roberts, J1
Mantovani, F1
Demola, MA1
Suriano, P1
Kozinski, M2
Castriota, F1
Hochholzer, W1
Contant, CF1
Nijjer, SS2
Watson, G1
Athanasiou, T1
Malik, IS1
Cohen, MG1
Rossi, JS1
Garbarino, J1
Bowling, R1
Motsinger-Reif, AA1
Schuler, C1
Dupont, AG1
Gabriel, D2
Quinlan, DJ1
Fitchett, DH1
Théroux, P3
Martin, MT1
Nutescu, EA1
Amin, AP1
Kennedy, KF1
Pencina, M1
Berger, P1
Piana, RN1
Lopez, J2
Kleiman, N1
Zabalza, M1
Subirana, I1
Sala, J1
Lluis-Ganella, C1
Lucas, G1
Tomás, M1
Masiá, R1
Brugada, R1
Elosua, R1
Biancari, F1
Airaksinen, KE1
Puymirat, E1
Coste, P1
Dentan, G1
Bataille, V1
Drouet, E1
Mulak, G1
Simon, T2
Bhala, N1
Taggar, JS1
Rajasekhar, P1
Banerjee, A1
Bakaeen, FG1
Alber, HF1
Pachinger, O1
Frick, M1
Yan, BP1
Brennan, AL1
Loane, P1
Lee, JS1
Ahn, SW1
Song, JW1
Shim, JK1
Yoo, KJ1
Kwak, YL1
Molines, L1
Abu-Yousef, MM1
Larson, JH1
Kuehn, DM1
Wu, AS1
Laroia, AT1
Awad, HH1
Zubaid, M1
Alsheikh-Ali, AA1
Al Suwaidi, J1
Anderson, FA1
Goldberg, RJ1
Qureshi, Z1
Hobson, AR1
Skolnick, BE1
Shenouda, M1
Khutoryansky, NM1
Pusateri, AE1
Carr, ME1
Kalinczuk, L1
Lubiszewska, B1
Demkow, M1
Labos, C1
Dasgupta, K1
Nedjar, H1
Turecki, G1
Rahme, E1
Dalén, M1
van der Linden, J2
Lindvall, G2
Ivert, T1
Nielsen, VG1
Chawla, N1
Mangla, D1
Gomes, SB1
Arkebauer, MR1
Wasko, KA1
Sadacharam, K1
Vosseller, K1
Mariscalco, G1
Bruno, VD1
Cottini, M1
Borsani, P1
Piffaretti, G1
Dominici, C1
Beghi, C1
Sala, A1
Ng, J1
Hohnloser, S1
Burcham, P1
Blais, D1
Firstenberg, MS1
French, J1
Basra, SS1
Tsai, P1
Lakkis, NM1
Brilakis, ES1
Rosiello, R1
Pant, S1
Neupane, P1
Ramesh, KC1
Barakoti, M1
Tang, HL1
Hu, YF1
Xie, HG1
Comin, J1
Kallmes, D1
Mercadier, A1
Lancar, R1
Costagliola, D1
Maitra, S1
Chakraborty, A1
Han, KR1
Hong, TJ1
Chung, WY1
Choi, YJ1
Kim, BO1
Wouter Jukema, J1
Mark, B2
Fichtlscherer, S1
Werner, G1
Schöller, R1
Diller, F1
Holmes, MV1
Perel, P1
Shah, T1
Hingorani, AD1
Casas, JP1
Nissen, SE2
Davies, JE1
Francis, DP1
Delle-Karth, G1
Lang, IM1
Neunteufl, T1
Linkowska, K1
Grzybowski, T1
Powers, D1
Stather, DR1
MacEachern, P1
Chee, A1
Tremblay, A1
You, JJ1
Howard, PA1
Eckman, MH1
Fang, MC1
Hylek, EM1
Schulman, S1
Hughes, M1
Spencer, FA2
Manning, WJ1
Mackay, SM1
Zhou, YH1
Wei, X1
Ye, XF1
Wu, MJ1
Xu, JF1
Qin, YY1
He, J1
Herout, PM1
Harshaw, Q1
Frye, CB1
Perera, M1
Suarez, A1
Luzardo, H1
Molero, T1
Hermanides, RS1
Ottervanger, JP1
Dambrink, JH1
Stella, PR1
Johnston, SS1
Bell, K1
Gdovin, J1
Jing, Y1
Boulé, S1
Marquié, C1
Vanesson-Bricout, C1
Kouakam, C1
Brigadeau, F1
Guédon-Moreau, L1
Acheré, C1
Goéminne-Boulé, C1
Lacroix, D1
Klug, D1
Kacet, S1
Stephens, JC1
Askari, AT1
Simonsen, KL1
Emison, ES1
Bhakta, N1
Cacoub, P2
Creager, MA2
Murugesan, G1
Kottke-Marchant, K1
Rossi, M1
Serraino, GF1
Spadafora, A1
Renzulli, A1
Reese, ES1
Daniel Mullins, C1
Beitelshees, AL1
Onukwugha, E1
Shuldiner, AR1
Vesely, MR1
Fisch, A1
Mega, JL1
Siasos, G1
Tousoulis, D1
Fosbol, EL1
Li, S1
Shah, B1
Mills, RM1
Klaskala, W1
Alexander, KP2
Di Pierro, F1
Rinaldi, F1
Lucarelli, M1
Rossoni, G1
Sorich, MJ1
Polasek, TM1
Wiese, MD1
Nusca, A1
Sheikh-Taha, M1
Ghosn, S1
Lyseng-Williamson, KA1
Mustonen, P1
Puurunen, M1
Varughese, CJ1
Konosic, S1
Burcar, I1
Tada, T1
Natsuaki, M1
Morimoto, T1
Furukawa, Y1
Nakagawa, Y1
Kadota, K1
Iwabuchi, M1
Shizuta, S1
Tazaki, J1
Abe, M1
Ehara, N1
Mizoguchi, T1
Mitsuoka, H1
Inada, T1
Araki, M1
Kaburagi, S1
Taniguchi, R1
Eizawa, H1
Nakano, A1
Suwa, S1
Takizawa, A1
Nohara, R1
Fujiwara, H1
Mitsudo, K1
Nobuyoshi, M1
Kita, T1
Steiner, S2
Moertl, D1
Coyle, D1
Smith, PK1
Goodnough, LT1
Poston, RS1
Short, MA1
Weerakkody, GJ1
Lenarz, LA1
Thompson, VP1
McClure, MW1
Gretler, DD1
Berdan, LG1
Paynter, G1
Madan, M2
Lawler, E1
Young, M1
Gaziano, M1
Warlé-Van Herwaarden, MF1
Roukens, M1
Pop, GA1
Lamfers, EJ1
De Smet, PA1
Kramers, C1
Ueno, T1
Igarashi, K1
Kobayashi, M1
Dai, ZL1
Chen, H1
Wu, XY1
Ahmad, S1
Laine, M1
Bessereau, J1
Sébastien, A1
Kar, S1
Foody, JM1
Funk, M1
Nielsen, LH1
Lindhardsen, J1
Ahlehoff, O1
Olsen, AM1
Rollini, F1
Tello-Montoliu, A1
Darnborough, S1
Geng, DF1
Jin, DM1
Wu, W1
Deng, J1
Wang, JF1
Shevelev, VI2
Kanorskiĭ, SG1
Limper, U1
Lynch, J1
Tamura, T1
Sakaeda, T1
Kadoyama, K1
Okuno, Y1
Ruwald, MH1
Hansen, CM1
Karasoy, D1
Vavalle, JP1
Kopjar, T1
Djuric, Z1
Svetina, L1
Burgess, S1
Mallard, TA1
McClure, LA1
Szychowski, JM1
El Mallah, W1
May, CH1
Einecke, D2
Uchiyama, S3
Tanahashi, N1
Minematsu, K1
Moore, TJ1
Bennett, CL1
Wieloch, M1
Lumsden, J1
Rydell, E1
Ohman, J1
Jones, GM1
Twilla, JD1
Hoit, DA1
Arthur, AS1
Meyer, S1
Lala, A1
Sharma, G1
Scott Braithwaite, R1
Ladapo, JA1
Abdel Samie A, A1
Sun, R1
Vöhringer, U1
Theilmann, L1
Zalt, MB1
Bechara, RI1
Parks, C1
Berkowitz, DM1
Salisbury, AC1
Jones, PG1
Spertus, JA1
Ghose, A1
Sharma, A1
Guha, G1
Mukherjee, D2
Frankel, R1
Hanna, EB1
Fusari, M1
Song, HG1
Lee, JY1
Kim, WJ1
Yun, SC1
Kanorsky, SG1
Cucherat, M1
Jacq, L1
Bernasconi, F1
Jeske, W1
Thethi, I1
Azoulay, L1
Dell'Aniello, S1
Renoux, C1
Weber, R1
Saut, N1
Cohen, W1
Chen, YD1
Lü, SZ1
Jin, ZN1
Song, XT1
Ducas, J1
Chan, MC1
Miller, A1
Kashour, T1
Sare, GM1
Lloyd, FR1
Stower, MJ1
Maier, C1
Gleim, M1
Weiss, T1
Stachetzki, U1
Nicolas, V1
Zenz, M1
Turpie, AG1
Tognoni, G2
Zhao, F5
Hunt, D1
Franzosi, MG1
Beasley, JW1
Cheitlin, MD1
Jones, RH1
Kereiakes, D1
Kupersmith, J1
Levin, TN1
Pepine, CJ1
Schaeffer, JW1
Smith, EE1
Steward, DE1
Gibbons, RJ1
Alpert, JS1
Gregoratos, G1
Hiratzka, LF1
Jacobs, AK1
Commerford, PJ2
Blumenthal, M1
Wittlinger, T1
Meyer, BJ1
Tsakiris, DA1
Mychaskiw, G1
Vaughn, C1
Watters, K1
McConn Walsh, R1
Gerschutz, GP1
von Bardeleben, RS1
Ehrlich, A1
Eimermacher, A1
Peetz, D1
Dahm, M1
Schroeder, WS1
Gandhi, PJ1
Friess, D1
Lämmle, B1
Alberio, L1
Brennan, D1
Kopp, CW1
Priglinger, U1
Probst, P1
Kopecky, SL1
Valentin, V1
Wodlinger, AM1
Pieper, JA1
Remes, V1
Helenius, I1
Robb-Nicholson, C1
Exaire, JE1
Wolski, K2
Raymond, RE2
Orford, JL1
Fasseas, P1
Melby, S1
Burger, K1
Golmard, JL1
Tanguy, ML2
Ankri, A2
Choussat, R2
Drobinski, G1
Vignolles, N1
Thomas, D2
Dumaine, R1
Gallois, V1
Wolski, KE1
Peters, R1
Lakkis, N1
Moore, M1
Power, M1
Kerr, JL1
Oppelt, TF1
Rowen, RC1
Betriu, A1
Rutsch, W1
Wilcox, RG1
Erdmann, E1
Jones, L1
Griffin, S1
Palmer, S1
Main, C1
Orton, V1
Sculpher, M1
Sudlow, C1
Henderson, R1
Hawkins, N1
Riemsma, R1
Bogousslavsky, J2
Mattle, HP1
Denardo, SJ1
Davis, KE1
Schleinitz, MD1
Heidenreich, PA1
Momi, S1
Pitchford, SC1
Alberti, PF1
Minuz, P1
Del Soldato, P1
Leopold, JA1
Hill, KA1
Skene, AM1
Wahidi, MM1
Garland, R1
Feller-Kopman, D1
Herth, F1
Becker, HD1
Ernst, A1
von Heymann, C1
Schoenfeld, H1
Sander, M1
Ziemer, S1
Grubitzsch, H1
Spies, C1
Buresly, K1
Eisenberg, MJ1
Madi-Jebara, S1
Rkeiby-Kassabian, N1
Yazigi, A1
Behounek, BD1
Carney, RJ1
Lazzam, C1
McKay, RG1
Sciagrà, R1
Memisha, G1
Moschi, G1
Pupi, A1
Tiaden, JD1
Wenzel, E1
Berthold, HK1
Müller-Oerlinghausen, B1
Kannan, S1
Arab, D1
Lewis, B1
Cho, L1
Steen, L1
Joyal, D1
Leya, F1
Nitschmann, S1
Hartung, HP1
Siebler, M1
Gill, SS1
Morrow, DA1
Hagiwara, A1
Matsuda, T1
Shimazaki, S1
Bezerra, DC1
Nakamura, T1
Yamazaki, M1
Kimura, Y1
Iwata, M1
Sauer, H1
Leschke, M1
Black, HR1
Mas, JL2
Pearson, TA2
Weber, MA1
Fabry-Ribaudo, L1
Booth, J1
Kapetanakis, EI1
Medlam, DA1
Petro, KR1
Haile, E1
Hill, PC1
Dullum, MK1
Bafi, AS1
Boyce, SW1
Corso, PJ1
Calvet, D1
Touzé, E1
Khurram, Z1
Chou, E1
Minutello, R1
Parikh, M1
Naidu, S1
Walsh, SJ1
McClelland, AJ1
Adgey, JA1
Lutsep, HL1
Kongsaengdao, S1
Arayawichanont, A1
Kamalesh, M1
Smith, SD1
Galor, A1
Hoffman, GS1
Kjaer, J1
Larsen, CH1
Poulsen, TS1
Møller, JE1
Mickley, H1
Bromberg-Marin, G1
Parsons, LS1
Canto, JG1
Rogers, WJ1
Sartipy, U1
Poston, R1
Soulat, L1
Lambert, Y1
Adgey, J1
Sánchez-Torrijos, J1
Gudín-Uriel, M1
Ridocci-Soriano, F1
Campbell, ME1
Mathias, J1
Pieper, KS1
Tolleson, TR1
O'Shea, JC1
Guo, W1
Wexler, RR1
Lam, PY1
Quan, ML1
Knabb, RM1
Liao, JK1
Tonelli, M1
Mann, JF2
Sitkei, E1
Hawken, S1
Fitzgerald, DJ2
DeEugenio, D1
Kolman, L1
DeCaro, M2
Andrel, J1
Chervoneva, I1
Duong, P1
Lam, L1
McGowan, C1
Lee, G1
Ruggiero, N1
Singhal, S1
Greenspon, A1
Cherfan, A1
Arabi, Y1
Al Askar, A1
Al Shimemeri, A1
de Borst, GJ1
Hilgevoord, AA1
de Vries, JP1
van der Mee, M1
van de Pavoordt, HD1
Ackerstaff, RG1
Jackson, AJ1
Teenan, RP1
Orr, DJ1
Macdonald, S1
Chow, G1
Collins, JS1
Meinertz, T1
Anand, S1
Xie, C1
Sussex, B1
Guzman, R1
Cina, C1
Crowell, R1
Gosselin, G1
Chassot, PG1
Delabays, A1
Spahn, DR1
Fox, K1
Wang, TH1
Helton, TJ1
Bavry, AA1
Kumbhani, DJ1
Duggal, S1
Roukoz, H1
Rivkin, A1
Vilahur, G1
Casaní, L1
Badimon, L1
Brulotte, S1
Sénéchal, M1
Lemieux, A1
Bergeron, S1
Motivala, AA1
Tamhane, U1
Saab, F1
Rogers, EK1
Froehlich, J1
Moscucci, M1
Peters, G1
Riesmeyer, J1
Bruskina, O1
Dotzer, F1
Walker, CW1
Dawley, CA1
Fletcher, SF1
Yow, E1
Berezny, KY1
Bokesch, PM1
Takahashi, M1
Graham, TP1
Sanders, SP1
Sidi, D1
Bonnet, D1
Ewert, P1
Michelson, AD1
Johnson, SG1
Rogers, K1
Delate, T1
Witt, DM1
Gitt, A1
Jünger, C1
Koeth, O1
Gottwik, M1
Popławski, C1
Jakubczyk, P1
Jakubczyk, M1
Kwa, AT1
Rogers, JH1
Foley, P1
Reaume, KT1
Regal, RE1
Dorsch, MP1
Schaerlig, E1
Lefebvre, CW1
Hoekstra, JW1
Bonaca, M1
Giugliano, R1
Schwartz, NE1
Best, PJ1
Dasgupta, A1
Szczech, LA1
Langton, PE1
Billett, HH1
Pinkau, T1
Purushothaman, B1
Hermosillo, AJ1
Voitk, J1
Hasin, Y1
Chandna, H1
Macias, W1
Alvarez, W1
Riley, AB1
Tafreshi, MJ1
Haber, SL1
Brommer, EJ1
Cortelazzo, S1
Finazzi, G1
Ruggeri, M1
Vestri, O1
Galli, M1
Rodeghiero, F1
Barbui, T1
Caliendo, G1
Bradbury, K1
Mehl, B1
Karrillon, GJ1
Benveniste, E1
Bunouf, P1
Aubry, P1
Chevalier, B1
Commeau, P1
Cribier, A1
Eiferman, C1
Grollier, G1
Guerin, Y1
Henry, M1
Lefevre, T1
Livarek, B1
Louvard, Y1
Marco, J1
Makowski, S1
Pernes, JM1
Rioux, P1
Spaulding, C1
Zemour, G1
Pan, M1
Suárez de Lezo, J1
Velasco, F1
Romero, M1
Medina, A1
Segura, J1
Hernández, E1
Pavlovic, D1
Melian, F1
Gallardo, A1
Zayas, R1
Ruiz, M1
Torres, A1
Schafer, AI1
Iturbe, T1
Sánchez, C1
Moreno, JA1
Olave, T1
Azaceta, G1
Varo, MJ1
Civeira, E1
Peleato, J1
Cornudella, R1
Anzuini, A1
Rosanio, S1
Tocchi, M1
Coppi, R1
Bonnier, H1
Sheiban, I1
Kulbertus, HE1
Chierchia, SL1
Fleck, E1
Bonnier, J1
Emmanuelson, H1
Missault, L1
Chierchia, S1
Casaccia, M1
Niccoli, L1
Oto, A1
White, C1
Webb-Peploe, M1
Van Belle, E1
McFadden, EP1
Baim, DS1
Popma, JJ1
Gordon, PC1
Ho, KK1
Giambartolomei, A1
Diver, DJ1
Lasorda, DM1
Williams, DO1
Kuntz, RE1
Ruf, A1
Pogátsa-Murray, G1
Dickfeld, T1
Zohlnhöfer, D1
Oetgen, M1
Roubin, G1
Iyer, S1
Maida, R1
Collins, M1
Kreps, E1
McCullough, PA1
Marks, KR1
Boysen, G1
Harker, LA1
Boissel, JP1
Pilgrim, AJ1
Gent, M1
Quinn, MJ1
Dunlop, H1
Siu, K1
Hirsch, AT1
Ringleb, PA1
Yip, HK1
Chang, HW1
Wu, CJ1
Chen, MC1
Hang, CL1
Fang, CY1
Hsieh, KY1
Hutten, BA1
Plokker, HW1
Yadav, JS1
Kilaru, PK1
Schweiger, MJ1
Kozman, HA1
Weil, TR1
Taniuchi, M1
Kurz, HI1
Lasala, JM1
Fox, KK1
Chapman, TW1
Bowley, DM1
Lambert, AW1
Walker, AJ1
Ashley, SA1
Wilkins, DC1
Owen, A1
Yende, S1
Doggrell, SA1
Ward, DJ1
Taylor, R1
Khot, UN1
Sone, R1
Nagayama, T1
Shibagaki, Y1
Kobayashi, I1
Maruyama, S1
Kusakabe, K1
Tsujinaka, T1
Itoh, T1
Uemura, Y1
Sakon, M1
Kambayashi, J1
Mori, T1
Hatsuoka, M1
Seiki, M1
Sasaki, K1
Kashii, A1
Criado, A1
Juffé, A1
Carmona, J1
Otero, C1
Avello, F1

Clinical Trials (191)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02513810]3,020 participants (Anticipated)Interventional2015-12-02Active, not recruiting
[NCT02494895]Phase 43,056 participants (Anticipated)Interventional2015-08-01Recruiting
Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-[NCT03971500]3,710 participants (Actual)Interventional2019-08-20Active, not recruiting
A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395]Phase 23,037 participants (Actual)Interventional2015-04-20Completed
Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319]1,000 participants (Anticipated)Observational2009-03-31Active, not recruiting
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998]Phase 39,326 participants (Actual)Interventional2008-06-30Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]Phase 318,624 participants (Actual)Interventional2006-10-31Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052]Phase 4634 participants (Anticipated)Interventional2021-07-02Recruiting
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989]Phase 42,106 participants (Anticipated)Interventional2020-01-01Active, not recruiting
Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227]Phase 43,773 participants (Actual)Interventional2011-12-31Completed
Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602]200 participants (Actual)Observational2020-10-07Completed
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864]Phase 32,725 participants (Actual)Interventional2014-07-22Completed
Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200]Phase 41,724 participants (Actual)Interventional2013-10-05Completed
Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI[NCT01959451]Phase 42,600 participants (Actual)Interventional2013-09-30Completed
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606]Phase 4272 participants (Anticipated)Interventional2016-12-31Recruiting
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]Phase 325,086 participants (Actual)Interventional2006-06-30Completed
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298]2,062 participants (Actual)Observational [Patient Registry]2012-12-21Completed
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984]Phase 260 participants (Anticipated)Interventional2021-08-01Recruiting
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862]350 participants (Anticipated)Interventional2023-04-24Recruiting
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081]1,067 participants (Anticipated)Observational [Patient Registry]2021-02-03Recruiting
Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699]Phase 42,690 participants (Anticipated)Interventional2023-03-28Recruiting
What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing[NCT00769938]Phase 4573 participants (Actual)Interventional2008-12-31Completed
Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536]Phase 41,798 participants (Actual)Interventional2009-01-31Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855]Phase 480 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Practice Patterns of Antithrombotic Therapy in REAL-world Patients Undergoing PCI in Spain: Parenteral Antiplatelet Agents[NCT05193019]1,000 participants (Anticipated)Observational2022-03-14Recruiting
International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt[NCT00396877]Phase 3906 participants (Actual)Interventional2006-11-30Completed
China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674]10,000 participants (Anticipated)Observational [Patient Registry]2017-06-01Not yet recruiting
Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009]Phase 33,000 participants (Actual)Interventional2016-11-30Completed
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589]Phase 35,100 participants (Actual)Interventional2009-12-31Completed
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314]144 participants (Anticipated)Interventional2022-05-01Recruiting
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710]10,179 participants (Actual)Observational2010-06-30Completed
Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial[NCT01830491]Phase 4162 participants (Actual)Interventional2009-03-31Completed
The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention[NCT01774955]2,047 participants (Actual)Observational [Patient Registry]2012-02-29Completed
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]Phase 43,750 participants (Anticipated)Interventional2010-06-30Recruiting
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934]Phase 464 participants (Anticipated)Interventional2018-09-26Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events[NCT01186146]Phase 45,000 participants (Actual)Interventional2010-08-31Completed
A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700]78,000 participants (Actual)Observational2006-01-31Active, not recruiting
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372]Phase 43,119 participants (Actual)Interventional2010-04-30Completed
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753]1,001 participants (Actual)Observational2008-02-29Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306]Phase 33,020 participants (Actual)Interventional2003-02-28Completed
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.[NCT01347580]Phase 41,875 participants (Actual)Interventional2011-09-30Completed
Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771]Phase 464 participants (Actual)Interventional2015-03-31Completed
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651]Phase 2140 participants (Anticipated)Interventional2019-06-01Not yet recruiting
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948]1,080 participants (Anticipated)Observational [Patient Registry]2018-02-09Active, not recruiting
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267]100 participants (Anticipated)Interventional2015-05-31Completed
"Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203]1,000 participants (Actual)Observational [Patient Registry]2016-01-01Completed
Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020]1,240 participants (Anticipated)Observational2011-11-30Not yet recruiting
Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815]Phase 4296 participants (Actual)Interventional2014-09-19Completed
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve[NCT00530894]1,057 participants (Actual)Interventional2007-04-30Completed
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206]Phase 44,005 participants (Actual)Interventional2008-09-30Active, not recruiting
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003]Phase 42,272 participants (Actual)Interventional2010-04-30Completed
Platelet Function in Resuscitated Patients-2[NCT03445546]25 participants (Actual)Observational2016-05-01Completed
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319]Phase 31,606 participants (Actual)Interventional2011-06-30Active, not recruiting
Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982]1,500 participants (Actual)Observational2012-10-31Completed
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]Phase 4450 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI[NCT00962416]Phase 41,161 participants (Actual)Interventional2009-09-30Completed
Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management[NCT01000701]4,000 participants (Anticipated)Observational2009-10-31Recruiting
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775]Phase 2203 participants (Actual)Interventional2013-02-06Completed
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]Phase 3220 participants (Actual)Interventional2009-04-30Completed
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254]Phase 4420 participants (Anticipated)Interventional2013-08-31Recruiting
An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes[NCT02944123]Phase 3120 participants (Actual)Interventional2016-09-30Completed
A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial[NCT04755387]Phase 42,000 participants (Anticipated)Interventional2021-02-15Recruiting
Zotarolimus Eluting Stent Versus Sirolimus Eluting Stent in High Bleeding Risk Angioplasty[NCT05240781]280 participants (Anticipated)Interventional2021-09-29Recruiting
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]8,575 participants (Actual)Observational2008-01-31Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]5,031 participants (Actual)Observational2009-06-30Completed
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281]1,079 participants (Actual)Interventional2010-10-31Completed
A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705]2,927 participants (Actual)Observational2019-09-20Completed
Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study.[NCT02054663]Phase 460 participants (Actual)Interventional2013-12-31Completed
The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503]12,227 participants (Actual)Observational2010-03-31Completed
Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503]Phase 42,000 participants (Anticipated)Interventional2012-11-30Recruiting
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822]Phase 313,885 participants (Actual)Interventional2012-12-04Completed
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890]Phase 4510 participants (Anticipated)Interventional2018-09-01Recruiting
"Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733]1,000 participants (Actual)Observational [Patient Registry]2018-06-18Completed
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803]Phase 42,808 participants (Anticipated)Interventional2022-06-17Recruiting
The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766]150 participants (Anticipated)Observational2020-09-30Not yet recruiting
PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843]1,000 participants (Anticipated)Interventional2010-04-30Recruiting
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054]Phase 44,570 participants (Actual)Interventional2005-11-30Completed
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]Phase 42,505 participants (Actual)Interventional2008-08-31Completed
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762]Phase 429 participants (Actual)Interventional2015-06-30Completed
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817]Phase 315,603 participants (Actual)Interventional2002-10-31Completed
Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT01158846]Phase 4800 participants (Anticipated)Interventional2010-08-31Not yet recruiting
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591]Phase 313,619 participants (Actual)Interventional2004-11-30Completed
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720]Phase 33,400 participants (Anticipated)Interventional2020-10-15Recruiting
Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial[NCT04259853]1,016 participants (Anticipated)Interventional2020-01-30Enrolling by invitation
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786]Phase 42,700 participants (Actual)Interventional2011-06-30Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]Phase 37,554 participants (Actual)Interventional2003-06-30Completed
[NCT01032668]Phase 3192 participants (Actual)Interventional2008-09-30Completed
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158]Phase 313,800 participants Interventional2003-08-31Completed
Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566]Phase 4624 participants (Actual)Interventional2004-12-31Completed
A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300]Phase 21,741 participants (Actual)Interventional2006-05-31Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330]Phase 3180 participants (Anticipated)Interventional2013-01-31Recruiting
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease[NCT02110303]Phase 2/Phase 3220 participants (Actual)Interventional2015-03-31Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301]1,140 participants (Anticipated)Observational2021-09-02Recruiting
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330]Phase 440 participants (Actual)Interventional2016-06-30Completed
A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943]Phase 4200 participants (Actual)Interventional2017-01-31Completed
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300]Phase 41,038 participants (Actual)Interventional2018-10-01Completed
Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364]Phase 470 participants (Anticipated)Interventional2011-09-30Recruiting
CARDIOBASE Bern PCI Registry[NCT02241291]10,000 participants (Anticipated)Observational2009-03-31Recruiting
A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157]1,576 participants (Actual)Observational2018-03-25Completed
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889]Phase 3516 participants (Anticipated)Interventional2023-11-09Recruiting
Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728]1,756 participants (Anticipated)Interventional2018-04-04Recruiting
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]889 participants (Actual)Interventional2013-06-30Terminated (stopped due to Ethics Committe decision)
Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293]1,505 participants (Actual)Observational2021-07-20Completed
A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493]1,066 participants (Actual)Observational [Patient Registry]2015-05-28Completed
Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363]20,000 participants (Anticipated)Observational2019-06-19Enrolling by invitation
Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205]Phase 290 participants (Actual)Interventional2017-11-07Completed
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events[NCT02291419]Phase 46 participants (Actual)Interventional2015-07-31Terminated (stopped due to Enrollment expectations were not met)
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004]Phase 460 participants (Anticipated)Interventional2015-06-30Recruiting
Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373]Phase 3100 participants (Anticipated)Interventional2012-08-31Recruiting
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]Phase 4300 participants (Anticipated)Interventional2015-05-31Recruiting
Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185]Phase 4154 participants (Actual)Interventional2011-05-31Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162]Phase 38,882 participants (Actual)Interventional2006-04-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture[NCT02475187]33 participants (Anticipated)Observational2015-09-30Terminated
A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558]Phase 390 participants (Actual)Interventional2016-12-31Completed
Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171]Phase 2/Phase 3150 participants (Anticipated)Interventional2018-08-01Active, not recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139]Phase 2/Phase 3102 participants (Actual)Interventional2011-09-30Completed
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477]180 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery[NCT00701142]Phase 280 participants (Actual)Interventional2008-06-30Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725]Phase 30 participants (Actual)InterventionalWithdrawn (stopped due to Study was not initiated, change in clinical development)
A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759]Phase 31,460 participants (Anticipated)Interventional2004-09-30Completed
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237]70 participants (Actual)Interventional2016-06-30Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268]Phase 4107 participants (Actual)Interventional2015-04-30Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851]Phase 45,000 participants (Anticipated)Interventional2016-06-30Recruiting
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574]84 participants (Actual)Observational2019-02-26Completed
Chinese People's Liberation Army General Hospital[NCT02798874]240 participants (Anticipated)Interventional2016-05-31Enrolling by invitation
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790]Phase 4600 participants (Anticipated)Interventional2014-12-31Not yet recruiting
Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044]120 participants (Anticipated)Interventional2015-11-30Active, not recruiting
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423]Phase 2113 participants (Actual)Interventional2006-05-31Completed
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevati[NCT00089895]Phase 39,406 participants (Actual)Interventional2004-11-01Completed
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345]Phase 31,008 participants (Actual)Interventional2011-07-31Completed
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918]2,800 participants (Actual)Interventional2008-06-30Completed
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785]90 participants (Actual)Observational2017-03-27Completed
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031]Phase 4500 participants (Anticipated)Interventional2012-08-31Not yet recruiting
Effect of the Omega n3 Fatty on Human Platelet Function[NCT00515541]Phase 243 participants (Actual)Interventional2007-09-30Completed
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607]Phase 41,466 participants (Anticipated)Interventional2008-06-30Active, not recruiting
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]31 participants (Actual)Interventional2014-09-30Completed
LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651]69 participants (Anticipated)Observational2016-05-31Enrolling by invitation
Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545]130 participants (Actual)Observational2012-06-30Completed
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]88 participants (Actual)Observational2018-01-01Completed
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838]1,200 participants (Anticipated)Observational2023-08-09Recruiting
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231]Phase 2652 participants (Actual)Interventional2008-12-31Completed
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639]Phase 4200 participants (Actual)Interventional2010-06-30Completed
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066]Phase 465 participants (Actual)Interventional2016-01-31Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]Phase 460 participants (Actual)Interventional2004-10-31Completed
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309]30 participants (Anticipated)Interventional2006-04-30Completed
Femoral Versus Radial Access for Coronary Intervention in the Acute Phase of ST-Elevation Myocardial Infarction[NCT00356044]Phase 4439 participants (Actual)Interventional2004-05-31Completed
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675]Phase 4378 participants (Actual)Interventional2017-05-12Completed
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013]42 participants (Actual)Observational2013-08-31Completed
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy[NCT00714961]Phase 33,491 participants (Actual)Interventional2003-02-28Completed
The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048]Phase 4300 participants (Anticipated)Interventional2023-05-01Not yet recruiting
The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589]0 participants (Actual)Interventional2011-04-30Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI)
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671]Phase 32,400 participants Interventional2000-01-31Active, not recruiting
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264]Phase 3200 participants (Anticipated)Interventional2020-01-09Recruiting
DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656]Phase 4159 participants (Actual)Interventional2020-06-08Completed
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615]4,500 participants (Actual)Observational2015-01-31Completed
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384]Phase 350 participants (Actual)Interventional2021-04-01Completed
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514]4,471 participants (Actual)Observational2009-10-31Terminated (stopped due to Administrative reasons)
The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566]Phase 420 participants (Actual)Interventional2009-11-30Completed
Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers)[NCT00115375]Phase 292 participants (Actual)Interventional2004-01-31Completed
Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667]Phase 4220 participants (Anticipated)Interventional2017-04-10Recruiting
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261]Phase 41,001 participants (Actual)Interventional2003-04-30Completed
Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414]Phase 255 participants (Actual)Interventional2015-02-28Completed
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]100 participants (Anticipated)Observational2021-03-10Not yet recruiting
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]300 participants Interventional2001-04-30Active, not recruiting
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401]Phase 32,399 participants (Actual)Interventional1996-07-31Completed
A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086]165 participants (Actual)Observational2006-03-31Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]280 participants (Actual)Observational2014-06-30Completed
The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism[NCT02447809]Phase 4400 participants (Anticipated)Interventional2015-01-31Recruiting
Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis[NCT00837954]Phase 432 participants (Actual)Interventional2009-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events

Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)

Interventionparticipants (Number)
Rivaroxaban 2.5 mg Twice Daily (BID)80
Acetylsalicylic Acid 100 mg Once Daily (OD)74

Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke

The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.61
Prasugrel: 75 Years of Age or Older27.04
Clopidogrel: <75 Years of Age11.12
Clopidogrel: 75 Years of Age or Older26.83

Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age10.06
Prasugrel: 75 Years of Age or Older24.64
Clopidogrel: <75 Years of Age10.96
Clopidogrel: 75 Years of Age or Older24.13

Percentage of Participants With a Composite Endpoint of CV Death and MI

The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age9.61
Prasugrel: 75 Years of Age or Older22.53
Clopidogrel: <75 Years of Age10.21
Clopidogrel: 75 Years of Age or Older22.69

Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA)

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Interventionpercentage of participants with an event (Number)
Prasugrel: <75 Years of Age12.13
Prasugrel: 75 Years of Age or Older26.27
Clopidogrel: <75 Years of Age12.83
Clopidogrel: 75 Years of Age or Older25.67

Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP)

Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months

,,,
Interventionpicograms per milliliter (pg/mL) (Geometric Mean)
Day 306 Months (n=725, 125, 701, 174)
Clopidogrel: <75 Years of Age319.345250.982
Clopidogrel: 75 Years of Age or Older951.359722.750
Prasugrel: <75 Years of Age313.494253.434
Prasugrel: 75 Years of Age or Older1082.396770.132

Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6

,,,
Interventionmilligrams per liter (mg/L) (Geometric Mean)
Day 306 Months (n=755, 143, 745, 178)
Clopidogrel: <75 Years of Age2.2872.149
Clopidogrel: 75 Years of Age or Older2.2261.543
Prasugrel: <75 Years of Age2.3302.272
Prasugrel: 75 Years of Age or Older2.4411.593

Economic and Quality of Life Outcomes

Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)

,
Interventionunits on a scale (Mean)
Baseline, physical limitationsBaseline, angina frequency24 Months, physical limitations (n=420, 412)24 Months, angina frequency (n=420, 412)
Clopidogrel67.073.174.589.5
Prasugrel67.873.675.189.7

Genotyping Related to Drug Metabolism

Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline

,,,
Interventionpercentage participants with geneotype (Number)
UM, *1/*17UM, *17/*17EM (non-UM), *1/*1IM, *1/*2IM, *1/*3IM, *1/*4IM, *1/*6IM, *1/*8PM, *2/*2PM, *2/*3PM, *2/*4PM, *2/*6PM, *2/*8PM, *3/*3UNK, *1/*10UNK, *1/*13UNK, *1/*9UNK, *1/*9, *9/*17UNK, *13/*17UNK, *2/*13UNK, *2/*17UNK, *2/*9UNK, *3/*17UNK, *4/*17UNK, *4/*9UNK, *6/*17UNK, *8/*17UNK, *9/*17UNK, Undefined genotype
Clopidogrel: <75 Years of Age25.15.435.719.80.50.10.00.44.30.30.20.00.00.20.10.00.00.00.00.06.80.10.00.20.00.00.10.00.5
Clopidogrel: 75 Years of Age or Older21.84.341.219.70.60.30.20.33.80.30.20.00.00.00.00.00.00.00.00.06.20.00.30.00.00.20.00.00.6
Prasugrel: <75 Years of Age24.05.138.818.60.80.40.00.13.90.30.00.00.00.00.00.00.10.00.00.06.30.00.10.20.00.00.20.00.7
Prasugrel: 75 Years of Age or Older25.03.642.118.30.60.00.20.52.20.20.20.00.00.00.00.20.20.00.00.06.10.00.00.20.00.00.00.00.6

Platelet Aggregation Measures

Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months

,,,
InterventionP2Y12 Reaction Units (PRU) (Least Squares Mean)
Day 30Month 12 (n=386, 76, 400, 103)
Clopidogrel: <75 Years of Age193.489199.003
Clopidogrel: 75 Years of Age or Older200.285181.360
Prasugrel: <75 Years of Age93.28094.529
Prasugrel: 75 Years of Age or Older151.872135.096

Summary of All Deaths

All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

,,,
Interventionparticipants (Number)
Congestive Heart FailureCardiogenic ShockCardiac RuptureMyocardial InfarctionDysrhythmiaStent ThrombosisDirectly Related to Revascularization-CABG or PCIIntracranial HemorrhageNon-Hemorrhagic StrokeSudden death due to cardiovascular eventPulmonary EmbolismStroke, unknown typeOther Cardiovascular EventCardiovascular event, unknown typeAccidentalTraumaHemorrhage, not intracranialInfectionMalignancySuicideOther Non-Cardiovascular eventCause unknown (nonadjudicated event)
Clopidogrel: <75 Years of Age13100246014470200451001614080
Clopidogrel: 75 Years of Age or Older2390213011343101451141711060
Prasugrel: <75 Years of Age1080165012475006401211414180
Prasugrel: 75 Years of Age or Older214124201143911141031217041

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR901
CLOPIDOGREL1065

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR1290
CLOPIDOGREL1456

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR569
CLOPIDOGREL668

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR864
CLOPIDOGREL1014

Participants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR961
CLOPIDOGREL929

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR619
CLOPIDOGREL654

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR329
CLOPIDOGREL341

Participants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR399
CLOPIDOGREL506

Participants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR353
CLOPIDOGREL442

Participants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR1339
CLOPIDOGREL1215

Participants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR504
CLOPIDOGREL593

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR362
CLOPIDOGREL306

Participants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR235
CLOPIDOGREL180

Participants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR125
CLOPIDOGREL106

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR21
CLOPIDOGREL16

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR84
CLOPIDOGREL51

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

Time to Adjudicated All Cause Death

Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg55
Dabigatran Etexilate 150mg30
Warfarin48
Warfarin (Excluding Elder Patients Outside USA)35

Time to Adjudicated CV

"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg37
Dabigatran Etexilate 150mg21
Warfarin31
Warfarin (Excluding Elder Patients Outside USA)24

Time to Adjudicated Non-CV

"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg14
Dabigatran Etexilate 150mg4
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to Adjudicated Undetermined Cause of Death

"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg4
Dabigatran Etexilate 150mg5
Warfarin4
Warfarin (Excluding Elder Patients Outside USA)3

Time to Composite Endpoint of Death + MI + Stroke

Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg107
Dabigatran Etexilate 150mg60
Warfarin80
Warfarin (Excluding Elder Patients Outside USA)57

Time to Composite Endpoint of Death or First Thrombotic Event

Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg108
Dabigatran Etexilate 150mg60
Warfarin83
Warfarin (Excluding Elder Patients Outside USA60
All Dabigatran Etexilate168

Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg149
Dabigatran Etexilate 150mg90
Warfarin131
Warfarin (Excluding Elder Patients Outside USA)98
All Dabigatran Etexilate239

Time to First Adjudicated ISTH MBE or CRNMBE

"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg151
Dabigatran Etexilate 150mg154
Warfarin264
Warfarin (Excluding Elder Patients Outside USA)196

Time to First Adjudicated MI

Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg44
Dabigatran Etexilate 150mg26
Warfarin29
Warfarin (Excluding Elder Patients Outside USA)22

Time to First Adjudicated SE

"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg3
Dabigatran Etexilate 150mg1
Warfarin3
Warfarin (Excluding Elder Patients Outside USA)3

Time to First Adjudicated ST

Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg15
Dabigatran Etexilate 150mg7
Warfarin8
Warfarin (Excluding Elder Patients Outside USA)7

Time to First Adjudicated Stroke

"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg17
Dabigatran Etexilate 150mg9
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to First Adjudicated Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg76
Dabigatran Etexilate 150mg51
Warfarin69
Warfarin (Excluding Elder Patients Outside USA)52

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

(NCT00335452)
Timeframe: 30 days

Interventionparticipants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose267
Clopidogrel 300/75/75 mg + ASA High Dose290
Clopidogrel 600/150/75 mg + ASA Low Dose282
Clopidogrel 600/150/75 mg + ASA High Dose240

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel + ASA High Dose52721125165
Clopidogrel + ASA Low Dose54623126055

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA55722227461
Clopidogrel 600/150/75 mg + ASA52222623759

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA39213222535
Clopidogrel 600/150/75 mg + ASA33013017228

Occurrence of Major Bleeding - ASA Dose Level Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel + ASA High Dose28221673
Clopidogrel + ASA Low Dose28521574

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA25519565
Clopidogrel 600/150/75 mg + ASA31323683

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Stent trombosis- Definite- Probable
Clopidogrel 300/75/75 mg + ASA20011189
Clopidogrel 600/150/75 mg + ASA1355877

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Number of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times. (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

,
Interventionparticipants (Number)
SpontaneousPost-traumaticPuncture (vascular access site)Surgical
Clopidogrel 0.2 mg/kg/Day5611917
Placebo6061910

Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)

"The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.~Only the first event was counted." (NCT00396877)
Timeframe: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)

,
Interventionparticipants (Number)
Death / Shunt Thrombosis / Cardiac Procedure- Death- Shunt thrombosis- Cardiac procedure <120 days of thrombotic nature
Clopidogrel 0.2 mg/kg/Day89512612
Placebo9060219

Number of Participants With Bleeding Events

"Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted." (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

,
Interventionparticipants (Number)
Any bleeding event- Serious- Serious with an outcome of death- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day873019
Placebo883219

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

1st Composite Clinical Endpoint

death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death (NCT01347580)
Timeframe: during the 30 days of treatment

Interventionpatients (Number)
Pre-hospital Ticagrelor41
In-hospital Ticagrelor42

2nd Composite Clinical Endpoint

Death/MI/urgent revascularization. Adjudicated events except death (NCT01347580)
Timeframe: within 30 days of study

Interventionpatients (Number)
Pre-hospital Ticagrelor39
In-hospital Ticagrelor34

Definite Stent Thrombosis

Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint (NCT01347580)
Timeframe: during 30 days of treatment

Interventionpatients (Number)
Pre-hospital Ticagrelor2
In-hospital Ticagrelor11

Major Bleeds After 48 Hours

non CABG related bleeds (PLATO definition) include life threatening and other major bleedings (NCT01347580)
Timeframe: after 48hours post-first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor11
In-hospital Ticagrelor11

Major Bleeds Within 48 Hours

non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds (NCT01347580)
Timeframe: within 48 hours of first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor16
In-hospital Ticagrelor15

Minor and Major Bleedings Within 48 Hours

non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: within 48 hours of first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor24
In-hospital Ticagrelor24

Minor and Major Bleeds After 48 Hours

non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: after 48 hours post first dose

Interventionpatients (Number)
Pre-hospital Ticagrelor18
In-hospital Ticagrelor16

ST Segment Elevation Resolution Post-PCI >= 70%

ST segment elevation resolution post PCI >=70% is defined as complete resolution (NCT01347580)
Timeframe: Between baseline and ECG 60 mn post-PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor410
In-hospital Ticagrelor390

ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)

ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (<70%) resolution. (NCT01347580)
Timeframe: Between baseline and PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor102
In-hospital Ticagrelor102

Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)

(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion. (NCT01347580)
Timeframe: At initial angiography, pre PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor143
In-hospital Ticagrelor145

Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI

Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention. (NCT01347580)
Timeframe: during PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor78
In-hospital Ticagrelor100

TIMI Flow Grade 3 Post -PCI

TIMI) flow grade 3 is complete perfusion post-PCI. (NCT01347580)
Timeframe: at coroangiography post-PCI

Interventionpatients (Number)
Pre-hospital Ticagrelor625
In-hospital Ticagrelor630

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Composite of Death and Recurrence Hospitalization.

Death from any cause or repeat hospitalization after intervention. (NCT00530894)
Timeframe: duration of study

Interventionparticipants (Number)
Inoperable: TAVR76
Inoperable: Medical Therapy126

Death

Death from any cause. (NCT00530894)
Timeframe: 1 Year

Interventionparticipants (Number)
High Risk: TAVR84
High Risk: SAVR89
Inoperable: TAVR55
Inoperable: Medical Therapy89

Functional Change of NYHA

NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. (NCT00530894)
Timeframe: Baseline to 1 year

InterventionUnits on scale (Least Squares Mean)
High Risk: TAVR2.50
High Risk: SAVR2.60
Inoperable: TAVR2.88
Inoperable: Medical Therapy3.92

Number of Participants With Major Adverse Cardiac and Cerebro-vascular Events (MACCE)

Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure (NCT00530894)
Timeframe: 1 year

Interventionparticipants (Number)
High Risk: TAVR93
High Risk: SAVR97
Inoperable: TAVR61
Inoperable: Medical Therapy93

Total Hospital Days From the Index Procedure

Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization. (NCT00530894)
Timeframe: 1 year

InterventionDays (Mean)
High Risk: TAVR17.42
High Risk: SAVR20.14
Inoperable: TAVR25.24
Inoperable: Medical Therapy17.04

Change in Quality of Life (QOL) From Baseline to 1 Year

"The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.~KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.~SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status." (NCT00530894)
Timeframe: Baseline and 1 Year

,,,
InterventionUnits on a scale (Mean)
KCCQ OverallSF-12 PhysicalSF-12 Mental
High Risk: SAVR71.136.952.9
High Risk: TAVR70.036.352.0
Inoperable: Medical Therapy46.9829.6846.59
Inoperable: TAVR69.4134.8553.31

Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm1.8
Thienopyridine Therapy2.0
Surveillance Arm4.8

Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects

"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Interventionpercentage of participants (Number)
Placebo Arm1.0
Thienopyridine Therapy0.5
Surveillance Arm2.4

Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm4.3
Thienopyridine Therapy4.8
Surveillance Arm16.9

Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period

Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel1
Edoxaban3

Number of Participants With Amputations

Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel3
Edoxaban1

Percentage of Participants With First Re-stenosis / Re-occlusion

Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months

Interventionpercentage of participants (Number)
Clopidogrel34.7
Edoxaban30.9

Safety Assessments

"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel30
Edoxaban31

Percentage of Participants With Clinically Relevant Bleeding During Treatment

Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months

,
Interventionpercentage of participants (Number)
Including Access Site Bleeding (IASB)Excluding Access Site Bleed (EASB)
Clopidogrel86
Edoxaban116

Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment

The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months

,
Interventionpercentage of participants (Number)
IASB : Major BleedingIASB: CRNM BleedingIASB: Minor BleedingEASB : Major BleedingEASB : CRNM BleedingEASB : Minor Bleeding
Clopidogrel5420.84317.8
Edoxaban110201519

Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Duke Coronary Artery Disease (CAD) Index

The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)

Interventionunits on a scale (Mean)
Prasugrel40.36
Other41.87

Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Pre-Procedure Hemoglobin

(NCT01088503)
Timeframe: Day 0 (study enrollment)

Interventiongrams/deciliter (g/dL) (Mean)
Prasugrel14.59
Other14

Percentage of Participants With Definite or Probable Stent Thrombosis (ST) Events

Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months

Interventionpercentage of participants (Number)
Prasugrel1.35
Clopidogrel1.79

Percentage of Participants With MACE and Who Had No Prior History of Transient Ischemic Attack (TIA)/Stroke, Weigh ≥60 Kilograms (kg), and Are Age <75 Years

MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months

Interventionpercentage of participants (Number)
Prasugrel12.67
Clopidogrel15.89

Percentage of Participants With Major Adverse Cardiovascular Events (MACE)

MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months

Interventionpercentage of participants (Number)
Prasugrel13.14
Clopidogrel17.12

Factors Associated With Initial Adenosine Diphosphate (ADP) Receptor Inhibitor Selection at Enrollment

Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)

,
Interventionparticipants (Number)
Received DESReceived only BMSSTEMIOther Race (Non-Caucasian)Cardiogenic Shock on PresentationMale ParticipantsEQ-5D US index = 1 vs. <1Married ParticipantsParticipant has DiabetesNo BMS or DES
Other62822491450810491766342387356012472331
Prasugrel236567218313657924511516204476786

Percentage of Participants With Cumulative Severe or Moderate Bleeding Events

Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months

,
Interventionpercentage of participants (Number)
Baseline1 month6 months12 months15 months
Clopidogrel0.451.622.773.864.21
Prasugrel0.541.221.932.723.10

Percentage of Participants With MACE Over 1, 6 and 15 Months

MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months

,
Interventionpercentage of participants (Number)
1 month6 months15 months
Clopidogrel5.4012.0419.13
Prasugrel4.639.6414.26

ALI

Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd117
Clopidogrel 75 mg od115

All-cause Mortality

Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd628
Clopidogrel 75 mg od635

Any Amputation Caused by PAD

Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd179
Clopidogrel 75 mg od208

Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])

Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1211
Clopidogrel 75 mg od1250

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke

Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipants (Number)
Ticagrelor 90 mg bd751
Clopidogrel 75 mg od740

Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)

Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd766
Clopidogrel 75 mg od759

Composite of CV Death, MI, Ischemic Stroke, and ALI

Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd839
Clopidogrel 75 mg od833

CV Death

Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd363
Clopidogrel 75 mg od343

CV-related Hospitalization

Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1312
Clopidogrel 75 mg od1314

Lower Extremity Revascularization

Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd846
Clopidogrel 75 mg od892

Major Amputation Caused by PAD

Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd100
Clopidogrel 75 mg od116

MI

Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd349
Clopidogrel 75 mg od334

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1119
Clopidogrel 75 mg od1140

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1183
Clopidogrel 75 mg od1199

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd983
Clopidogrel 75 mg od992

Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd789
Clopidogrel 75 mg od786

Non-CV Death

Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd250
Clopidogrel 75 mg od272

PLATO Major Bleeding Events

Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd206
Clopidogrel 75 mg od188

Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event

Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd168
Clopidogrel 75 mg od112

TIMI Major Bleeding Events

Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd113
Clopidogrel 75 mg od109

TIMI Major or Minor Bleeding Events

Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd193
Clopidogrel 75 mg od175

Change in ABI/TBI From Baseline

"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,
InterventionChange in ABI/TBI (Mean)
ABI - 6 months N = 6184(Tica), 6319(Clopi)ABI - End of treatment N = 4951(Tica), 5073(Clopi)TBI - 6 months N = 55(Tica), 48(Clopi)TBI - End of treatment N = 36(Tica), 21(Clopi)
Clopidogrel 75 mg od0.0110.0160.036-0.065
Ticagrelor 90 mg bd0.0160.0220.0500.059

Changes in Fontaine Stage

"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,,,,,,,,,
InterventionParticipant (Number)
Stage I - End of treatmentStage IIa - End of treatmentStage IIb - End of treatmentStage III - End of treatmentStage IV - End of treatmentMissing - End of treatment
Clopidogrel - Stage I7432305694250
Clopidogrel - Stage IIa7231956311157724
Clopidogrel - Stage IIb1985574502310370
Clopidogrel - Stage III33333823560
Clopidogrel - Stage IV192115121345
Ticagrelor - Stage I7752274577248
Ticagrelor - Stage IIa6831948269247743
Ticagrelor - Stage IIb171560469125403
Ticagrelor - Stage III15413931159
Ticagrelor - Stage IV26281971347

Changes in Rutherford Classification

"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,,,,,,,,,,,
InterventionParticipant (Number)
Category 0 - End of treatmentCategory 1/2 - End of treatmentCategory 3 - End of treatmentCategory 4 - End of treatmentCategory 5 - End of treatmentCategory 6 - End of treatmentMissing - End of treatment
Clopidogrel - Cat 074323056922250
Clopidogrel - Cat 1/272319563111561724
Clopidogrel - Cat 31985574502364370
Clopidogrel - Cat 4333338234160
Clopidogrel - Cat 51318121112034
Clopidogrel - Cat 663311011
Ticagrelor - Cat 077522745752248
Ticagrelor - Cat 31715604691232403
Ticagrelor - Cat 4154139311059
Ticagrelor - Cat 5232313411033
Ticagrelor - Cat 635630214
Ticagrelor - Stage II68319482692443743

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel692
Clopidogrel822

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel797
Clopidogrel938

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel502573
Prasugrel389462

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months

,
InterventionParticipants (Number)
UA/NSTEMI (n=5044, n=5030)STEMI (n=1769, n=1765)All ACS (n=6813, n=6795)
Clopidogrel565216781
Prasugrel469174643

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel504588
Prasugrel399472

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)

,
InterventionParticipants (Number)
TIMI Major or Minor BleedingTIMI Major BleedingTIMI Major Bleeding - Life-threatening (LT)LT - FatalLT - Symptomatic intracranial hemorrage (ICH)LT - Requiring inotropesLT - Requiring surgical interventionLT - Requiring transfusion (>=4 units)TIMI Minor Bleeding
Clopidogrel2311115651781930125
Prasugrel303146852119211945164

Adjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA251
Placebo + ASA162

Death From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA825
Placebo + ASA841

Occurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA296
Placebo + ASA408

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Non-CNS systemic embolism- Vascular death
Clopidogrel + ASA8328428550413
Placebo + ASA92410539148380

Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

Interventionpercentage of participants (Number)
Placebo6.1
Apixaban 2.5mg BID15.1
Apixaban 10mg QD17.6
Apixaban 10mg BID24.2
Apixaban 20 mg QD23.9

Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study

Interventionpercentage of participants (Number)
Placebo10.5
Apixaban 2.5mg BID20.6
Apixaban 10mg QD22.5

Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B

Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

Interventionpercentage of participants (Number)
Placebo0.8
Apixaban 2.5mg BID5.0
Apixaban 10mg QD5.6
Apixaban 10mg BID7.8
Apixaban 20 mg QD7.3

Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study

Interventionpercentage of participants (Number)
Placebo3.0
Apixaban 2.5mg BID5.7
Apixaban 10mg QD7.9

Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

Interventionpercentage of participants (Number)
Placebo0.0
Apixaban 2.5mg BID0.8
Apixaban 10mg QD0.0
Apixaban 10mg BID2.9
Apixaban 20 mg QD4.1

Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study

Interventionpercentage of participants (Number)
Placebo0.8
Apixaban 2.5mg BID1.6
Apixaban 10mg QD1.9

Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)

Interventionparticipants (Number)
Placebo54
Apixaban 2.5mg BID24
Apixaban 10mg QD20

Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)

Interventionparticipants (Number)
Placebo53
Apixaban 2.5mg BID24
Apixaban 10mg QD19

Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007

Interventionparticipants (Number)
Placebo16
Apixaban 2.5mg BID6
Apixaban 10mg QD4
Apixaban 10mg BID8
Apixaban 20 mg QD7

Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007

Interventionparticipants (Number)
Placebo16
Apixaban 2.5mg BID6
Apixaban 10mg QD4
Apixaban 10mg BID8
Apixaban 20 mg QD7

All-cause Death

Time to first occurence of All-cause death. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Cardiovascular Death

Time to first occurence of Cardiovascular death. The number of patients with events was reported. (NCT02291419)
Timeframe: Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Major Adverse Cardiovascular Events

Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Non-fatal Myocardial Infarction or Coronary Revascularization

Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Non-fatal Stroke

Time to first occurence of Non-fatal stroke. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions

(NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.

InterventionParticipants (Count of Participants)
Ticagrelor0
Aspirin0

Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI

(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI

Interventionparticipants (Number)
Cangrelor Arm127
Clopidogrel Arm141

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm151
Clopidogrel Arm120

Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)

excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm78
Clopidogrel Arm65

Incidence of All Cause Mortality

(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization

Interventionparticipants (Number)
Cangrelor Arm116
Clopidogrel Arm120

Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm34
Clopidogrel Arm29

Incidence of All-cause Mortality and MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm285
Clopidogrel Arm261

Incidence of All-cause Mortality or MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm321
Clopidogrel Arm298

Incidence of All-cause Mortality, MI or IDR

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm343
Clopidogrel Arm327

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm290
Clopidogrel Arm276

Incidence of GUSTO Severe / Life-threatening Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm10
Clopidogrel Arm11

Incidence of IDR

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm44
Clopidogrel Arm52

Incidence of MI

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm297
Clopidogrel Arm276

Incidence of Stroke

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm5
Clopidogrel Arm7

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm19
Clopidogrel Arm14

Individual Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm8
Clopidogrel Arm5

Individual Incidence of IDR

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm13
Clopidogrel Arm23

Incidence of Stroke

"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization

,
Interventionparticipants (Number)
primary hemorrhagicinfarction with hemorrhagic conversioncerebral infarctionuncertain type
Cangrelor Arm1050
Clopidogrel Arm0070

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel4
Placebo5

Incidence of Major Bleeding Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel1
Placebo0

Vein Graft Angiographic Patency

Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery

Interventionpercentage (Number)
75mg Clopidogrel94.3
Placebo93.2

Vein Graft Intimal Area

IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery

Interventionmm (Mean)
75mg Clopidogrel4.1
Placebo4.5

Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.

(NCT00089895)
Timeframe: 96 hours after randomization

Interventionpercentage of participants (Number)
Eptifibatide9.3
Placebo10.0

Incidence of the Composite of Death/MI.

(NCT00089895)
Timeframe: 30 days after randomization

Interventionpercentage of participants (Number)
Eptifibatide11.2
Placebo12.3

Any Bleeding Event

"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy17
Individualized Therapy9

Definite Stent Thrombosis

"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days

Interventionparticipants (Number)
Standard Therapy1
Individualized Therapy0

Probable Stent Thrombosis

"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy2
Individualized Therapy0

The Occurence of Any Type of Bleeding

was there any bleeding occurance during the accessed interval (NCT00515541)
Timeframe: up to and including closeout at 24 weeks

InterventionNumber of occurance (Number)
Group A: Subject on Lovaza Only0
Group B: Subject on Lovaza + Aspirin1
Group C: Subject on Lovaza + Clopidogrel + Aspirin0
Group D: Subject on Lovaza + Warfarin + Aspirin0

Bleeding Time

Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks

,,,
Interventionseconds (Median)
Baseline (Week 0)1 gram Lovaza Daily (Week 6)2 grams Lovaza Daily (Week 12)4 grams Lovaza Daily (Week 18)8 grams Lovaza Daily (Week 24)
Group A: Subject on Lovaza Only150240240255255
Group B: Subject on Lovaza + Aspirin240345390330360
Group C: Subject on Lovaza + Clopidogrel + Aspirin570720690600600
Group D: Subject on Lovaza + Warfarin + Aspirin240285285240270

EQELS (Electrophoretic Quasi Elastic Light Scattering: Change in Mobility After the Addition of Arachidonic Acid

Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks

,,,
Interventionmobility units (Median)
Baseline (Week 0)1 gram Lovaza Daily (Week 6)2 grams Lovaza Daily (Week 12)4 grams Lovaza Daily (Week 18)8 grams Lovaza Daily (Week 24)
Group A: Subject on Lovaza Only0.28-0.45-0.95-1.08-0.88
Group B: Subject on Lovaza + Aspirin-0.04-0.72-1.30-0.94-0.97
Group C: Subject on Lovaza + Clopidogrel + Aspirin-1.04-0.73-1.29-1.14-0.89
Group D: Subject on Lovaza + Warfarin + Aspirin-1.10-0.50-0.58-0.44-0.19

Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.)

The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks

,,,
Interventionpercent (Median)
Baseline (Week 0)1 gram Lovaza Daily (Week 6)2 grams Lovaza Daily (Week 12)4 grams Lovaza Daily (Week 18)8 grams Lovaza Daily (Week 24)
Group A: Subject on Lovaza Only79.579.587.58283
Group B: Subject on Lovaza + Aspirin032.503
Group C: Subject on Lovaza + Clopidogrel + Aspirin5.56.5645
Group D: Subject on Lovaza + Warfarin + Aspirin89121022

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Percentage Leukocyte-Platelet Aggregate

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline14.06
Placebo Follow up13.84
Aspirin Baseline11.18
Aspirin Randomization12.11
Clopidogrel Baseline13.06
Clopidogrel Randomization12.29

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline15.53
Placebo Follow up15.43
Aspirin Baseline13.15
Aspirin Follow up14.96
Clopidogrel Baseline16.03
Clopidogrel Follow up14.85

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With ADP 5μM for 5 Min

(NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min

The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline72.35
Placebo Follow up79.11
Aspirin Baseline72.79
Aspirin Randomization26.77
Clopidogrel Baseline71.07
Clopidogrel Randomization65.00

Reviews

206 reviews available for ticlopidine and Bleeding

ArticleYear
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
    Current neurology and neuroscience reports, 2022, Volume: 22, Issue:11

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre

2022
Monotherapy with a P2Y
    Lancet (London, England), 2020, 05-09, Volume: 395, Issue:10235

    Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He

2020
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:7

    Topics: Asian People; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; H

2017
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2017
[Management of the bleeding risk associated with antiplatelet agents].
    La Revue de medecine interne, 2017, Volume: 38, Issue:7

    Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans

2017
Antiplatelet Therapy, Platelet Function Testing, and Bleeding Complications in Cardiac Surgery Patients.
    Seminars in thrombosis and hemostasis, 2017, Volume: 43, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Hemorrhage; Humans; Platelet Aggregation Inhi

2017
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
    Clinical therapeutics, 2017, Volume: 39, Issue:7

    Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo

2017
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    BMC cardiovascular disorders, 2017, 06-15, Volume: 17, Issue:1

    Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis;

2017
[Antiplatelet agents and transfusion].
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3

    Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pla

2017
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Zhonghua xin xue guan bing za zhi, 2017, Jun-24, Volume: 45, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He

2017
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:20

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2017
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1

    Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona

2018
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
    The Cochrane database of systematic reviews, 2017, 12-14, Volume: 12

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel

2017
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
    Platelets, 2018, Volume: 29, Issue:5

    Topics: Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; P-Selectin; Platelet Aggreg

2018
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Clinical research in cardiology : official journal of the German Cardiac Society, 2018, Volume: 107, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule

2018
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
    European journal of neurology, 2018, Volume: 25, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages;

2018
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
    The Cochrane database of systematic reviews, 2018, 07-18, Volume: 7

    Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische

2018
Triple therapy: worth the risk?
    Minerva medica, 2018, Volume: 109, Issue:5

    Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor

2018
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochl

2014
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:4

    Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperaz

2013
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg

2013
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
    Chest, 2013, Volume: 144, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Met

2013
[The most important aspects of risk assessment].
    Zentralblatt fur Chirurgie, 2013, Volume: 138, Issue:3

    Topics: Algorithms; Aspirin; Cardiovascular Diseases; Clopidogrel; Digestive System Surgical Procedures; Dru

2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel;

2013
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Current medical research and opinion, 2014, Volume: 30, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans

2014
[Thrombocyte aggregation inhibitors: what are the risks?].
    Praxis, 2013, Oct-02, Volume: 102, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions

2013
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2013, Oct-18, Issue:10

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent

2013
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
    Clinical therapeutics, 2013, Volume: 35, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal

2013
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2013, Nov-08, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H

2013
[Differentiated antiplatelet therapy for acute coronary syndromes].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro

2014
New antiplatelet agents in the treatment of acute coronary syndromes.
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel;

2014
Efficacy and safety of prasugrel in acute coronary syndrome patients.
    Clinical biochemistry, 2014, Volume: 47, Issue:7-8

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibito

2014
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug

2014
[Dual platelet inhibitors in intensive care units].
    Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2014, Volume: 109, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Hum

2014
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Strok

2014
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
    Nature reviews. Cardiology, 2014, Volume: 11, Issue:11

    Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; My

2014
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:1

    Topics: Algorithms; Animals; Blood Platelets; Clopidogrel; Coronary Thrombosis; Decision Support Techniques;

2015
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Clinical therapeutics, 2014, Sep-01, Volume: 36, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2014
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
    Heart, lung & circulation, 2015, Volume: 24, Issue:2

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc

2015
Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis.
    Postgraduate medicine, 2014, Volume: 126, Issue:5

    Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged;

2014
Resistance to antiplatelet drugs: what progress has been made?
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:17

    Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent

2014
[Added value of clopidogrel in cardiology and neurology].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2014
Use of antiplatelet drugs after cardiac operations.
    Seminars in thoracic and cardiovascular surgery, 2014,Autumn, Volume: 26, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio

2014
Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.
    Polskie Archiwum Medycyny Wewnetrznej, 2015, Volume: 125, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; He

2015
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
    Cerebrovascular diseases (Basel, Switzerland), 2015, Volume: 39, Issue:1

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla

2015
[Anticoagulant therapy in secondary prevention of coronary events].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:12

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine

2014
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9

    Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; H

2015
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre

2015
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis.
    Coronary artery disease, 2015, Volume: 26, Issue:5

    Topics: Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Drug Resistance; Heart Diseases; He

2015
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Apr-20, Volume: 21

    Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum

2015
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
    European heart journal, 2015, Jul-14, Volume: 36, Issue:27

    Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronar

2015
Antiplatelet therapy following transcatheter aortic valve implantation.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:14

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz

2015
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
    Platelets, 2016, Volume: 27, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction;

2016
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
    The American journal of cardiology, 2015, Aug-01, Volume: 116, Issue:3

    Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Pla

2015
Practical experience with ticagrelor: an Australian and New Zealand perspective.
    Current medical research and opinion, 2015, Volume: 31, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors

2015
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13

    Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl

2015
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine

2015
Antiplatelet therapy in acute coronary syndromes.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary

2015
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Oct-01, Volume: 72, Issue:19

    Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L

2015
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Current medical research and opinion, 2015, Volume: 31, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona

2015
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
    BMC cardiovascular disorders, 2015, Oct-09, Volume: 15

    Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu

2015
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:1

    Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Purinergic P2Y Receptor A

2016
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
    Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness

2015
On-treatment platelet reactivity: State of the art and perspectives.
    Vascular pharmacology, 2016, Volume: 77

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2

2016
Clopidogrel Response Variability: Review of the Literature and Practical Considerations.
    Journal of pharmacy practice, 2016, Volume: 29, Issue:1

    Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosi

2016
Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies.
    Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:4

    Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Agg

2016
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2015, Volume: 36, Issue:12

    Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At

2015
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Heart (British Cardiac Society), 2016, 05-15, Volume: 102, Issue:10

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage

2016
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    BMJ open, 2016, Mar-17, Volume: 6, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische

2016
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, May-01, Volume: 73, Issue:9

    Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percuta

2016
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
    Zhonghua yi xue za zhi, 2016, May-10, Volume: 96, Issue:17

    Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans;

2016
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Circulation, 2016, May-24, Volume: 133, Issue:21

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Hem

2016
[Switching from clopidogrel to prasugrel: Efficacy and safety data].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015, Volume: 43 Suppl 2

    Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Agg

2015
Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis.
    Thrombosis research, 2016, Volume: 147

    Topics: Clopidogrel; Cytochrome P-450 CYP3A; Drug Resistance; Genetic Association Studies; Hemorrhage; Human

2016
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:11

    Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu

2016
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
    Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:6

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; He

2016
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
    American heart journal, 2016, Volume: 181

    Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine;

2016
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    European heart journal, 2017, 04-07, Volume: 38, Issue:14

    Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Lancet (London, England), 2017, 03-11, Volume: 389, Issue:10073

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H

2017
Dual antiplatelet therapy with clopidogrel and aspirin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-15, Volume: 65, Issue:12

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Coronary Artery Bypass; Hemorrhage

2008
[Clopidogrel--clinical use and potential therapeutic problems].
    Herz, 2008, Volume: 33, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Dose-Response Relationship, Dr

2008
Prasugrel development - claims and achievements.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu

2009
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
    The American journal of cardiology, 2009, Feb-02, Volume: 103, Issue:3 Suppl

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo

2009
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me

2009
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Clinical therapeutics, 2008, Volume: 30 Pt 2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-

2008
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
    The American journal of emergency medicine, 2009, Volume: 27, Issue:3

    Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration

2009
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
    The American journal of cardiology, 2009, Apr-15, Volume: 103, Issue:8

    Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com

2009
Clopidogrel in acute coronary syndromes.
    BMJ (Clinical research ed.), 2009, Apr-14, Volume: 338

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction

2009
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic;

2009
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
    Pharmacology & therapeutics, 2009, Volume: 123, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platel

2009
Prasugrel for the treatment of patients with acute coronary syndrome.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Tri

2009
[Drug-eluting stents: implications for modern coronary revascularization].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor

2009
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug

2008
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Pharmacotherapy, 2009, Volume: 29, Issue:7

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H

2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
    Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, C

2009
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Dec-01, Volume: 74, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co

2009
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
    Current opinion in cardiology, 2009, Volume: 24, Issue:6

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hemorrhage; Huma

2009
Platelet function testing and implications for clinical practice.
    Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:3

    Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl

2009
[Long-term use of oral antiplatelet therapy: from studies to practice].
    Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:4

    Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Fibrinolytic

2010
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Vascular health and risk management, 2009, Volume: 5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazine

2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T

2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T

2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T

2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T

2009
Prasugrel: Clinical development and therapeutic application.
    Advances in therapy, 2009, Volume: 26, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggrega

2009
[Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].
    Kardiologiia, 2009, Volume: 49, Issue:12

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel

2009
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
    QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:6

    Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inh

2010
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem

2010
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
    Vascular health and risk management, 2010, Mar-03, Volume: 6

    Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio

2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi

2010
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
    Pharmacotherapy, 2010, Volume: 30, Issue:4

    Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Arte

2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
    Hospital practice (1995), 2010, Volume: 38, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedu

2010
Safety evaluation of tirofiban.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:5

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

2010
[Reduction of haemorrhagic risk in acute coronary syndromes].
    Medicina clinica, 2011, Nov-26, Volume: 137, Issue:14

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma

2011
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido

2010
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr

2011
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    The Cochrane database of systematic reviews, 2010, Sep-08, Issue:9

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H

2010
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
    Kardiologiia, 2010, Volume: 50, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D

2010
[New aspects on "triple therapy" after coronary stent implantation].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:41

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation;

2010
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
    Blood, 2011, Feb-17, Volume: 117, Issue:7

    Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; F

2011
The safety of clopidogrel.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:1

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; H

2011
[Antithrombotic therapy in patients with prosthetic heart valves].
    Kardiologiia, 2010, Volume: 50, Issue:9

    Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Heart Valve Diseases

2010
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:4

    Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials

2010
Platelet function testing in clinical diagnostics.
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial T

2011
[New approaches and indications for the analysis of platelet function in cardiology].
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos

2011
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
    Therapeutic advances in cardiovascular disease, 2011, Volume: 5, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fib

2011
Antiplatelet therapy in the perioperative period.
    European journal of internal medicine, 2011, Volume: 22, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H

2011
Thienopyridines in Acute Coronary Syndrome.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platel

2011
Antiplatelet agents in cardiovascular disease.
    Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2011
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15

    Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electroca

2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as To

2011
[Myocardial infarction: Role of new antiplatelet agents].
    Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Com

2011
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
    Advances in therapy, 2011, Volume: 28, Issue:6

    Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi

2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia;

2011
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Fema

2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
    European heart journal, 2011, Volume: 32, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorr

2011
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Clinical therapeutics, 2011, Volume: 33, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemo

2011
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genot

2012
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 143, Issue:3

    Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Di

2012
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
    BMJ (Clinical research ed.), 2011, Jul-21, Volume: 343

    Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease

2011
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazi

2011
Clopidogrel "resistance": where are we now?
    Cardiovascular therapeutics, 2013, Volume: 31, Issue:1

    Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Substitution; Hemorrhage; Human

2013
Antiplatelet options for secondary prevention in acute coronary syndromes.
    Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hum

2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
    Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel;

2011
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Predisposition to Dise

2012
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
    Current medical research and opinion, 2012, Volume: 28, Issue:2

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Pip

2012
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
    JAMA, 2011, Dec-28, Volume: 306, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel;

2011
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
    International journal of cardiology, 2012, Jul-12, Volume: 158, Issue:2

    Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel

2012
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2

    Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cl

2012
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar

2012
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
    Postgraduate medicine, 2012, Volume: 124, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet A

2012
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
    Interactive cardiovascular and thoracic surgery, 2012, Volume: 15, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking

2012
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:1

    Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Association S

2012
Platelet function and inhibition in ischemic heart disease.
    Current cardiology reports, 2012, Volume: 14, Issue:4

    Topics: Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Myocardial Ischemia; Platelet Agg

2012
[New antithrombotic drugs].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7

    Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr

2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; H

2012
Clinical use of clopidogrel.
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug I

2012
Development and clinical use of prasugrel and ticagrelor.
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hem

2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug

2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole

2012
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
    Platelets, 2012, Volume: 23, Issue:7

    Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A

2012
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
    Stroke, 2012, Volume: 43, Issue:8

    Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist

2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil

2012
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr

2012
Review of ticagrelor in the management of acute coronary syndromes.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I

2012
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
    Expert opinion on drug safety, 2012, Volume: 11, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I

2012
New anti-platelet agents: the end of resistance?
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resista

2012
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
    Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:8

    Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; T

2012
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors;

2013
Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an update.
    Current pharmaceutical design, 2013, Volume: 19, Issue:22

    Topics: Aspirin; Clopidogrel; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Platelet Aggregation

2013
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    JAMA, 2012, Dec-19, Volume: 308, Issue:23

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H

2012
Metabolic differences of current thienopyridine antiplatelet agents.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug

2013
State of the art--a journey through the world of antithrombotic therapy.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A

2002
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
    Current cardiology reports, 2003, Volume: 5, Issue:4

    Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemor

2003
The role of clopidogrel in the management of acute coronary syndromes.
    Clinical therapeutics, 2003, Volume: 25, Issue:8

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C

2003
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Circulation, 2004, Aug-24, Volume: 110, Issue:8

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl

2004
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
    Pharmacotherapy, 2004, Volume: 24, Issue:8

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans;

2004
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:38

    Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr

2004
Antiplatelet therapy in anticoagulated patients requiring coronary intervention.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hem

2005
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
    The American journal of medicine, 2006, Volume: 119, Issue:2

    Topics: Aspirin; Clopidogrel; Depressive Disorder; Drug Interactions; Hemorrhage; Humans; Platelet Aggregati

2006
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:4 Pt 2

    Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage;

2006
Clopidogrel in the treatment of ischaemic heart disease.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Hemorrhage; H

2006
MATCH results: implications for the internist.
    The American journal of medicine, 2006, Volume: 119, Issue:6

    Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru

2006
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Circulation, 2007, Mar-27, Volume: 115, Issue:12

    Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr

2007
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Circulation, 2007, Apr-24, Volume: 115, Issue:16

    Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers

2007
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:3

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass

2007
Perioperative use of anti-platelet drugs.
    Best practice & research. Clinical anaesthesiology, 2007, Volume: 21, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Periope

2007
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2007
Clopidogrel: who, when, and how?
    Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 3

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A

2007
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
    American family physician, 2007, Dec-01, Volume: 76, Issue:11

    Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B

2007
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
    Journal of interventional cardiology, 2008, Volume: 21, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A

2008
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron

2008
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:3

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel;

2008
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
    The Journal of emergency medicine, 2008, Volume: 35, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas

2008
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
    Current neurology and neuroscience reports, 2008, Volume: 8, Issue:1

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi

2008
Will prasugrel supersede clopidogrel for acute coronary syndromes?
    The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7

    Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Art

2008
Antiplatelet agents and arterial thrombosis.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggreg

2008
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:6

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com

2008
Prasugrel: a novel antiplatelet agent.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation

2008
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
    Texas Heart Institute journal, 1997, Volume: 24, Issue:2

    Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla

1997
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    The American journal of cardiology, 1998, Oct-22, Volume: 82, Issue:8B

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As

1998
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co

1999
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
    Journal of internal medicine, 1999, Volume: 246, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors

1999
Ticlopidine and clopidogrel.
    Circulation, 1999, Oct-12, Volume: 100, Issue:15

    Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo

1999
Stroke prevention: antiplatelet and antithrombolytic therapy.
    Haemostasis, 2000, Volume: 30 Suppl 3

    Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog

2000
Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance.
    Journal of the American College of Cardiology, 2002, Jul-17, Volume: 40, Issue:2

    Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet

2002

Trials

231 trials available for ticlopidine and Bleeding

ArticleYear
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022, Aug-19, Volume: 18, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D

2022
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
    Journal of the American Heart Association, 2023, 10-17, Volume: 12, Issue:20

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage;

2023
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    JAMA, 2020, 06-16, Volume: 323, Issue:23

    Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S

2020
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice
    American heart journal, 2021, Volume: 236

    Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Drug-Eluting Stents; Dual Anti-Platel

2021
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet (London, England), 2017, May-06, Volume: 389, Issue:10081

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M

2017
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
    Heart (British Cardiac Society), 2017, Volume: 103, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Dose-Response

2017
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
    Journal of the American Heart Association, 2017, Apr-14, Volume: 6, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Dru

2017
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    JACC. Cardiovascular interventions, 2017, 05-08, Volume: 10, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug

2017
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
    European heart journal, 2017, Nov-01, Volume: 38, Issue:41

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combina

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
    JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
    Annals of internal medicine, 2017, Jul-04, Volume: 167, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2017
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
    Kardiologia polska, 2017, Volume: 75, Issue:9

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy,

2017
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
    JACC. Cardiovascular interventions, 2017, 06-26, Volume: 10, Issue:12

    Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D

2017
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    JACC. Cardiovascular interventions, 2017, 06-26, Volume: 10, Issue:12

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu

2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet (London, England), 2017, Oct-14, Volume: 390, Issue:10104

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female;

2017
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
    Trials, 2017, Sep-22, Volume: 18, Issue:1

    Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con

2017
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Journal of the American Heart Association, 2017, Nov-03, Volume: 6, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He

2017
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Journal of thrombosis and thrombolysis, 2018, Volume: 46, Issue:4

    Topics: Aged; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Hemorr

2018
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
    Lancet (London, England), 2013, Mar-30, Volume: 381, Issue:9872

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug;

2013
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
    Lancet (London, England), 2013, Mar-30, Volume: 381, Issue:9872

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug;

2013
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
    Lancet (London, England), 2013, Mar-30, Volume: 381, Issue:9872

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug;

2013
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
    Lancet (London, England), 2013, Mar-30, Volume: 381, Issue:9872

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug;

2013
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
    Trials, 2013, Feb-21, Volume: 14

    Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2013
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
    The American journal of cardiology, 2013, Sep-15, Volume: 112, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar

2013
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
    The New England journal of medicine, 2013, Jun-20, Volume: 368, Issue:25

    Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, C

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F

2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Circulation, 2013, Aug-20, Volume: 128, Issue:8

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Managem

2013
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013, Volume: 13, Issue:6

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female;

2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Thera

2013
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:9

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy,

2013
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
    Circulation, 2014, Jan-21, Volume: 129, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Arte

2014
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Rela

2014
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    JAMA, 2013, Dec-18, Volume: 310, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc

2013
Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:4

    Topics: Adult; Aged; Anticoagulants; Brazil; Clopidogrel; Cross-Sectional Studies; Databases, Factual; Dose-

2014
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage

2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2014, Jun-14, Volume: 35, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin

2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
    European heart journal, 2014, Aug-14, Volume: 35, Issue:31

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Esti

2014
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
    European heart journal, 2014, Oct-01, Volume: 35, Issue:37

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans;

2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th

2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
    European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:4

    Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; M

2014
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    European journal of preventive cardiology, 2015, Volume: 22, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma

2015
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Angiology, 2015, Volume: 66, Issue:4

    Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule

2015
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:2

    Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron

2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad

2014
Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.
    Stroke, 2014, Volume: 45, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap

2014
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    European heart journal. Acute cardiovascular care, 2015, Volume: 4, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female

2015
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
    Thrombosis research, 2014, Volume: 134, Issue:5

    Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Female; Hemorrhage; Humans; Male;

2014
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, Volume: 11, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass;

2015
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12

    Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St

2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El

2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    American heart journal, 2014, Volume: 168, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardi

2014
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu

2015
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
    Contemporary clinical trials, 2015, Volume: 40

    Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combina

2015
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
    Journal of the American College of Cardiology, 2014, Dec-23, Volume: 64, Issue:24

    Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Foll

2014
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-

2015
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
    Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:3

    Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middl

2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery

2015
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat

2015
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Current vascular pharmacology, 2015, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel

2015
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2015, Volume: 22, Issue:2

    Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Fe

2015
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co

2015
Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial.
    International journal of cardiology, 2015, Volume: 190

    Topics: Aged; Clopidogrel; Coronary Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male;

2015
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug

2015
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2015, Volume: 169, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    European heart journal. Acute cardiovascular care, 2016, Volume: 5, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Est

2016
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He

2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    European heart journal, 2016, Apr-07, Volume: 37, Issue:14

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora

2016
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
    European heart journal, 2016, Apr-21, Volume: 37, Issue:16

    Topics: Acute Coronary Syndrome; C-Reactive Protein; Growth Differentiation Factor 15; Hemorrhage; Humans; N

2016
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M

2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M

2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M

2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M

2015
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Journal of cardiology, 2016, Volume: 68, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind

2016
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
    European heart journal, 2016, Jan-21, Volume: 37, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; L

2016
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
    Journal of the American Heart Association, 2015, Dec-07, Volume: 4, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2015
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
    Journal of the American Heart Association, 2015, Dec-07, Volume: 4, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2015
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
    Journal of the American Heart Association, 2015, Dec-07, Volume: 4, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2015
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
    Journal of the American Heart Association, 2015, Dec-07, Volume: 4, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2015
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    JACC. Cardiovascular interventions, 2015, Dec-21, Volume: 8, Issue:14

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co

2015
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
    Journal of the American Heart Association, 2016, Mar-21, Volume: 5, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method

2016
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:2

    Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com

2016
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
    Heart (British Cardiac Society), 2016, 08-01, Volume: 102, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
    Journal of cardiovascular pharmacology and therapeutics, 2016, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem

2016
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
    International journal of cardiology, 2016, Jul-15, Volume: 215

    Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Hu

2016
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
    The American journal of cardiology, 2016, Jun-15, Volume: 117, Issue:12

    Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat

2016
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug

2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2016, Volume: 177

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular

2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:6

    Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Do

2016
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015, Volume: 43 Suppl 2

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochlo

2015
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:5

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopid

2016
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    JAMA, 2016, Jul-05, Volume: 316, Issue:1

    Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co

2016
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Journal of cardiology, 2017, Volume: 69, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin

2017
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
    Heart, lung & circulation, 2017, Volume: 26, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorr

2017
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D

2016
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    American heart journal, 2016, Volume: 178

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D

2016
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    JACC. Cardiovascular interventions, 2016, 09-12, Volume: 9, Issue:17

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C

2016
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
    Acta cardiologica, 2016, Volume: 71, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Respons

2016
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
    Scientific reports, 2016, 09-14, Volume: 6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Huma

2016
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes
    Thrombosis and haemostasis, 2017, 01-05, Volume: 117, Issue:1

    Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Adminis

2017
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo

2016
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
    Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Ove

2017
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    American heart journal, 2016, Volume: 181

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy

2016
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
    American heart journal, 2016, Volume: 182

    Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolim

2016
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
    The New England journal of medicine, 2017, 01-05, Volume: 376, Issue:1

    Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma

2017
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, May-15, Volume: 13, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female

2017
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
    Medicine, 2017, Volume: 96, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The

2017
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona

2017
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
    Neurological research, 2017, Volume: 39, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati

2017
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Doubl

2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Platelets, 2008, Volume: 19, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions;

2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
    European heart journal, 2008, Volume: 29, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Huma

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7

    Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
    American heart journal, 2008, Volume: 156, Issue:3

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hos

2008
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
    European heart journal, 2009, Volume: 30, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F

2009
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
    American heart journal, 2008, Volume: 156, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi

2008
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    American heart journal, 2009, Volume: 157, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, C

2009
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
    European heart journal, 2009, Volume: 30, Issue:7

    Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met

2009
Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
    Acta cardiologica, 2009, Volume: 64, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Female;

2009
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
    American heart journal, 2009, Volume: 157, Issue:4

    Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Double-Blind Method; Ethnicity; Female; Follow-U

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel

2008
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula

2008
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C

2008
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    Circulation, 2009, Jun-09, Volume: 119, Issue:22

    Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp

2009
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr

2009
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Dec-01, Volume: 74, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron

2009
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon,

2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
    Circulation, 2009, Dec-08, Volume: 120, Issue:23

    Topics: Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hemorrha

2009
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp

2009
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:1

    Topics: Administration, Oral; Adult; Bleeding Time; Clopidogrel; Cross-Over Studies; Dose-Response Relations

2010
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Resp

2010
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies

2010
Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers.
    Clinical therapeutics, 2010, Volume: 32, Issue:2

    Topics: Adult; Asian People; Bleeding Time; Blood Platelets; Chromatography, High Pressure Liquid; Cross-Ove

2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Circulation, 2010, Jun-15, Volume: 121, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema

2010
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2011, Volume: 18, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A

2011
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
    Annals of surgery, 2010, Volume: 252, Issue:1

    Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor

2010
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt

2010
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
    Circulation, 2010, Sep-07, Volume: 122, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche

2010
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2010, Volume: 31, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Dia

2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2010, Sep-14, Volume: 122, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem

2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2010, Sep-14, Volume: 122, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem

2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2010, Sep-14, Volume: 122, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem

2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2010, Sep-14, Volume: 122, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo

2010
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F

2010
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cyto

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
    Circulation, 2010, Dec-21, Volume: 122, Issue:25

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr

2010
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
    Circulation, 2010, Dec-21, Volume: 122, Issue:25

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr

2010
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
    Circulation, 2010, Dec-21, Volume: 122, Issue:25

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr

2010
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
    Circulation, 2010, Dec-21, Volume: 122, Issue:25

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr

2010
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
    The American journal of cardiology, 2011, Volume: 107, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem

2011
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
    Heart and vessels, 2011, Volume: 26, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona

2011
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
    Drugs & aging, 2011, Feb-01, Volume: 28, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar

2011
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
    Circulation, 2011, Feb-22, Volume: 123, Issue:7

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardio

2011
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
    Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:4

    Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Angiography; Female; Fibrinolysis; Glomerular Filtrat

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    JAMA, 2011, Mar-16, Volume: 305, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh

2011
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:11

    Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As

2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
    European heart journal, 2011, Volume: 32, Issue:22

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-

2011
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Jun-01, Volume: 77, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi

2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Circulation, 2011, Jun-14, Volume: 123, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged

2011
Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
    Thrombosis research, 2011, Volume: 128, Issue:4

    Topics: Adult; Aspirin; Bleeding Time; Blood Platelets; Chi-Square Distribution; Clopidogrel; Dose-Response

2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    American heart journal, 2011, Volume: 162, Issue:1

    Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind M

2011
Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:10

    Topics: Aged; Aspirin; Blood Coagulation; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pum

2011
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
    Anesthesia and analgesia, 2011, Volume: 113, Issue:4

    Topics: Adult; Biopsy; Clopidogrel; Double-Blind Method; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; H

2011
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:12

    Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Fe

2011
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial

2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind

2011
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2012, Volume: 101, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Emergency Medical Services; Femal

2012
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Hu

2012
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas

2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    European heart journal, 2012, Volume: 33, Issue:17

    Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot

2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
    Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause

2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Do

2012
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
    International heart journal, 2012, Volume: 53, Issue:2

    Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality

2012
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
    Trials, 2012, Aug-25, Volume: 13

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Croatia; Drug Resistance; Dru

2012
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
    The New England journal of medicine, 2012, Aug-30, Volume: 367, Issue:9

    Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut

2012
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2012, Volume: 34, Issue:3

    Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double-

2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Mid

2013
Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke.
    Stroke, 2013, Volume: 44, Issue:3

    Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinati

2013
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
    Circulation, 2002, Sep-24, Volume: 106, Issue:13

    Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Comb

2002
Early and late effects of clopidogrel in patients with acute coronary syndromes.
    Circulation, 2003, Feb-25, Volume: 107, Issue:7

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio

2003
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    American heart journal, 2003, Volume: 145, Issue:4

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure

2003
Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA).
    Thrombosis research, 2003, Jan-25, Volume: 109, Issue:2-3

    Topics: Administration, Oral; Adult; Aged; Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fe

2003
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Circulation, 2003, Aug-26, Volume: 108, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450

2003
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:4

    Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C

2003
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Circulation, 2003, Oct-07, Volume: 108, Issue:14

    Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin

2003
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
    American heart journal, 2004, Volume: 147, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter

2004
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Circulation, 2004, Sep-07, Volume: 110, Issue:10

    Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel;

2004
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Disease;

2004
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar

2005
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Circulation, 2005, Jun-28, Volume: 111, Issue:25

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-

2005
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies

2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Circulation, 2005, Dec-20, Volume: 112, Issue:25

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera

2005
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
    Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 20 Suppl 2

    Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal

2005
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation,

2006
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
    Journal of thrombosis and thrombolysis, 2007, Volume: 23, Issue:3

    Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me

2007
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combi

2007
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:2

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Mi

2007
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2007, Volume: 14, Issue:2

    Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom

2007
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2007, Volume: 34, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas

2007
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
    Journal of the American College of Cardiology, 2007, Jul-24, Volume: 50, Issue:4

    Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme

2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    European heart journal, 2007, Volume: 28, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me

2007
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2008, Volume: 97, Issue:3

    Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Biomarkers; Cardiovascular Surgica

2008
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
    Circulation, 2008, Jan-29, Volume: 117, Issue:4

    Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Infant; Infant, Newborn;

2008
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    American heart journal, 2008, Volume: 155, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema

2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com

2008
The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy.
    The Journal of international medical research, 1981, Volume: 9, Issue:3

    Topics: Bleeding Time; Hemorrhage; Humans; Male; Platelet Function Tests; Postoperative Complications; Prost

1981
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
    The New England journal of medicine, 1995, Apr-27, Volume: 332, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea;

1995
Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.
    Circulation, 1996, Oct-01, Volume: 94, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Coronary Vessels; Female; France; Hemorrhage; Heparin, Low-Molecular-

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:2

    Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
    Circulation, 1998, Oct-20, Volume: 98, Issue:16

    Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease;

1998
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
    The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi

1998
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
    The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi

1998
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
    The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi

1998
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
    The New England journal of medicine, 1998, Dec-03, Volume: 339, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi

1998
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
    Circulation, 1999, May-11, Volume: 99, Issue:18

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D

1999
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Drug safety, 1999, Volume: 21, Issue:4

    Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest

1999
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
    American heart journal, 2000, Volume: 140, Issue:1

    Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem

2000
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
    Japanese heart journal, 2000, Volume: 41, Issue:6

    Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel

2000
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
    Circulation, 2001, Apr-24, Volume: 103, Issue:16

    Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere

2001
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
    Circulation, 2001, Jul-31, Volume: 104, Issue:5

    Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide;

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    The New England journal of medicine, 2001, Aug-16, Volume: 345, Issue:7

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect

2001
Clopidogrel: a CURE in acute coronary syndromes?
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:3

    Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage

2002

Other Studies

500 other studies available for ticlopidine and Bleeding

ArticleYear
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:2

    Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; C

2022
Platelet function assessed by ROTEM
    Scandinavian journal of clinical and laboratory investigation, 2022, Volume: 82, Issue:1

    Topics: Aspirin; Clopidogrel; Deamino Arginine Vasopressin; Hemorrhage; Humans; Platelet Aggregation Inhibit

2022
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients.
    Value in health regional issues, 2022, Volume: 30

    Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi

2022
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:10

    Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T

2022
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022, Volume: 31, Issue:9

    Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2022
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
    Journal of atherosclerosis and thrombosis, 2023, Aug-01, Volume: 30, Issue:8

    Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic

2023
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
    The American journal of medicine, 2023, Volume: 136, Issue:5

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percut

2023
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.
    European journal of medical research, 2023, Feb-24, Volume: 28, Issue:1

    Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; MicroR

2023
Reduced bleeding with genotype-guided antiplatelet therapy.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; T

2019
One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
    JAMA, 2019, 11-05, Volume: 322, Issue:17

    Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors

2019
1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
    JAMA, 2019, 11-05, Volume: 322, Issue:17

    Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors

2019
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
    Archivos de cardiologia de Mexico, 2019, Volume: 89, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrha

2019
Adenosine Diphosphate Receptor Inhibitors: Balancing Perioperative Bleeding and Protection From Adverse Coronary Events.
    The Annals of thoracic surgery, 2021, Volume: 111, Issue:1

    Topics: Adenosine Diphosphate; Clopidogrel; Hemorrhage; Humans; Purinergic P2Y Receptor Antagonists; Ticlopi

2021
Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel.
    Scientific reports, 2021, 01-29, Volume: 11, Issue:1

    Topics: Administration, Oral; Aged; Anticoagulants; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Gastro

2021
Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
    Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:6

    Topics: Administration, Oral; Adult; Aged; Anticoagulants; Clopidogrel; Coronary Artery Disease; Female; Hem

2017
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Jul-20, Volume: 13, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Hemorrhage;

2017
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:10

    Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethni

2017
Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect.
    Journal of the American College of Cardiology, 2017, 04-25, Volume: 69, Issue:16

    Topics: Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine

2017
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
    Neurological research, 2017, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio

2017
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female;

2017
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Journal of the American Heart Association, 2017, Apr-24, Volume: 6, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Fem

2017
Association of measured platelet reactivity with changes in P2Y
    American heart journal, 2017, Volume: 187

    Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; M

2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    American heart journal, 2017, Volume: 186

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Huma

2017
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
    Drugs & aging, 2017, Volume: 34, Issue:6

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male;

2017
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece;

2017
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    JACC. Cardiovascular interventions, 2017, 06-12, Volume: 10, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A

2017
The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.
    Pharmacogenomics, 2017, Volume: 18, Issue:10

    Topics: Adenosine; Aged; Clopidogrel; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Thera

2017
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
    International journal of oral and maxillofacial surgery, 2017, Volume: 46, Issue:9

    Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Ca

2017
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospita

2017
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
    Journal of cardiology, 2018, Volume: 71, Issue:1

    Topics: Aged; Asian People; Calcium Channel Blockers; Clopidogrel; Female; Hemorrhage; Hospitalization; Huma

2018
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Clinical cardiology, 2017, Volume: 40, Issue:10

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi

2017
A retrospective comparison between delayed and early hip fracture surgery in patients taking clopidogrel: same total bleeding but different timing of blood transfusion.
    International orthopaedics, 2017, Volume: 41, Issue:9

    Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Female; Fracture Fixation, Internal; Hemiar

2017
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
    Pharmacogenomics, 2017, Volume: 18, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; G

2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    JACC. Cardiovascular interventions, 2017, 10-23, Volume: 10, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr

2017
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi

2017
Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage.
    Vox sanguinis, 2017, Volume: 112, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Decompression, Surgical; Female; Hemorrhage; Humans; In

2017
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Coronary artery disease, 2018, Volume: 29, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi

2018
Proton Pump Inhibitors may Reduce Bleeding Risk in Older Patients on Antiplatelet Therapy.
    The American journal of nursing, 2017, Volume: 117, Issue:9

    Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Risk Fac

2017
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
    Internal medicine journal, 2017, Volume: 47, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; M

2017
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, 12-08, Volume: 13, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Pla

2017
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:7

    Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi

2017
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy - author's reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:7

    Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi

2017
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
    Chinese medical journal, 2017, Oct-05, Volume: 130, Issue:19

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human

2017
Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series.
    Journal of endourology, 2017, Volume: 31, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carcinoma, Transitional Cell; Clopidogrel; C

2017
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Therapeutic advances in cardiovascular disease, 2017, Volume: 11, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; D

2017
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Nov-20, Volume: 13, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D

2017
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec

2018
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:4

    Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition

2018
Perioperative Management of Dual Antiplatelet Therapy.
    Journal of cardiothoracic and vascular anesthesia, 2018, Volume: 32, Issue:3

    Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation

2018
A clinical risk score to identify patients at high risk of very late stent thrombosis.
    Journal of interventional cardiology, 2018, Volume: 31, Issue:2

    Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A

2018
Perioperative Use of Anticoagulant and Platelet-inhibiting Medications for Elective Spine Surgery: Results of a Nationwide Survey.
    Journal of neurological surgery. Part A, Central European neurosurgery, 2018, Volume: 79, Issue:5

    Topics: Anticoagulants; Clopidogrel; Elective Surgical Procedures; Fibrinolytic Agents; Health Care Surveys;

2018
Moving towards personalised antiplatelet therapy after PCI using risk scores.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2018, 03-20, Volume: 13, Issue:16

    Topics: Acute Coronary Syndrome; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio

2018
Bleeding after stenting: statistics in daily practice.
    International journal of cardiology, 2018, 10-01, Volume: 268

    Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary I

2018
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
    JAMA, 2018, 08-14, Volume: 320, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar

2018
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag

2019
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Chinese medical journal, 2018, Sep-05, Volume: 131, Issue:17

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Perc

2018
Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; P

2019
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019, Oct-20, Volume: 15, Issue:8

    Topics: Anticoagulants; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Interven

2019
A Randomized Trial of Interrupted Clopidogrel in Patients Undergoing Polypectomy: More Questions Than Answers?
    Gastroenterology, 2019, Volume: 157, Issue:2

    Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine

2019
RE: Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized, Trial.
    Gastroenterology, 2019, Volume: 157, Issue:2

    Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine

2019
Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Aged; Cohort Studies; Drug Combinations; Female; Ginkgo biloba; Hemorrhage; Humans; Incidence; Male;

2019
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Dist

2013
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
    Molecular bioSystems, 2013, Volume: 9, Issue:6

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integr

2013
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
    Kardiologiia, 2013, Volume: 53, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ

2013
Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties.
    Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology, 2013, Volume: 14, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Comorbidity; Databases, Factual; Female; He

2013
Bleeding complications during percutaneous coronary intervention.
    The Journal of invasive cardiology, 2004, Volume: 16, Issue:7 Suppl

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog

2004
Operative treatment of hip fractures in patients on clopidogrel: a case-control study.
    The Iowa orthopaedic journal, 2012, Volume: 32

    Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Clopidogrel;

2012
Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel.
    Eye (London, England), 2013, Volume: 27, Issue:6

    Topics: Clopidogrel; Diagnosis, Differential; Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Mi

2013
Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?
    The journal of trauma and acute care surgery, 2013, Volume: 74, Issue:5

    Topics: Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregatio

2013
Anti-thrombotic treatment in patients with a long-term indication for anticoagulant therapy undergoing coronary stenting.
    Internal and emergency medicine, 2013, Volume: 8, Issue:6

    Topics: Anticoagulants; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemor

2013
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
    World journal of urology, 2014, Volume: 32, Issue:1

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal

2014
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:4

    Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S

2013
Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel.
    The journal of trauma and acute care surgery, 2013, Volume: 74, Issue:6

    Topics: Adult; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibito

2013
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:7

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Ho

2013
Is clopidogrel adequate in 2013?
    Cardiovascular journal of Africa, 2013, Volume: 24, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet

2013
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:8

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage;

2013
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru

2013
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
    Anaesthesia and intensive care, 2013, Volume: 41, Issue:4

    Topics: Adenosine Diphosphate; Adjuvants, Anesthesia; Aged; Aspirin; Cholecystectomy, Laparoscopic; Clopidog

2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf

2013
Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:5

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Vessels; Drug I

2013
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Clinical therapeutics, 2013, Volume: 35, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benef

2013
Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.
    International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Human

2013
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:10

    Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S

2013
'Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel' by Tehrani et al.
    Eye (London, England), 2013, Volume: 27, Issue:11

    Topics: Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Platelet Aggregation Inhibitors; Sweat G

2013
Comment on 'Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel'.
    Eye (London, England), 2013, Volume: 27, Issue:11

    Topics: Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Platelet Aggregation Inhibitors; Sweat G

2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecu

2013
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Interv

2013
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
    Heart and vessels, 2014, Volume: 29, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co

2014
Is it possible? Predicting complications and morbidity in surgical patients on clopidogrel therapy with Thrombelastography Platelet Mapping.
    Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology, 2014, Volume: 15, Issue:1

    Topics: Female; Hemorrhage; Hip Fractures; Humans; Male; Postoperative Complications; Ticlopidine

2014
Withholding clopidogrel for 3 to 6 versus 7 days or more before surgery in hip fracture patients.
    Journal of orthopaedic surgery (Hong Kong), 2013, Volume: 21, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Female; Hemorrhage; Hip Fractures; Human

2013
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Me

2013
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution;

2014
Novel uses for platelet function testing in the clinical laboratory: where are we now?
    Clinical chemistry, 2014, Volume: 60, Issue:3

    Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Hemorrhage; Humans; Platelet Aggrega

2014
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:1

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aspirin; Child; Child, Preschool;

2014
[The CHAMPION PHOENIX study].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D

2013
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    European heart journal, 2014, Volume: 35, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents;

2014
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
    World journal of gastroenterology, 2013, Oct-14, Volume: 19, Issue:38

    Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi

2013
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Journal of vascular surgery, 2014, Volume: 59, Issue:3

    Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag

2014
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
    Cardiovascular intervention and therapeutics, 2014, Volume: 29, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera

2014
Thromboelastography platelet mapping for surgical patients: lessons from cardiac surgery.
    Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology, 2014, Volume: 15, Issue:1

    Topics: Female; Hemorrhage; Hip Fractures; Humans; Male; Postoperative Complications; Ticlopidine

2014
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
    Advances in therapy, 2014, Volume: 31, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole

2014
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper

2014
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper

2014
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adenosine Diphosphate; Animals; Antidepressive Agents; Blotting, Western; Calcium; Carotid Artery Th

2014
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Circulation, 2014, Apr-15, Volume: 129, Issue:15

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2014
Warfarin: Impact on hemostasis after radial catheterization.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2015, Jan-01, Volume: 85, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiac Catheterization; Catheterization, Peripher

2015
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined

2014
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
    Journal of vascular surgery, 2014, Volume: 59, Issue:4

    Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther

2014
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
    Drug safety, 2014, Volume: 37, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage

2014
Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Substitution; Female; Fibrinolytic Agents

2014
Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:8

    Topics: Clopidogrel; Confounding Factors, Epidemiologic; Drug-Eluting Stents; Electronic Health Records; Hem

2014
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.
    Journal of interventional cardiology, 2014, Volume: 27, Issue:2

    Topics: Aspirin; Biodegradable Plastics; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male;

2014
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation.
    Journal of interventional cardiology, 2014, Volume: 27, Issue:2

    Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; T

2014
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:1

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona

2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Dr

2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Th

2014
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
    Journal of the American Heart Association, 2014, Apr-14, Volume: 3, Issue:2

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherenc

2014
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha

2014
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:1

    Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrh

2014
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
    Life sciences, 2014, Aug-21, Volume: 110, Issue:2

    Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggre

2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middl

2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
    Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248

    Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemo

2014
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
    Journal of the American Heart Association, 2014, Aug-21, Volume: 3, Issue:4

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies;

2014
Perioperative aspirin: to give or not to give?
    BJU international, 2014, Volume: 114, Issue:3

    Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Female; Fibrinolytic Agents; H

2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh

2014
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Carboxylic Ester Hydrolases; Clop

2014
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
    The Journal of invasive cardiology, 2014, Volume: 26, Issue:11

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic

2014
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
    The Journal of invasive cardiology, 2014, Volume: 26, Issue:11

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic

2014
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
    The Journal of invasive cardiology, 2014, Volume: 26, Issue:11

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic

2014
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
    The Journal of invasive cardiology, 2014, Volume: 26, Issue:11

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic

2014
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr

2015
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
    Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll

2015
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
    BMC cardiovascular disorders, 2014, Dec-16, Volume: 14

    Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Ele

2014
From innovation to implementation: optimizing long-term outcomes after TAVR.
    Journal of the American College of Cardiology, 2014, Dec-23, Volume: 64, Issue:24

    Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcat

2014
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    American heart journal, 2015, Volume: 169, Issue:2

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem

2015
Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.
    Clinical cardiology, 2015, Volume: 38, Issue:2

    Topics: Aged; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Resistance; Femal

2015
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D

2015
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem

2015
Stent selection and antiplatelet therapy duration: one size does not fit all.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage;

2015
[Triple anticoagulant therapy - now what can I give for pain?].
    MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3

    Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Con

2015
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
    Chest, 2015, Volume: 148, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido

2015
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
    European journal of pharmacology, 2015, Jul-05, Volume: 758

    Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Lactone

2015
Glanzmann's thrombasthenia: meeting the anticoagulation challenge.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2015, Volume: 21, Issue:4

    Topics: Aminocaproic Acid; Aspirin; Clopidogrel; Factor VIIa; Hemorrhage; Humans; Isoantibodies; Male; Middl

2015
Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series.
    Journal of surgical orthopaedic advances, 2015,Summer, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clopidogre

2015
Platelet Function Testing and Prediction of Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Surgery.
    Clinical cardiology, 2015, Volume: 38, Issue:7

    Topics: Blood Platelets; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhi

2015
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2015, Volume: 16, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He

2015
Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI).
    Thrombosis research, 2015, Volume: 136, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio

2015
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
    Internal medicine journal, 2015, Volume: 45, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic

2015
Redesigning TRACER trial after TRITON.
    International journal of cardiology, 2015, Oct-15, Volume: 197

    Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera

2015
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
    Journal of endourology, 2015, Volume: 29, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre

2015
Iatrogenic Endobronchial Bleeding: Speed Things Up or Cool It Down?
    Journal of bronchology & interventional pulmonology, 2015, Volume: 22, Issue:3

    Topics: Biopsy; Bronchoscopy; Clopidogrel; Epinephrine; Hemorrhage; Humans; Iatrogenic Disease; Platelet Agg

2015
Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2015, Volume: 73, Issue:10

    Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; P

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:8

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc

2015
Authors' Reply.
    Clinical cardiology, 2015, Volume: 38, Issue:7

    Topics: Blood Platelets; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhi

2015
Platelet reactivity in MitraClip patients.
    Vascular pharmacology, 2016, Volume: 77

    Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit

2016
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Sep-01, Volume: 72, Issue:17 Suppl 2

    Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardia

2015
Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.
    Journal of neurointerventional surgery, 2016, Volume: 8, Issue:9

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic;

2016
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
    International journal of cardiology, 2015, Dec-15, Volume: 201

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor

2015
[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
    Medicina, 2015, Volume: 75, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate

2015
Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
    Thrombosis research, 2015, Volume: 136, Issue:6

    Topics: Apoptosis Regulatory Proteins; Arachidonic Acid; Aspirin; Blood Platelets; Blood Transfusion; Clopid

2015
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
    Archives of cardiovascular diseases, 2016, Volume: 109, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2016
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration while Receiving Aspirin and Clopidogrel: Is It Always Safe?
    Annals of the American Thoracic Society, 2015, Volume: 12, Issue:11

    Topics: Aspirin; Clopidogrel; Contraindications; Echocardiography, Doppler, Color; Endoscopic Ultrasound-Gui

2015
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
    Platelets, 2016, Volume: 27, Issue:4

    Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiac Surgical Procedures; Clopidogrel; Comorbidity; Female

2016
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
    Platelets, 2016, Volume: 27, Issue:4

    Topics: Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substituti

2016
Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016, Volume: 154, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cochlear Implantation; Female; Hem

2016
[Impact of preoperative dual antiplatelet therapy on perioperative bleeding in patients undergoing off-pump coronary artery bypass grafting].
    Zhonghua yi xue za zhi, 2015, Jun-23, Volume: 95, Issue:24

    Topics: Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Plate

2015
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.
    JACC. Cardiovascular interventions, 2015, Dec-21, Volume: 8, Issue:14

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H

2015
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
    Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:3

    Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China;

2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
    Clinical cardiology, 2016, Volume: 39, Issue:1

    Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination

2016
Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study.
    Thrombosis and haemostasis, 2016, 05-02, Volume: 115, Issue:5

    Topics: Aged; Asia, Eastern; Asian People; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 C

2016
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
    Cardiology, 2016, Volume: 134, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F

2016
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy.
    Coronary artery disease, 2016, Volume: 27, Issue:4

    Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female

2016
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Internal medicine journal, 2016, Volume: 46, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Fe

2016
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
    Nephron, 2016, Volume: 132, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage;

2016
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human

2016
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
    Journal of vascular surgery, 2016, Volume: 63, Issue:5

    Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel;

2016
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Mar-15, Volume: 73, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Databases, Factual; Disease Management; Female; Health R

2016
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
    Lung, 2016, Volume: 194, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female

2016
Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Diphtheri

2016
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
    Journal of the American College of Cardiology, 2016, May-17, Volume: 67, Issue:19

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St

2016
One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
    Archives of cardiovascular diseases, 2016, Volume: 109, Issue:5

    Topics: Aged; Clopidogrel; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Ag

2016
Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition stu
    Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2

    Topics: Aged; Algorithms; Clinical Decision-Making; Clopidogrel; Hemorrhage; Humans; Middle Aged; Percutaneo

2016
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhonghua xin xue guan bing za zhi, 2016, Apr-24, Volume: 44, Issue:4

    Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Cl

2016
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
    International journal of cardiology, 2016, Jul-15, Volume: 215

    Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Pe

2016
[Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy].
    Zhonghua yi xue za zhi, 2016, May-10, Volume: 96, Issue:17

    Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hematoma; Hemo

2016
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Mar-01, Volume: 89, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu

2017
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Feb-01, Volume: 89, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:4

    Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl

2016
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, Jun-18, Volume: 48, Issue:3

    Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction;

2016
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2016
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.
    International journal of cardiology, 2016, Oct-01, Volume: 220

    Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Clopidogrel; Europe; Female; Follow-Up Studies; Hemorr

2016
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
    Journal of endourology, 2016, Volume: 30, Issue:10

    Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; H

2016
EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel.
    Journal of bronchology & interventional pulmonology, 2016, Volume: 23, Issue:4

    Topics: Age Factors; Aged; Biopsy, Fine-Needle; Clopidogrel; Endoscopic Ultrasound-Guided Fine Needle Aspira

2016
Successful multivessel percutaneous coronary intervention for acute coronary syndrome in a HIV-positive severe haemophiliac.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Hematuria; Hemophilia A; Hemorrhage; HIV Infections; Humans; M

2016
Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection.
    Clinical spine surgery, 2017, Volume: 30, Issue:2

    Topics: Aged; alpha-Cyclodextrins; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contr

2017
Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling.
    Journal of neurointerventional surgery, 2017, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Hemorrhag

2017
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug

2017
Resuscitation experience in a patient with left ventricular assist device.
    Journal of clinical anesthesia, 2016, Volume: 34

    Topics: Anesthesia, General; Anticoagulants; Capnography; Cardiopulmonary Resuscitation; Clopidogrel; Defibr

2016
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
    Journal of the American Heart Association, 2016, 10-21, Volume: 5, Issue:10

    Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv

2016
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
    Journal of the American Heart Association, 2016, 11-04, Volume: 5, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy

2016
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
    American heart journal, 2016, Volume: 181

    Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical

2016
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul

2017
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Kidney international, 2017, Volume: 91, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co

2017
Life-threatening Wunderlich's syndrome with concurrent clopidogrel use.
    BMJ case reports, 2016, Nov-09, Volume: 2016

    Topics: Acute Kidney Injury; Blood Transfusion; Clopidogrel; Embolization, Therapeutic; Hemorrhage; Humans;

2016
Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review.
    Journal of vascular and interventional radiology : JVIR, 2017, Volume: 28, Issue:1

    Topics: Aged; Aged, 80 and over; Biopsy, Large-Core Needle; Clopidogrel; Drug Administration Schedule; Femal

2017
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
    BMC cardiovascular disorders, 2016, 12-08, Volume: 16, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl

2016
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
    American heart journal, 2017, Volume: 183

    Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Fem

2017
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:5

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Fema

2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery

2017
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
    Translational stroke research, 2017, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll

2017
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
    Archives of cardiovascular diseases, 2017, Volume: 110, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl

2017
Dyspnea in patients treated with P2Y
    Platelets, 2017, Volume: 28, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Female; Greece; Hematocrit; Hemorrhage; Humans; Male; M

2017
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
    The Pan African medical journal, 2016, Volume: 24

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle A

2016
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Dipeptidyl-Peptidase IV Inhibitors; H

2017
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, 02-07, Volume: 12, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther

2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
Platelet turnover predicts outcome after coronary intervention.
    Thrombosis and haemostasis, 2017, 05-03, Volume: 117, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square D

2017
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA).
    Thrombosis and haemostasis, 2017, 05-03, Volume: 117, Issue:5

    Topics: Aged; Aspirin; Cause of Death; Chi-Square Distribution; Clopidogrel; Disease-Free Survival; Drug Adm

2017
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
    American heart journal, 2017, Volume: 185

    Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb

2017
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction

2017
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
Safety and efficacy of clopidogrel in children with heart disease.
    The Journal of pediatrics, 2008, Volume: 153, Issue:1

    Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Human

2008
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Chest, 2008, Volume: 134, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As

2008
Haemorrhagic herpes zoster associated with clopidogrel treatment.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:3

    Topics: Clopidogrel; Female; Hemorrhage; Herpes Zoster; Humans; Middle Aged; Platelet Aggregation Inhibitors

2009
Stroke prevention--insights from incoherence.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam

2008
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
    The New England journal of medicine, 2008, Oct-23, Volume: 359, Issue:17

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co

2008
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug

2008
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug

2008
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree

2009
A paradigm shift in anti-platelet therapy?
    Platelets, 2008, Volume: 19, Issue:8

    Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Platelet Aggrega

2008
Clopidogrel under scrutiny.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Dec-01, Volume: 72, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Dec-01, Volume: 72, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron

2008
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
    The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Contusions; Coronary Angiography; Coronary Artery

2008
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D

2008
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
    Journal of thrombosis and thrombolysis, 2009, Volume: 28, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru

2009
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
    Drugs & aging, 2009, Volume: 26, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relatio

2009
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials

2009
Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits.
    Thrombosis research, 2009, Volume: 123, Issue:6

    Topics: Abdomen; Animals; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Flow Cytom

2009
Another view on prasugrel.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu

2009
Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug-Eluting Stents;

2009
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogr

2009
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coumarins; Dipyridamo

2008
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:6

    Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagula

2008
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulation.
    International journal of cardiology, 2011, Jan-07, Volume: 146, Issue:1

    Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidog

2011
rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:4

    Topics: Animals; Clopidogrel; Factor VII; Factor VIIa; Hemorrhage; Hemostasis; Platelet Count; Rats; Recombi

2009
Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
    ACS chemical biology, 2009, Feb-20, Volume: 4, Issue:2

    Topics: Acrylamides; Animals; Clopidogrel; Dinoprostone; Female; Hemorrhage; Humans; Male; Platelet Aggregat

2009
Ischaemia versus bleeding: the art of clinical decision-making.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; H

2009
Point-of-care platelet function analysis ready for prime time?
    Journal of the American College of Cardiology, 2009, Mar-10, Volume: 53, Issue:10

    Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation;

2009
The ischaemia/bleeding balance in PCI.
    Lancet (London, England), 2009, Mar-14, Volume: 373, Issue:9667

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Lactones;

2009
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
    Annals of internal medicine, 2009, Mar-17, Volume: 150, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2009
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
    Annals of internal medicine, 2009, Mar-17, Volume: 150, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans

2009
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
    Annals of internal medicine, 2009, Mar-17, Volume: 150, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal

2009
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi

2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
    International journal of clinical practice, 2009, Volume: 63, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Byp

2009
[Do antiplatelet agents (aspirin and other antiplatelets such as clopidogrel) increase the risk of hemorrhagic complications after endoscopic polypectomy or endoscopic sphincterotomy and should these drugs therefore be withdrawn 7-10 days before these pro
    Gastroenterologia y hepatologia, 2009, Volume: 32, Issue:4

    Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Hemorrhage; Humans; Platelet Aggregation Inhibito

2009
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
    Circulation, 2009, May-12, Volume: 119, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido

2009
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo

2009
[Patients with coronary artery stents: when and how should operations be carried out?].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru

2009
[Drug-eluting stents: implications for surgery patients].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res

2009
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Chronic Disease; Clopidogrel; Coronary Disease

2009
Clopidogrel. Bleeding and resistance.
    BMJ (Clinical research ed.), 2009, May-20, Volume: 338

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Platelet Aggregation Inhi

2009
External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
    International journal of radiation oncology, biology, physics, 2010, Mar-01, Volume: 76, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anticoagulants; Clopidogrel; F

2010
Future of oral antiplatelet therapy: four challenged hypotheses.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorr

2009
Clopidogrel in ESRD patients with acute coronary syndrome.
    Kidney international, 2009, Volume: 76, Issue:4

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet

2009
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad

2009
Femoral artery complications after cardiac catheterization: a study of patient profile.
    Annals of vascular surgery, 2010, Volume: 24, Issue:3

    Topics: Aged; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Female; Femoral

2010
[Pulmonary haemorrhage and haemothorax after massive ingestion of clopidogrel as a suicide attempt].
    Archivos de bronconeumologia, 2009, Volume: 45, Issue:11

    Topics: Clopidogrel; Female; Hemorrhage; Hemothorax; Humans; Lung Diseases; Middle Aged; Platelet Aggregatio

2009
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
    The Journal of thoracic and cardiovascular surgery, 2009, Volume: 138, Issue:4

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
    The American journal of cardiology, 2009, Oct-15, Volume: 104, Issue:8

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi

2009
[Prasugrel or clopidogrel in patients with coronary intervention].
    Der Internist, 2009, Volume: 50, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint

2009
Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery.
    Interactive cardiovascular and thoracic surgery, 2010, Volume: 10, Issue:1

    Topics: Aged; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug

2010
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
    European heart journal, 2010, Volume: 31, Issue:2

    Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Mal

2010
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2009
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic;

2009
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica

2009
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
    Nature reviews. Cardiology, 2009, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as To

2009
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:2

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; C

2010
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Se

2009
There is no place like home after successful percutaneous coronary intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Dec-01, Volume: 74, Issue:7

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar

2009
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
    The Canadian journal of cardiology, 2009, Volume: 25, Issue:12

    Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combina

2009
The right oral antithrombotics in acute coronary syndromes.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
    Lancet (London, England), 2009, Dec-12, Volume: 374, Issue:9706

    Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He

2009
eComment: Controversies on the antiplatelet therapy before coronary artery bypass grafting surgery.
    Interactive cardiovascular and thoracic surgery, 2010, Volume: 10, Issue:1

    Topics: Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug Therap

2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
    Circulation, 2010, Jan-05, Volume: 121, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cos

2010
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis;

2008
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor

2008
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:5

    Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Hemorrhage;

2009
Ticagrelor versus clopidogrel in acute coronary syndromes.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocard

2009
Ticagrelor versus clopidogrel in acute coronary syndromes.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors

2009
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010, Volume: 30, Issue:5

    Topics: 4-Aminobenzoic Acid; Animals; Disease Models, Animal; Drug Design; Female; Fibrinolytic Agents; Hemo

2010
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
    Journal of neurosurgery, 2010, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E

2010
Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.
    Journal of cardiology, 2010, Volume: 55, Issue:1

    Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Pla

2010
Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention.
    Thrombosis research, 2010, Volume: 126, Issue:2

    Topics: Aged; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Vessels; Female; Hemorrhage; Humans;

2010
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:4

    Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagula

2010
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4

    Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther

2010
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis

2010
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Drug Administration Schedule; Drug-Eluting St

2010
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
    Circulation, 2010, Mar-09, Volume: 121, Issue:9

    Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug

2010
Delays of event adjudication in the TRITON trial.
    Cardiology, 2010, Volume: 115, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary

2010
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
    Chirurgie de la main, 2010, Volume: 29, Issue:2

    Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrh

2010
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2010, Volume: 29, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol

2010
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
    MMW Fortschritte der Medizin, 2010, Mar-25, Volume: 152, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar

2010
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
    American heart journal, 2010, Volume: 159, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di

2010
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
    Heart and vessels, 2010, Volume: 25, Issue:3

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art

2010
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
    Texas Heart Institute journal, 2010, Volume: 37, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr

2010
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:3

    Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri

2010
[Dental management of patients using anti agregant drugs: background, risks and clinical guidelines].
    Refu'at ha-peh veha-shinayim (1993), 2009, Volume: 26, Issue:4

    Topics: Atherosclerosis; Clopidogrel; Dentistry; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practi

2009
High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake.
    Scandinavian journal of clinical and laboratory investigation, 2010, Volume: 70, Issue:6

    Topics: Aspirin; Clopidogrel; Drug Interactions; Fibrinogen; Glasgow Coma Scale; Hemorrhage; Hemostatics; Hu

2010
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
    Journal of the American College of Cardiology, 2010, Jul-20, Volume: 56, Issue:4

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Pur

2010
Letter by Aboyans et al regarding article, "Smoking, clopidogrel, and mortality in patients with established cardiovascular disease".
    Circulation, 2010, Jul-20, Volume: 122, Issue:3

    Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Fact

2010
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhag

2010
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:4

    Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination;

2010
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Blood, 2010, Nov-25, Volume: 116, Issue:22

    Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi

2010
Fine-tuning therapy for acute coronary syndromes.
    The New England journal of medicine, 2010, Sep-02, Volume: 363, Issue:10

    Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Clopidogrel and cardiac operations.
    The Annals of thoracic surgery, 2010, Volume: 90, Issue:4

    Topics: Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlo

2010
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, Oct-01, Volume: 76, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi

2010
It is standard practice, but is it really best practice or clinical biocreep?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, Oct-01, Volume: 76, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiog

2010
Emerging oral antiplatelet therapies for acute coronary syndromes.
    Hospital practice (1995), 2010, Volume: 38, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug The

2010
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
    American heart journal, 2010, Volume: 160, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Electrocardiogr

2010
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
    Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21

    Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over;

2010
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
    Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21

    Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over;

2010
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
    Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21

    Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over;

2010
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
    Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21

    Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over;

2010
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topi

2010
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
    American heart journal, 2010, Volume: 160, Issue:6 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Age

2010
A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients.
    The Journal of trauma, 2011, Volume: 70, Issue:1

    Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Injury Severity Score; Male; Platelet Aggregation Inh

2011
Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.
    Fundamental & clinical pharmacology, 2012, Volume: 26, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female;

2012
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
    The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dos

2011
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
    Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar

2011
Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting.
    American heart journal, 2011, Volume: 161, Issue:2

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Emergency Treatment; Female; Hemorrhage; Humans; Male; Mi

2011
Immortal person-time bias in observational studies in cardiac surgery.
    The Journal of thoracic and cardiovascular surgery, 2011, Volume: 141, Issue:3

    Topics: Aspirin; Bias; Clopidogrel; Coronary Artery Bypass; Data Interpretation, Statistical; Drug Therapy,

2011
Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.
    Journal of the American College of Cardiology, 2011, Mar-08, Volume: 57, Issue:10

    Topics: Aged; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Artery Bypass; Denmark; Female;

2011
The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:9

    Topics: Case-Control Studies; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Mi

2011
Can endoscopists become more aggressive or have more options for patients with antithrombotic agents?
    Digestive diseases and sciences, 2011, Volume: 56, Issue:9

    Topics: Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inh

2011
[Do genetic factors reduce the effects of clopidogrel?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15

    Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Hum

2011
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 6, Issue:9

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants;

2011
Dual antiplatelet therapy and the risk of bleeding.
    Archives of internal medicine, 2011, Apr-25, Volume: 171, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag

2011
[The CURRENT-OASIS 7 study].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr

2011
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
    The American journal of cardiology, 2011, Jun-15, Volume: 107, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; H

2011
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    JAMA, 2011, Jun-22, Volume: 305, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; M

2011
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor

2011
Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
    The American journal of cardiology, 2011, Sep-15, Volume: 108, Issue:6

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Transfusion; Clopidogrel; Female; France; Hemor

2011
Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
    Anesthesia and analgesia, 2011, Volume: 113, Issue:4

    Topics: Clopidogrel; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; Humans; Male; Platelet Aggregation In

2011
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
    Journal of the American College of Cardiology, 2011, Aug-02, Volume: 58, Issue:6

    Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Th

2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
    The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb

2011
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    The American journal of cardiology, 2011, Nov-15, Volume: 108, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B

2011
Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications.
    Ultrasound quarterly, 2011, Volume: 27, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biopsy, Fine-Needle; Chi-Square

2011
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
    The American journal of cardiology, 2011, Nov-01, Volume: 108, Issue:9

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri

2011
Normal chest radiograph and ground glass opacities on a thoracic computed tomographic scan in a patient with diffuse alveolar haemorrhage due to dual antiplatelet therapy prescribed after patent foramen ovale percutaneous device closure.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Foramen Ovale, Patent; Hemoptysis; H

2011
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Nov-08, Volume: 183, Issue:16

    Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag

2011
Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery.
    Scandinavian cardiovascular journal : SCJ, 2012, Volume: 46, Issue:1

    Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Female; Hem

2012
Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:8

    Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carbon Monoxide; Clopidogr

2011
Platelet inhibition and surgical bleeding. A plea for more science and evidence-based guidelines.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:12

    Topics: Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Female; Hemorrhage; Humans; Male; Plate

2011
No free lunches: balancing bleeding and efficacy with ticagrelor.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregat

2011
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2012
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Cardiology journal, 2011, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan

2011
Clopidogrel (plavix).
    AJNR. American journal of neuroradiology, 2011, Volume: 32, Issue:11

    Topics: Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2011
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Jan-01, Volume: 79, Issue:1

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidog

2012
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    American heart journal, 2012, Volume: 163, Issue:1

    Topics: Atherosclerosis; Female; Hemorrhage; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibit

2012
Pharmacogenomics and clopidogrel: irrational exuberance?
    JAMA, 2011, Dec-28, Volume: 306, Issue:24

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Hemor

2011
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardi

2012
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012, Volume: 15, Issue:1

    Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Dis

2012
Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: a report of 12 consecutive cases.
    Respiration; international review of thoracic diseases, 2012, Volume: 83, Issue:4

    Topics: Aged; Aged, 80 and over; Biopsy, Fine-Needle; Bronchoscopy; Clopidogrel; Endosonography; Female; Fol

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor

2012
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
    Hospital practice (1995), 2012, Volume: 40, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Hospital Cos

2012
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
    Pacing and clinical electrophysiology : PACE, 2012, Volume: 35, Issue:5

    Topics: Cardiac Resynchronization Therapy; Case-Control Studies; Clopidogrel; Comorbidity; Drug-Related Side

2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
    Pharmacotherapy, 2012, Volume: 32, Issue:4

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Comput

2012
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
    The American journal of cardiology, 2012, Mar-15, Volume: 109, Issue:6

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr

2012
CYP2C19 genotype and cardiovascular events.
    JAMA, 2012, Apr-11, Volume: 307, Issue:14

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl

2012
CYP2C19 genotype and cardiovascular events.
    JAMA, 2012, Apr-11, Volume: 307, Issue:14

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl

2012
CYP2C19 genotype and cardiovascular events.
    JAMA, 2012, Apr-11, Volume: 307, Issue:14

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl

2012
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A

2012
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat

2012
Interaction between ticlopidine or warfarin or cardioaspirin with a highly standardized deterpened Ginkgo biloba extract (VR456) in rat and human.
    Acta bio-medica : Atenei Parmensis, 2010, Volume: 81, Issue:3

    Topics: Animals; Aspirin; Blood Pressure; Drug Interactions; Ginkgo biloba; Ginkgolides; Heart Rate; Hemorrh

2010
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
    Journal of pharmacy practice, 2012, Volume: 25, Issue:5

    Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi

2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel

2012
How to prevent bleeding events in on- and off-pump coronary artery bypass patients exposed to clopidogrel preoperatively.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4

    Topics: Acute Coronary Syndrome; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male; Platele

2012
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies;

2012
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera

2012
Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.
    European journal of preventive cardiology, 2014, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Clopidogrel; Community Pharma

2014
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2012, Volume: 10, Issue:6

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19;

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh

2012
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
    European heart journal, 2012, Volume: 33, Issue:20

    Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf

2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart advisor, 2010, Volume: 13, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infar

2010
Practice observed.
    Menopause international, 2012, Volume: 18, Issue:3

    Topics: Aged; Buttocks; Clopidogrel; Contusions; Drug Interactions; Female; Ginkgo biloba; Hematuria; Hemorr

2012
Ticagrelor FDA approval issues revisited.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response

2012
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo

2012
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
    Der Anaesthesist, 2012, Volume: 61, Issue:8

    Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive Syste

2012
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
    International journal of medical sciences, 2012, Volume: 9, Issue:6

    Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Data Mining; Hemorrhage; Humans; Plat

2012
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Circulation, 2012, Sep-04, Volume: 126, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi

2012
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem

2012
[General antithrombotic therapy practice facing fundamental change].
    MMW Fortschritte der Medizin, 2012, Sep-10, Volume: 154, Issue:15

    Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A

2012
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?
    Clinical cardiology, 2012, Volume: 35, Issue:11

    Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomeru

2012
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2012, Volume: 8, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorb

2012
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
    BMJ case reports, 2012, Oct-26, Volume: 2012

    Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial An

2012
[Platelet inhibition in clinical practice].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo

2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp

2013
Safety of endoscopic sphincterotomy in patients under dual antiplatelet therapy.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:124

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Clopidogre

2013
Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis.
    Journal of bronchology & interventional pulmonology, 2012, Volume: 19, Issue:4

    Topics: Clopidogrel; Contraindications; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation

2012
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:12

    Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat

2012
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
    American heart journal, 2013, Volume: 165, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo

2013
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combinat

2013
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7

    Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Mole

2013
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
    Zhonghua xin xue guan bing za zhi, 2012, Volume: 40, Issue:11

    Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Human

2012
Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2002, Volume: 56, Issue:2

    Topics: Aged; Feasibility Studies; Female; Fibrinolytic Agents; Hemorrhage; Hemostasis, Surgical; Heparin An

2002
Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel.
    BJU international, 2002, Volume: 90, Issue:4

    Topics: Clopidogrel; Hematoma; Hemorrhage; Humans; Lithotripsy; Male; Middle Aged; Platelet Aggregation Inhi

2002
Severe bleeding following lumbar sympathetic blockade in two patients under medication with irreversible platelet aggregation inhibitors.
    Anesthesiology, 2002, Volume: 97, Issue:3

    Topics: Aged; Anesthesia, Spinal; Autonomic Nerve Block; Fatal Outcome; Female; Hemorrhage; Humans; Magnetic

2002
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    Circulation, 2002, Oct-01, Volume: 106, Issue:14

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;

2002
Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
    Circulation, 2002, Oct-22, Volume: 106, Issue:17

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Hemorrhage

2002
Clopidogrel plus aspirin for stroke prevention.
    Stroke, 2002, Volume: 33, Issue:11

    Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow-

2002
[Anticoagulation and antiaggregation in cardiac patients].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo

2003
[New antiaggregants and their importance for the practitioner].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiov

2003
Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm.
    Anesthesia and analgesia, 2003, Volume: 96, Issue:4

    Topics: Catheter Ablation; Clopidogrel; Hemorrhage; Humans; Intraoperative Complications; Lung Neoplasms; Pl

2003
Spontaneous pharyngeal haemorrhage in the anticoagulated patient.
    Irish medical journal, 2003, Volume: 96, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Male; Pharyngeal Disease

2003
Statistical versus clinical significance of the CURE study in acute coronary syndromes.
    Journal of the American College of Cardiology, 2003, Apr-02, Volume: 41, Issue:7

    Topics: Angina, Unstable; Clinical Trials as Topic; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggr

2003
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
    Hamostaseologie, 2003, Volume: 23, Issue:3

    Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation

2003
[Sudden edema and pain in the knee].
    Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:17

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactio

2003
By the way, doctor. A new television ad says I should ask my doctor about Plavix, a drug that reduces the risk of heart attack and stroke. I'm 65 years old and healthy. Should I be taking Plavix preventively?
    Harvard women's health watch, 2003, Volume: 11, Issue:3

    Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Health Status; Hemorrhage; Humans; Platelet Aggr

2003
When guidelines collide...
    American heart journal, 2004, Volume: 147, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy

2004
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
    American heart journal, 2004, Volume: 147, Issue:3

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin;

2004
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath

2004
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
    Anesthesiology, 2004, Volume: 101, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; G

2004
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
    MMW Fortschritte der Medizin, 2004, Jun-10, Volume: 146, Issue:24

    Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemo

2004
[Peridural injections during acetylsalicylic acid and clopidogrel therapy?].
    Deutsche medizinische Wochenschrift (1946), 2004, Oct-08, Volume: 129, Issue:41

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Injections, Epidural; I

2004
[Clopidogrel protection is not increased further by ASS!].
    Praxis, 2004, Aug-25, Volume: 93, Issue:35

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische

2004
[Clopidogrel as basic therapy in high-risk stroke patients].
    Praxis, 2004, Aug-18, Volume: 93, Issue:34

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemo

2004
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
    American heart journal, 2005, Volume: 149, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat

2005
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
    Annals of internal medicine, 2005, Feb-15, Volume: 142, Issue:4

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A

2005
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Annals of internal medicine, 2005, Feb-15, Volume: 142, Issue:4

    Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A

2005
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
    Thrombosis and haemostasis, 2005, Volume: 93, Issue:3

    Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combin

2005
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A

2005
Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy.
    Chest, 2005, Volume: 127, Issue:3

    Topics: Animals; Aspirin; Biopsy, Needle; Bronchoscopy; Clopidogrel; Hemorrhage; Lung; Platelet Aggregation

2005
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
    The heart surgery forum, 2005, Volume: 8, Issue:1

    Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa;

2005
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
    Archives of internal medicine, 2005, Apr-11, Volume: 165, Issue:7

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug

2005
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
    Annales francaises d'anesthesie et de reanimation, 2005, Volume: 24, Issue:5

    Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl

2005
Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
    Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4

    Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Aspirin; Association;

2005
Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes.
    Medical hypotheses, 2006, Volume: 66, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Eicosanoids; Hemorrhage; Humans; Ticlopidine

2006
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
    Der Internist, 2005, Volume: 46, Issue:11

    Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma

2005
Bleeding complications in elderly patients following acute myocardial infarction.
    Archives of internal medicine, 2005, Nov-14, Volume: 165, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia

2005
Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report.
    Emergency radiology, 2005, Volume: 12, Issue:1-2

    Topics: Abdominal Injuries; Accidental Falls; Aged, 80 and over; Aspirin; Embolization, Therapeutic; Female;

2005
New modalities and aspects of antiplatelet therapy for stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 21 Suppl 1

    Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi

2006
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
    Deutsche medizinische Wochenschrift (1946), 2006, Feb-24, Volume: 131, Issue:8

    Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; He

2006
Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?
    Circulation, 2006, Apr-04, Volume: 113, Issue:13

    Topics: Aged; Blood Transfusion; Case-Control Studies; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female

2006
Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He

2006
Good old warfarin for stroke prevention in atrial fibrillation.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pla

2006
Clopidogrel for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Jul-27, Volume: 355, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incide

2006
Clopidogrel for the prevention of atherothrombotic events.
    The New England journal of medicine, 2006, Jul-27, Volume: 355, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel

2006
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose-

2006
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
    Ugeskrift for laeger, 2006, Sep-18, Volume: 168, Issue:38

    Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent

2006
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
    Ugeskrift for laeger, 2006, Sep-18, Volume: 168, Issue:38

    Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com

2006
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    The American journal of cardiology, 2006, Nov-01, Volume: 98, Issue:9

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary

2006
Letter by van der Linden et al regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
    Circulation, 2006, Nov-14, Volume: 114, Issue:20

    Topics: Aprotinin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Hemostatics; Humans; Platelet

2006
Letter by Poston regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
    Circulation, 2006, Nov-14, Volume: 114, Issue:20

    Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Platelet Aggregation Inhibitors;

2006
[Safety of aspirin, clopidogrel, and acenocumarol combination in patients requiring anticoagulation].
    Revista espanola de cardiologia, 2006, Volume: 59, Issue:12

    Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorr

2006
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:1

    Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination;

2007
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    Pharmacotherapy, 2007, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2007
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
    Pharmacotherapy, 2007, Volume: 27, Issue:5

    Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo

2007
The use of clopidogrel in carotid endarterectomy: an audit of current practice.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2007, Volume: 34, Issue:3

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Endarterectomy, Carotid; Hemorrhage; Humans; Medica

2007
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2007, Volume: 34, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri

2007
Clopidogrel: the good, the bad, and the ugly.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:3

    Topics: Acute Disease; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; Platelet Ag

2007
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Der Internist, 2007, Volume: 48, Issue:8

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny

2007
Admissions to a medical intensive care unit related to adverse drug reactions.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Sep-01, Volume: 64, Issue:17

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse

2007
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:3

    Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Diseas

2007
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
    The Canadian journal of cardiology, 2007, Volume: 23 Suppl B

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema

2007
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
    The American journal of cardiology, 2007, Nov-01, Volume: 100, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheteriza

2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem

2007
Outcomes associated with combined antiplatelet and anticoagulant therapy.
    Chest, 2008, Volume: 133, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea

2008
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido

2008
Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
    Advances in medical sciences, 2007, Volume: 52

    Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Clopidogrel; Fe

2007
A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2008, Volume: 9, Issue:1

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Fe

2008
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
    Revue medicale suisse, 2008, Feb-13, Volume: 4, Issue:144

    Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet A

2008
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    The Journal of emergency medicine, 2009, Volume: 36, Issue:2

    Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans;

2009
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platel

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial

2008
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, May-01, Volume: 71, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri

2008
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Cardiology, 2008, Volume: 111, Issue:4

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

2008
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
    Cardiology, 2008, Volume: 111, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hem

2008
Anti-platelet agents and surgical delay in elderly patients with hip fractures.
    Journal of orthopaedic surgery (Hong Kong), 2008, Volume: 16, Issue:1

    Topics: Aged; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hip Fractures; Hum

2008
For better or for worse: the future of antiplatelet therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial

2008
Ticlopidine, bleeding, and surgery.
    The Mount Sinai journal of medicine, New York, 1994, Volume: 61, Issue:4

    Topics: Hemorrhage; Humans; Platelet Aggregation; Surgical Procedures, Operative; Ticlopidine

1994
Reduction of thrombotic and hemorrhagic complications after stent implantation.
    American heart journal, 1996, Volume: 132, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up St

1996
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
    Sangre, 1997, Volume: 42, Issue:5

    Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation

1997
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

1998
Adverse haematological effects of ticlopidine.
    Prescrire international, 1998, Volume: 7, Issue:33

    Topics: Clinical Trials as Topic; Cost-Benefit Analysis; France; Hemorrhage; Humans; Leukopenia; Platelet Ag

1998
Serious hematologic reactions associated with ticlopidine--update.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1999, Oct-05, Volume: 161, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Hemorrhage; Humans; Leukopenia; Patient Education as Topic;

1999
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod

2001
Diffuse alveolar hemorrhage after clopidogrel use.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Hemorrhage; Humans; Lung Diseases; Ma

2001
Haemorrhage associated with combined clopidogrel and aspirin therapy.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2001, Volume: 22, Issue:5

    Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aspirin; Clopidogrel; Drug Therapy, Combination

2001
Treatment of acute coronary syndromes.
    The New England journal of medicine, 2002, Jan-17, Volume: 346, Issue:3

    Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage;

2002
Treatment of acute coronary syndromes.
    The New England journal of medicine, 2002, Jan-17, Volume: 346, Issue:3

    Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage;

2002
Guidelines for acute coronary syndrome without ST elevation.
    Lancet (London, England), 2002, Apr-13, Volume: 359, Issue:9314

    Topics: Clopidogrel; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycopr

2002
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
    Stroke, 1989, Volume: 20, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P

1989
Clinical application of a new in vitro bleeding time device on surgical patients.
    The Japanese journal of surgery, 1988, Volume: 18, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Bleeding Time; Epoprostenol; Hemorrhage; Hemostasis; H

1988
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
    Thrombosis research, 1986, May-01, Volume: 42, Issue:3

    Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techni

1986
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
    Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:9

    Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Pos

1985